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 Contact between human beings and dogs may allow sharing of antimicrobial 
resistant and virulent bacteria.  Objectives of this study were to determine the 
prevalence of cross-species sharing of fecal E. coli based on pulse field gel 
electrophoresis (PFGE) profile similarity, to compare antimicrobial susceptibility 
patterns and virulence factor patterns between dog-owner pairs, and to analyze the 
epidemiology of cross-species sharing using a questionnaire.   
A cross-sectional study comparing fecal E. coli isolates from dogs and their 
owners was conducted.  A questionnaire and fecal sample was collected from 61 dog-
owner pairs and 30 controls.  Three E. coli colonies were isolated from each 
participant and confirmed biochemically.  Antimicrobial susceptibility of each isolate 
was determined via disc diffusion for 17 antimicrobial agents routinely monitored by 
the National Antimicrobial Resistance Monitoring System.  PFGE profiles were used 
to establish relatedness among bacterial isolates.  A multiplex PCR was developed to 
determine presence or absence of 4 urovirulence factor genes: cnf, hlyD, sfa, and 
papGIII.  The questionnaire asked about medical history, antimicrobial therapy, 
hygiene, and relationship with dog. 
A wide array of PFGE profiles was observed in E. coli isolates from all 
participants.  Within-household sharing occurred with 9.8% prevalence, and across-
household sharing occurred with 0.26% prevalence.  No specific behaviors were 
associated with increased clonal sharing between dog and owner.   
No differences were found in susceptibility results or virulence factor patterns 
between dog-owner pairs.  Control isolates were more resistant than canine isolates, 
and human beings carried more multiple-drug resistant E. coli than dogs.  Isolates 
from owners who did not wash their hands after petting their dogs had increased 
resistance to ampicillin.  An association was found in women between history of UTI 
and presence of each virulence factor in their dog’s fecal E. coli.  Antimicrobial 
resistance was associated with reduction of virulence factors.  
 Within-household sharing of E. coli occurred more commonly than across-
household sharing, but both direct contact and environmental reservoirs may be 
important routes for cross-species sharing of bacteria and genes for resistance and 
virulence.  Cross-species bacterial sharing is a potential public health concern, and 
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 Escherichia coli (E. coli) is a gram-negative, non-spore-forming, motile, 
coccobacillus in the Family, Enterobacteriaceae.  Strains of this species are highly 
versatile bacteria that can respond and adapt to environmental changes in 
temperature, pH, chemicals, oxygen and nutrient availability.  This versatility allows 
them to survive as benign commensal flora in various body sites of mammals such as 
the gastrointestinal (GI) and distal urogenital tracts, and to cause opportunistic 
infections when host defenses are compromised.  Some strains of E. coli are naturally 
pathogenic, such as E. coli O157:H7, while other strains are normally nonpathogenic; 
however, new pathogenic strains can arise quickly through acquisition of virulence 
genes.  A better understanding of the epidemiology, genetics, and response of E. coli 
to antimicrobial agents will help advance strategies to control transmission and 
treatment of these infections while reducing the economic impact of E. coli and 
improving overall public health. 
 
Classification Schemes of E. coli 
 Several classification schemes are used to identify and characterize strains of 
E. coli because of their diversity.  These are based on colony morphology, 
biochemical reactions, antimicrobial susceptibility, antigenic variation, production of 
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virulence factors, and deoxyribonucleic acid (DNA) fingerprint profiles.  Serologic 
testing is used to classify strains based on outer surface antigens, including somatic 
antigens (O-antigens) that are part of the lipopolysaccharide (LPS), capsular antigens 
(K-antigens), flagellar antigens (H-antigens), and fimbrial antigens (F-antigens).  
Serogroups are determined based on the O-antigen, and serotypes are determined by 
the full compliment of O, K, F, and H-antigens, resulting in nomenclature such as E. 
coli O157:H7.  Classification schemes based on newer molecular techniques are 
emerging, including use of polymerase chain reaction (PCR) to determine presence of 
virulence factors (virotyping), and use of DNA fingerprinting techniques 
(genotyping).   
 
Role of E. coli in the Normal Gastrointestinal and Urogenital Flora 
 The Enterobacteriaceae family was so named because its members are 
primarily found in the enteric tract of mammals.  In addition to E. coli, other 
prominent Enterobacteriaceae include Proteus, Klebsiella, Enterobacter, Salmonella, 
and Shigella.  The mammalian GI tract is sterile during fetal development, and the 
fetus is originally exposed to bacteria during passage through the birth canal.  
Bacteria are ingested from the local environment and travel through the GI tract, 
competing with other bacteria and ultimately colonizing in their ideal niche.  Initially, 
as the flora evolves it is very similar to the mother’s GI flora, due to close physical 
contact and nursing; however, with maturation and independence, the adult GI flora 
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becomes an individualized complex ecosystem based on environment, health, stress 
level, nutrition, and exposure to antimicrobial drugs and probiotics [1].  As a result of 
these contributory factors, there can be marked variation in the bacterial microflora of 
the intestinal compartments and feces even among individuals living in the same 
environment [2, 3].   
 The oral cavity is inhabited by a mixture of aerobic and anaerobic bacteria.  
The esophagus is not colonized by bacteria but is contaminated by saliva that contains 
a mixture of aerobic and anaerobic bacteria.  The stomach and intestines are inhabited 
by a combination of anaerobes, coliforms, gram-positive bacteria, and spirochetes, 
with the total number of bacteria increasing progressively and peaking in the large 
intestine [4].    
 The GI flora remains fairly stable over prolonged periods, experiencing 
gradual shifts in bacterial species and predominant strains.  Rapid changes can occur 
with administration of antimicrobial therapy or infection with virulent pathogens [3].  
Administration of nutraceuticals such as prebiotics and probiotics will alter the GI 
flora.  Prebiotics are undigested foods that alter replication of specific enteric 
bacteria.  Soluble fibers such as fructooligosaccharides are prebiotics that reach the 
colon undigested, are fermented by anaerobic bacteria, and may decrease growth of 
E. coli and Clostridium.  Probiotics are live microorganisms, such as Lactobacilli, 
Bifidobacteria, and Enterococcus faecium that incorporate into the GI flora, inhibit 
pathogenic bacteria, and stimulate immune defense mechanisms [3].   
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 The normal GI flora is a symbiotic partner with the host mammal and is 
responsible for several physiologic and metabolic activities.  A major role is to 
compete with potential pathogens for binding sites, stimulate immunoglobulin A 
(IgA) production, and produce antibacterial compounds to suppress activity of 
potential pathogens.  The normal GI flora also plays a role in regulating GI transit 
time, carbohydrate fermentation, bile acid metabolism, short-chain fatty acid 
production, and folic acid synthesis [1, 3, 5].   
 In addition to the GI flora, E. coli are part of the normal flora in the distal 
urogenital tract, including the distal urethra, prepuce, and vagina [6].  Although E. 
coli may be a source of ascending infection, they are also protective, competing to 
inhibit adherence, growth, and ascension of potential pathogens up the urethra into 
the urinary bladder, prostate, and uterus [6].  As in the GI tract, the normal distal 
urogenital flora contains a mixture of bacteria, and E. coli comprise only a small 
fraction.  Lactobacilli are more commonly recognized bacteria in the urogenital 
defense system.  When outside pressures such as antimicrobial treatment alter 
Lactobacillus numbers, risk of ascending urinary tract infections (UTI) and 
opportunistic vaginal yeast infections is increased.  Therapeutically replacing 
Lactobacilli via live cultures in yogurt or probiotics may restore the normal urogenital 
flora and assist in management of opportunistic and pathogenic ascending infections. 
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Acquisition of Virulence 
 Although some E. coli live in harmony with and protect the mammalian host, 
other strains of E. coli cause significant disease.  This distinction is determined by 
bacterial and host factors.  Bacterial factors can increase virulence and pathogenicity, 
while decreased host immune defenses allow opportunistic infections to occur.  
Certain strains of E. coli acquire genes that encode virulence factors and increase the 
bacterium’s ability to adhere to host cells, invade, produce toxins, utilize host 
nutrients, and avoid the host’s immune system.  By definition, virulence is the relative 
ability of an organism to cause disease in a particular host, and virulence genes are 
major factors involved in determining if a bacterial strain is benign or pathogenic [7].  
Host factors such as immunosuppression, anatomical abnormalities, and previous 
antimicrobial therapy are also important in E. coli epidemiology. 
 Increased virulence can develop from chromosomal mutations in individual 
bacteria or acquisition of virulence genes through horizontal gene transfer.  Mutations 
occur spontaneously within the genome, and the effect of the mutation depends on 
which gene is mutated and the type of mutation.  Certain mutations improve survival, 
allowing propagation into a clone within the host environment.  If chromosomal 
mutations promote increased virulence or antimicrobial resistance, the mutated clone 
can overcome the host’s normal flora and immune defenses and cause clinical 
disease.  Nonsense, deletion, and inversion mutations can cause fatal defects in 
protein products, leading to premature bacterial death.   
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 Horizontal gene transfer is a more common, rapid, and efficient method of 
acquiring virulence genes.  This is the spread of DNA from one bacterium to another, 
occurring via three main routes: transformation, transduction, and conjugation.  With 
transformation, transduction, and conjugation, new DNA is brought into a recipient 
bacterium, and if it has similar base pair (bp) segments as the recipient’s 
chromosomal DNA, homologous recombination can occur to integrate the new DNA 
into the recipient’s chromosome. 
 Transformation is the direct uptake of naked DNA from a nearby ruptured 
bacterium.  Transduction is the transfer of DNA between bacteria via bacteriophages.  
Phages have the ability to integrate into the chromosome, via lysogeny, and during 
times of DNA stress, including ultraviolet light damage or use of an antimicrobial 
drug inhibiting DNA replication, the phage can excise from the host chromosome.  
Occasionally when this occurs, a small portion of bacterial host DNA is packaged 
into phage nucleocapsids when virus particles are assembled and released from 
infected host cells.  These new virions with chimeric genomes can bind and inject 
their nucleic acid into new bacterial hosts, and recombination can then occur with the 
recipient’s chromosome.   
 Conjugation is the most common and efficient route of horizontal gene 
transfer, a form of direct mating between bacteria that results in transfer of plasmids 
from a donor to a recipient bacterium.  Plasmids are pieces of DNA independent from 
a bacterium’s chromosome that often carry genes for virulence and antimicrobial 
resistance.  In short, during conjugation, a donor bacterium with a self-transmissible 
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or mobilizable plasmid extends a pilus to attract a recipient bacterium that lacks the 
same type of plasmid.  Following attachment of donor to recipient, the pair comes 
into very close contact, a hollow pore is formed between the two, and a copy of the 
plasmid is transferred from donor to recipient.  Homologous recombination then 
occurs between the plasmid and the recipient’s chromosome to produce offspring 
unlike either parent bacterium.  When a donor bacterium with a unique plasmid is 
first introduced to a new population, conjugation occurs rapidly, providing plasmids 
and their genes for virulence or antimicrobial resistance to the majority of naïve 
recipients.  The pilus that attracts recipients also attracts bacteriophages, so tight 
regulation stops conjugation after the initial burst to prevent destruction of the donor 
by phage lysis.   
 Transposons and integrons are DNA segments that can jump between strands 
of DNA.  This action is classified as nonhomologous recombination, because its 
occurrence is determined by transposases and integrases that recognize specific sites 
in recipient DNA.  Transposons carry genes for virulence factors and antimicrobial 
resistance and can be carried on plasmids or phages and transfer DNA after 
conjugation or transduction.  This most often occurs within the same species of 
bacteria, but can also occur between different genera and species.  Integrons are a 
type of transposon that encodes integrase, an enzyme helping them serve as recipients 
for antimicrobial resistance genes.  The functional integrity of genetic elements 
acquired by nonhomologous recombination may be readily lost, leaving behind 
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unique insertion sequences that are sometimes used for species identification or 
genomic clusters of genes encoding antimicrobial resistance or virulence traits. 
 Pathogenicity islands (PAI) are condensed clusters of genes encoding 
virulence factors able to be acquired through horizontal gene transfer.  PAI sequences 
are large (>30 kilobase) blocks of DNA located near tRNA genes and have a guanine-
cytosine (GC) content that differs from the rest of the genome [8].  They contain 
transposases and integrases to allow insertion into recipient DNA as transposons, but 
PAI gene clusters can also transfer via plasmids or phages [9].  Due to frequent 
recombination and genetic rearrangement, PAIs have constant modifications in exact 
composition of virulence factors [9].  PAIs and virulence genes they contain play an 
important role in the uropathogenesis of E. coli.  One study using PCR showed that 
40% of commensal fecal E. coli isolates but 93% of uropathogenic E. coli (UPEC) 
carried PAIs [10].  Another study identified PAIs in 22% of fecal strains from healthy 
subjects, but in 79% of isolates from patients with acute pyelonephritis and 82% of 
isolates from patients with cystitis (82%) [8]. 
   
Pathogenic E. coli and their Virulence Factors 
 Disease from E. coli can come from either opportunistic or pathogenic E. coli.   
Opportunistic infection and disease occur when there is a change in the local 
environment or temporary break in immune defenses.  Many bacterial strains, 
irrespective of their possession or lack of virulence traits, can cause opportunistic 
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infection and disease.  Common risk factors include immunosuppressive, 
chemotherapeutic, and antimicrobial therapies, natural diseases such as GI ulceration, 
and iatrogenic damage such as that caused by an indwelling urinary catheter.  
Alternatively, pathogenic E. coli can cause infection and illness without concurrent 
disease or immunosuppression, because they have virulence factors that can 
overcome the host’s intact natural defenses.   
 Four major categories of virulence factors in E. coli are: adhesins, toxins, 
iron-acquisition systems, and the outer capsule.  Adhesins are critical proteins that 
mediate adherence of pathogenic bacteria to their target host cells.  Toxins either 
locally destroy host target cells or enter the bloodstream and cause systemic damage, 
and stimulate the immune system by triggering inflammatory cascades.  Iron-
acquisition systems help bacteria compete with host cells for critical iron supplies.  
Finally, the capsule is an outer polysaccharide layer that helps E. coli avoid being 
recognized and killed by phagocytes and protects E. coli from lysis by the membrane 
attack complex of complement.  Within these general categories are many specific 
fine-tuned virulence factors that have evolved through natural selective pressures.  
Individual distribution of virulence factors in each E. coli strain determines which 
organ system it can target and the type of disease it will cause. 
 Infections with pathogenic E. coli are typically classified as either intestinal or 
extraintestinal infections.  There are five main types of intestinal pathogenic E. coli, 
including: enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), 
enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), and enteroaggregative 
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E. coli (EAggEC).  Of the extraintestinal pathogenic E. coli (ExPEC), the most 
common is uropathogenic E. coli (UPEC), but significant disease can be associated 
with ExPEC infection of the bloodstream, central nervous system, reproductive 
organs, and other sites within the body.   
 
Intestinal Pathogenic E. coli 
 Enterohemorrhagic E. coli (EHEC) include strains of E. coli, such as E. coli 
0157:H7, responsible for the majority of E. coli food-borne GI illnesses in human 
beings.  They are also responsible for edema disease in pigs, dysentery in calves and 
lambs, and are implicated in cutaneous and renal glomerular vasculopathy in 
greyhounds (CRGV).  The main virulence factors present in EHEC are the locus for 
enterocyte effacement (LEE) carrying the gene for the classic attaching and effacing 
lesion (eaeA), and shigatoxins.  Other suspected virulence factors involved in 
pathogenicity of EHEC include hemolysin and acid resistance [11].  LEE represents 
genes mediating attachment of E. coli to host cells, architectural and metabolic 
changes within enterocytes, and effacement of microvilli on the brush border of 
enterocytes.  Shigatoxins have receptors in both the GI tract and kidneys, and 
shigatoxin 2 (stx2) is the major virulence factor involved in the pathogenesis of 
hemolytic uremic syndrome (HUS).  EHEC initially damages enterocytes, causing 
dysentery and allowing shigatoxins to be absorbed into the bloodstream.   
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 HUS develops in 2-15% of patients with shigatoxin-producing E. coli, and is 
characterized by dysentery, followed 5-7 days later by microangiopathic hemolytic 
anemia, thrombocytopenia, and acute renal failure (ARF) [12].  The exact 
pathogenesis of ARF remains unclear but may be directly toxin-mediated or induced 
by microangiopathic hemolysis and thrombosis [12].  Although most cases of HUS 
have stx2-positive E. coli, some HUS and ARF cases are associated with shigatoxin-
negative and non-O157:H7 E. coli, suggesting that other virulence factors are 
involved and need to be elucidated [12, 13].  Genes for shigatoxins are carried on 
bacteriophages and are often integrated into the bacterium’s chromosome.  Thus 
antimicrobial drugs that damage DNA or inhibit DNA synthesis (including 
fluoroquinolones and sulfonamides) encourage integrated lysogenic bacteriophages to 
exit the host chromosome, replicate quickly, lyse the host bacterium, and invade new 
bacteria.  This process causes a dramatic increase in toxin production, thus worsening 
systemic disease and overall prognosis; therefore supportive care is warranted but 
antimicrobial therapy may be more harmful than beneficial in cases of EHEC [14].   
 Cattle represent the largest reservoir of EHEC, and management of food 
contamination from this source is a major public health concern.  Adult cattle can 
carry and intermittently shed E. coli O157:H7 as enteric commensal organisms 
without becoming ill.  EHEC may also be found in calves and lambs with diarrhea 
and dysentery.  In pigs, EHEC causes edema disease, which affects the fastest-
growing post-weanling piglets, and is characterized by inappetence, severe edema, 
neurologic disease, and sudden death [11].  
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 Dogs and cats can be healthy carriers or develop diarrhea or HUS from EHEC 
[15].  A prevalence study documented 3.1% of dogs on feedlots and dairy farms had 
positive fecal samples for E. coli O157:H7 [16].  Another study analyzed canine feces 
collected from 4 beaches and isolated E. coli O157:H7 from 7.8% of samples [17].  A 
study in urban Argentina isolated stx2-positive EHEC from 3.7% of dogs and 4% of 
cats but concluded that dogs and cats were not a major reservoir for EHEC in children 
[18].  Dogs are susceptible to CRGV, a systemic disease similar to HUS involving 
ARF, vasculitis with pitting edema and ulceration of the distal limbs, 
microangiopathic anemia, and thrombocytopenia [19].  CRGV has most often been 
reported in young adult racing greyhounds, and consumption of raw condemned 
contaminated beef has been implicated as a source.  Due to its similarities with HUS, 
a shigatoxin produced by EHEC is the suspected etiology [11]. 
 Enteropathogenic E. coli (EPEC) causes watery secretory diarrhea in infants 
in developing countries as well as in dogs, rabbits, and young farm animals.  
Gastroenteritis from EPEC is invasive and triggers a large inflammatory response.  
Toxins are not a major component of EPEC’s virulence, however an enterotoxin, 
EspC, has been identified in a PAI within EPEC and most likely plays an accessory 
role in its pathogenesis [20].  Important adhesins include bundle forming pili in dogs 
and Ral in rabbits.  The attaching and effacing lesion has a critical role in EPEC 
pathogenesis.  After loose adhesion, type III secretion system genes are expressed in 
E. coli and inject proteins for tight adhesion and signal transduction into intestinal 
cells, including a receptor, Tir, for the adhesin intimin.  This triggers rearrangement 
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of underlying actin, villi destruction, and influx of white blood cells.  Diarrhea may 
be caused by destruction of the host cells with subsequent malabsorption and 
translocation of water and electrolytes or by alteration of the signal transduction 
pathways causing electrolyte and water loss.  EPEC was a common cause of 
infectious diarrhea in dogs in one study, isolated from 35% of dogs with acute 
diarrhea, 31% of dogs with chronic diarrhea, and 6% of healthy control dogs [21].  
Puppies from 1-3 months of age living in overcrowded pet shops or kennels may be at 
increased risk for EPEC diarrhea, but dogs of all ages can be affected [11, 21]. 
 Gastroenteritis caused by enterotoxigenic E. coli (ETEC) is most often a 
problem with infants and children in developing countries or “travelers’ diarrhea” in 
adults, but can also affect farm animals and dogs.  ETEC are usually acquired from 
drinking water contaminated with sewage, but the infectious dose is higher than for 
other strains of E. coli [22].  Major virulence factors present in ETEC are adhesins 
(fimbriae, type 1 pili, adhesin involved in diffuse adherence, and colonization factor 
antigens) and enterotoxins (various heat-stable and heat-labile toxins).  The genes for 
enterotoxins and adhesin colonization factor antigens are carried on plasmids and can 
be easily transferred among E. coli in the GI tract [23]. 
 Disease caused by ETEC is characterized by a toxin-induced secretory watery 
diarrhea with mild inflammation and no significant histopathologic changes.  
Diarrhea is self-limiting in healthy adults; however, in infants or immunosuppressed 
patients it can cause dehydration, metabolic acidosis, shock, and death.  It is the most 
common cause of diarrheogenic E. coli in farm animals, and in pigs it often 
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progresses to shock and death prior to the development of diarrhea, likely from an 
acute release of LPS endotoxin [11].  In dogs, studies have shown that 2-31% of 
diarrhea cases have been associated with ETEC, usually in young animals and most 
often involving the STa toxin [24].  In contrast, ETEC has low prevalence in healthy 
dogs and both healthy and diarrheic cats [21, 24]. 
 Enteroinvasive E. coli (EIEC) has specific tropism for colonic cells, where it 
penetrates, invades, and causes destruction.  EIEC enters the GI wall via M cells, 
which are antigen-sampling cells, and it avoids immune destruction by inducing 
apoptosis of macrophages [25].  Virulence factors include nonfimbrial adhesins that 
likely involve outer membrane proteins.  Transmission is from fecal-oral exposure, 
either directly or through contaminated food or water, and the infectious dose is as 
low as 10 organisms [26].  Clinical signs occur within 12-72 hours of ingestion, and 
include fever, dysentery, and abdominal pain.  This presentation is very similar to 
Shigella infection, and the two are often confused clinically.  Although EIEC 
infections are usually self-limiting, complications including HUS can occur, 
especially in pediatric patients.  EIEC has low prevalence in canine GI disease but has 
been associated with cases of both acute and chronic diarrhea [21]. 
 Enteroaggregative E. coli (EAggEC) infection causes persistent diarrhea in 
children in developing countries, but this virotype has not been identified as causing 
disease in dogs.  Like ETEC, it binds to small intestinal cells, is not invasive, and 
causes no inflammation or histological changes.  Unlike ETEC, it does not bind 
uniformly, but rather in clumps or aggregates like stacked bricks.  Virulence factors 
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present in EAggEC include very thin fibrillar adhesins, an enterotoxin, and 
hemolysin.  The enterotoxin is similar to the heat-stabile toxin in ETEC.  Hemolysin, 
which is also produced by UPEC, forms pores in host cell membranes.  The complete 
role of both enterotoxin and hemolysin in the virulence of EAggEC has not yet been 
fully elucidated.   
 Most pathogenic intestinal E. coli causing disease in dogs are EPEC and 
ETEC, but E. coli strains more characteristic of ExPEC have recently been implicated 
as the cause of histiocytic or granulomatous ulcerative colitis in Boxer dogs [27].  
Colonic thickening and ulceration with loss of goblet cells occurs, causing severe 
chronic large bowel diarrhea with frequent bloody mucoid feces and dramatic weight 
loss in young Boxer dogs, usually less than 4-years-old.  Traditionally, the suspected 
etiology has been breed-specific immune-mediated inflammatory bowel disease.  A 
recent study using in situ hybridization documented E. coli adhering and invading the 
colonic mucosa and localizing within histiocytes of affected Boxer dogs, while dogs 
with other types of colitis had no invasive or intracellular E. coli [27].  PCR 
virotyping and phylogenetic analysis found these E. coli more characteristic of UPEC 
than intestinal pathogenic E. coli [27].  A second study used immunohistochemistry 
and found positive immunoreactivity to E. coli antibodies, demonstrating presence of 
E. coli antigen, in every section of diseased colon from 10 dogs with ulcerative colitis 
[28].  Since other enteropathogenic bacteria tested for were not immunoreactive, it 
was concluded that E. coli is the causative agent of this disease in Boxer dogs [28].  
Historically, cases of ulcerative colitis in Boxer dogs have been treated with 
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immunosuppressive therapy with minimal success, and most cases have been 
euthanized because of this condition; however, recent success with antimicrobial 
treatment, specifically enrofloxacin and metronidazole, supports the theory of an 
underlying infectious cause such as E. coli [29]. 
 
Extraintestinal Pathogenic E. coli  
 Although it traditionally does not cause intestinal disease, extraintestinal 
pathogenic E. coli (ExPEC) can be isolated from the GI tract with commensal E. coli 
strains [30].  ExPEC colonizes the oropharynx, colon, and vagina, and in accordance 
with the pathogenicity theory, virulence factors help it gain access to normally sterile 
locations such as the urinary tract [30, 31].  ExPEC can cause a wide variety of 
disease and be associated with high morbidity, mortality, and healthcare costs [30].  
In human medicine, ExPEC infections of major importance include: urogenital tract 
infections, peritonitis, neonatal meningitis, surgical wound infections, and bacteremia 
[30].  In veterinary medicine, a prevalence study of nonenteric E. coli cultured from 
dogs found 63% isolates from the urinary tract, 9% from skin, 7.7% from the 
respiratory tract, 6.7% from the ear, 6.4% from the female reproductive tract, 3.7% 
from the male reproductive tract, and 3.4% from other organ systems [32].  Other 
reports describe ExPEC in cats causing UTIs [33, 34], prostatitis [35], endocarditis 
[36], septic peritonitis [37], and hepatic abscesses [38].  The various combinations of 
virulence factors present in different ExPEC strains allows them access to and ability 
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to invade organs throughout the body, making E. coli a significant pathogen in both 
human and veterinary medicine. 
  E. coli bacteremia can be caused by translocation through an immature or 
damaged GI tract, secondary to pyelonephritis or pneumonia, or external introduced 
from intravascular catheters or traumatic wounds.  Neonatal puppies and kittens may 
acquire ExPEC from their mother’s vaginal flora, milk, or feces [39].  Parvovirus is a 
common precursor to septicemia in older puppies and adult dogs, with E. coli 
translocating through the damaged GI tract [24].  ExPEC can persist outside of the GI 
tract partly because they possess virulence genes for iron acquisition, specifically 
aerobactin, allowing adaptation to iron-restricted areas of the body [11].  Other 
virulence factors that contribute to serum resistance and help avoid phagocytosis are 
the O polysaccharide, capsular antigens, and p fimbriae, while LPS directly triggers 
septic shock.  Isolation of E. coli from the bloodstream carries a mortality rate of up 
to 31% in people, and perhaps higher in animals [30]. 
 Like bacteremia, meningitis caused by E. coli is a problem in infants.  These 
ExPEC are acquired from the mother’s urogenital tract or environment and are spread 
from either the nasopharynx or GI tract to the meninges, where they cause 
inflammation.  The major virulence factor involved is the K1 capsular antigen, which 
is present in 35-38% of GI E. coli strains, but is found in 79% of neonatal meningitis 
strains [7].  The K1 antigen is a poor immunogen, thus bacteria with this capsule 
avoid phagocytosis and destruction by complement.  Protective anti-K1 antibodies are 
found in adults; however, these antibodies are restricted to an immunoglobulin 
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subclass that does not readily cross the placenta, leaving neonates unprotected.  
Antimicrobial resistance has been an increasing problem with neonatal meningitis, 
with up to 85% of cases being resistant to ampicillin, and case fatality rate ranges 
between 25-40% [30].  
 Pneumonia caused by E. coli is usually acquired by aspiration of enteric 
bacteria, however other routes of transmission are also possible, such as inhalation of 
bacteria or secondary to sepsis from GI translocation.  In human beings, E. coli is a 
major cause of nosocomial pneumonia, due to increased oropharyngeal colonization 
of E. coli during times of illness and antimicrobial therapy [30].   In dogs, there are 
several reports of peracute hemorrhagic pneumonia caused by E. coli [40, 41].  
Shipment of dogs may increase risk by inducing immunosuppression, stress colitis 
which can compromise GI integrity and allow translocation, or vomiting from motion 
sickness followed by aspiration [40].  Cytotoxic necrotizing factor (cnf), hemolysin 
(hlyD), and pyelonephritis associated pili G allele III (papGIII) have all been 
identified from ExPEC isolated from these cases and likely contribute to pathogenesis 
of fulminant fatal pneumonia [40, 41].   
 E. coli frequently infect the reproductive organs causing mastitis, pyometra, 
metritis, and prostatitis.  Mastitis can be caused by hematogenous spread of E. coli, 
traumatic introduction into the mammary gland, or ascending infection through the 
teat or nipple.  Most women and bitches with mastitis respond well to oral 
antimicrobial therapy, but some infections progress to necrotic abscesses requiring 
surgical drainage or removal.  Pyometra is accumulation of purulent material within 
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the uterus of a bitch or queen within 8 weeks of standing heat or induction of 
ovulation [42].  Estrogen, followed by progesterone production, induces cystic 
endometrial hyperplasia, which makes the uterus more prone to infection and 
inflammation.  This is followed by bacterial infection, most commonly with E. coli 
ascending from normal vaginal and fecal flora.  E. coli become trapped in the uterus 
by functional closure of the cervix and produce endotoxemia leading to septic shock 
and ARF.  Endotoxemia occurs when LPS endotoxins are released from E. coli cell 
walls and stimulate release of local cytokines including tumor necrosis factor, 
interleukins, and platelet activating factor.  These cytokines contribute to hypotension 
and shock.  E. coli endotoxins decrease sensitivity of renal tubules to vasopressin, 
decreasing water reabsorption and causing polyuria and polydipsia and ARF [43].  
Glomerulonephritis secondary to antibody-antigen complex deposition in glomeruli 
may also result from bacterial pyometra [42].   Recommended treatment of pyometra 
in dogs and cats is ovariohysterectomy and antimicrobial therapy, and prognosis is 
generally good, although complications including sepsis, shock, and death can occur 
if not diagnosed and treated promptly.  In women, bacterial endometritis is a common 
complication of cesarean section, with polymicrobial infections including E. coli 
occurring despite prophylactic antimicrobial therapy [44].   
 In men, prostatitis is most commonly caused by E. coli, and hemolysin has 
been identified as the main virulence factor in its pathogenesis [45].  E. coli isolated 
from prostatitis cases are more likely to produce biofilms than isolates from cystitis or 
pyelonephritis cases, which likely contributes to the persistent nature of prostatitis 
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[45].  E. coli is the most common cause of prostatitis in dogs and is responsible for 
the only reported case of bacterial prostatitis in a cat [6, 35].   
 
Uropathogenic E. coli 
 The most common type of ExPEC is uropathogenic E. coli (UPEC), which 
adhere, multiply and persist in the urinary tract causing UTI.  E. coli is the most 
prevalent bacterial species isolated from UTIs in both human beings and dogs.  UPEC 
cause up to 95% of uncomplicated cystitis cases and over 90% of uncomplicated 
pyelonephritis cases in women [30, 46].  In dogs, E. coli is isolated from 44% of all 
UTIs and up to 47% of recurrent and persistent UTIs [47-49].  This high prevalence 
of E. coli UTI corresponds to a significant economic impact, with an estimated 1.6 
billion dollars spent annually on community-acquired UTIs in human beings [50].  
The tendency of clinicians to treat UTIs empirically with antimicrobial therapy has 
also contributed to increased antimicrobial-resistant E. coli UTIs  [30, 51].   For these 
reasons, there has been a strong research focus on the epidemiology of UPEC, the 
various manifestations of clinical disease caused by UPEC, and strategies to control 
emerging antimicrobial resistance within UPEC. 
 Individual UTIs can be classified as simple or complicated, symptomatic or 
asymptomatic, community-acquired or nosocomial, and by location within the urinary 
tract.  Simple UTIs occur when there is a temporary breach in the host’s local 
defenses, allowing bacteria to ascend, adhere, multiply, and persist.  In contrast, 
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complicated UTIs occur with an underlying structural, functional, or neurologic 
defect, involvement of the kidneys or reproductive tract, or a concurrent 
immunosuppressive disease or medication.  Specific factors that predispose 
development of complicated UTIs in human beings and dogs include: alteration of 
normal flora with antimicrobial therapy, indwelling urinary catheters, concurrent 
urologic disease, spinal cord injury, diabetes mellitus, and immunosuppression from 
either disease (human immunodeficiency virus) or medication (glucocorticoids or 
chemotherapy) [6, 50].  Although most UTIs are symptomatic, some women and dogs 
remain asymptomatic, which may occur due to a lack of or decreased expression of 
adhesin virulence factors within the strain of UPEC [52].  Community-acquired UTIs 
develop outside of a hospital, and these infections tend to be symptomatic, causing 
the patient to seek medical attention quickly, and responsive to treatment.  
Nosocomial infections develop while a patient is hospitalized, may be recognized and 
treated later in the course of the infection, and tend to be more resistant to 
antimicrobial therapy.  Location within the urinary tract is also important, with 
bladder infections (cystitis) often being uncomplicated and more responsive to 
treatment, whereas renal infection (pyelonephritis) or prostatic infections (prostatitis) 
cause more systemic illness and require longer courses of antimicrobial treatment. 
 Two etiological theories of bacterial UTI include the prevalence theory and 
the pathogenicity theory [53, 54].  The prevalence theory suggests that bacteria with 
high prevalence in the GI tract and perineum are likely to spread horizontally across 
urogenital mucosa and ascend the distal urethra.  Supporting studies have shown that 
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the strain of UPEC colonizing the bladder of dogs with UTI was also the predominant 
strain of E. coli colonizing the GI tract [55, 56].  Although E. coli are highly prevalent 
in the GI flora, other bacteria with high prevalence, such as Bacteroides, are not 
frequently isolated from UTIs, suggesting other factors are likely involved.  The 
pathogenicity theory suggests that only bacteria possessing virulence factors giving 
them enhanced ability to colonize and invade the urinary tract will succeed in 
traveling from the GI tract or urogenital flora to ascend the urinary tract and cause 
infection [53, 55].    
 Most strains of UPEC possess multiple virulence factors that contribute to 
development and severity of UTI.  These urovirulence factors are rare in commensal 
GI E. coli strains [30].  Using PCR to test for urovirulence factors in fecal E. coli 
allows differentiation between benign commensal enteric organisms and potential 
pathogens of the urogenital tract.  Urovirulence factors are identified and studied by 
comparing their presence in infected urine with their presence in the fecal flora of 
healthy volunteers and patients with UTI [7, 55].  These virulence factors can then be 
further refined by classifying them by location of UTI and severity of clinical signs 
with which they are associated.  Identifying prevalence of these virulence factors in 
healthy fecal samples has also been used to search for reservoirs of UPEC, and dogs 
have been implicated as a potential source [56-58].  Specific virulence factors found 
in UPEC include: type 1 fimbriae, P fimbriae, S fimbriae, hemolysin, aerobactin, 
cytotoxic necrotizing factor, capsular polysaccharide antigens, and serum resistance.  
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 The ability to adhere to uroepithelium is a crucial step in colonization and 
establishing a UTI, because it protects bacteria from mechanical removal during 
micturition.  Fimbriae (from the Latin word for threads) also known as pili (from the 
Latin word for hairs) are adhesin virulence factors that are long thin extensions from 
bacteria facilitating attachment to epithelial lining, erythrocytes (hemoagglutination), 
leukocytes, platelets, spores, sperm, pollen, and latex beads [7].  Adherence is also, in 
part, determined by host factors [7].  E. coli isolates from recurrent UTIs did not 
adhere more strongly than other E. coli strains to control vaginal epithelial cells; 
however, vaginal cells from patients with recurrent UTIs had greater adherence 
capacity for standard E. coli strains than vaginal cells from control patients, 
suggesting altered host cells rather than increased bacterial virulence [7]. 
 Type 1 fimbriae are mannose-sensitive adhesins, commonly expressed in both 
intestinal and extraintestinal E. coli.  Receptors comprised of mannose residues are 
widespread throughout the body, and type 1 fimbriae play an important role in E. coli 
adherence within the oral cavity, intestinal cells, vaginal cells, and urinary tract.  
During UTIs, type 1 fimbriae help trigger host defenses by mediating adherence to 
phagocytes, stimulating phagocytosis and releasing toxic granules, and ultimately 
inducing destruction of E. coli [59].  E. coli with type 1 fimbriae strongly adhere to 
Tamm-Horsfall proteins within urine, inhibiting their binding to uroepithelial cells 
and promoting excretion of E. coli during micturition [59].  Type 1 fimbriae have also 
been associated with persistent infections, specifically in patients with long-term 
indwelling urinary catheters [60].   
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 Expression of type 1 fimbriae is affected by environmental conditions and 
undergoes phase variation controlled at the transcriptional level [7].  Phase variation 
is a type of polyphenism, where one genotype can be manifest as several different 
phenotypes.  Phase variation occurs when the promoter for type 1 fimbriae is on an 
invertible element of DNA.  Specifically, two homologous regions of DNA form a 
loop containing the promoter, allowing two fimbrial genes to come into close contact.  
Invertase recognizes homologous sites and allows site-specific recombination and 
inversion of the looped DNA, switching the promoter’s direction.  When the promoter 
faces the structural genes, the E. coli are phase on and produce type 1 fimbriae, when 
the promoter is inverted the E. coli are phase off and do not produce type 1 fimbriae 
[61].  Type 1 fimbrial phase variation is regulated by three global regulators: leucine-
responsive regulatory protein, integration host-factor, and histone-like proteins [62].  
 Research aimed at transcriptional manipulation and development of vaccines 
targeting type 1 fimbriae and their receptors is ongoing to minimize adherence of 
UPEC and establishment of UTI [62].  D-mannose is used as a nutraceutical to 
competitively bind FimH on type 1 fimbriae, blocking adherence of UPEC to 
mannose receptors on the uroepithelium.  A benefit of d-mannose is that it can help 
control UTIs without risk of altering the GI or urogenital flora or inducing selection 
pressure. 
 P fimbriae adhere to glycolipids with specific Galactose(α1-4)Galactoseβ 
(Gal-Gal) moiety receptors on P-blood-group antigens expressed throughout the 
urinary tract and are considered mannose-resistant adhesins.  While type 1 fimbriae 
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receptors predominate in the urinary bladder, receptors for P fimbriae predominate in 
the renal uroepithelium, and P fimbriae are thought to facilitate ascending infection to 
the ureters and kidney [63].  Binding of E. coli with P fimbriae to Gal-Gal receptors 
in the kidneys triggers inflammation, permits renal damage, and can result in 
pyelonephritis.  While type 1 fimbriae are commonly found on commensal E. coli in 
the GI tract of healthy human beings, P fimbriae are more often found on E. coli 
strains in the GI tract of human beings with pyelonephritis than from fecal flora of 
healthy individuals [7].  For this reason, detection of P fimbriae is a common marker 
of urovirulence in E. coli isolates.  The genes for P fimbriae are contained on a 
chromosomal multicistronic gene cluster named pyelonephritis-associated pili (pap) 
[7].  Various subunits are named Pap and designated with a letter, such as PapA, 
which is the major structural subunit, and PapG, which is the major adhesin that binds 
to Gal-Gal.  PapGIII has been associated with presence of cnf, hly, and sfa and has 
been found on E. coli isolated from both dogs and human beings [64-66]. 
 S fimbriae adhesins (sfa), also mannose-resistant adhesins, are named for their 
binding to sialosyl-oligosaccharide residues on the uroepithelium throughout the 
urinary tract and other extraintestinal sites [67].  S fimbriae mediate binding to human 
erythrocytes that express blood group antigens other than blood group P, but they also 
mediate binding to renal epithelium in dogs with pyelonephritis.  In human beings S 
fimbriae are more frequently associated with neonatal meningitis and bacteremia than 
with UTI [7].   
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 Alpha-hemolysin is a cytolytic toxin secreted by some strains of E. coli and is 
found with a high prevalence in cases of pyelonephritis in dogs and human beings 
[67-69].  The toxin damages neutrophils, monocytes, mast cells, basophils, 
lymphocytes, platelets, and renal epithelial cells [67].  Its production is partially 
regulated by local iron concentrations, with more hemolysin being produced in low 
iron conditions, thus making iron available for bacterial metabolism.  In UTIs, α-
hemolysin causes uroepithelial cell lysis, triggers inflammation, and impairs host 
defenses [7].  Alpha-hemolysin promotes neutrophil degranulation and release of 
leukotrienes, mast cells to release histamine, and impairs both phagocytosis and 
chemotaxis [7].   
 Aerobactin (aer) is part of a bacterial iron sequestration and transport system 
that makes iron available for bacterial growth in iron-poor environments.  This is 
beneficial during infections when iron supplies are limited, in dilute urine, and in 
complement-depleted serum [70].  Iron is a critical nutrient utilized for oxygen 
transport and storage, DNA synthesis, electron transport, and peroxide metabolism 
[7].  During inflammation and infection, iron is sequestered within macrophages of 
the liver, spleen, and bone marrow, in an attempt to inhibit bacterial replication [71].  
Aerobactin extracts Fe3+ (oxidized iron) from host iron-binding proteins and delivers 
it directly to bacterial iron centers [72].  The aerobactin system is commonly found in 
intestinal strains of E. coli, but prevalence is greatest in strains isolated from cases of 
pyelonephritis, cystitis, and bacteremia [7, 73].  One study identified aer in 78% of E. 
coli strains from the blood of human patients with urosepsis [70].  Aer are carried on 
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chromosomal DNA or plasmids.  Chromosomal location is more commonly 
associated with noncompromised patients and concurrent uropathogenic virulence 
factors such as P fimbriae and hemolysin [70].  Plasmid location is associated with 
compromised patients and multiple antimicrobial resistance genes [70].  This suggests 
that antimicrobial therapy may select for both virulent and resistant strains leading to 
increasingly severe UTI and urosepsis in already compromised human beings [7, 70].  
Cytotoxic necrotizing factor (cnf) is a bacterial protein toxin that causes direct 
uroepithelial cell injury, cytoskeletal rearrangement, and inflammation.  It may 
contribute to progression of a UTI to febrile pyelonephritis or sepsis [69].  While cnf 
is commonly expressed in E. coli isolates from human beings with pyelonephritis, it 
has only recently been found in fecal strains from human beings [67, 74].  Cnf is 
found with high frequency in E. coli strains isolated from UTIs of both dogs and cats; 
however, cnf is also expressed in E. coli strains from dogs with diarrhea and from 
feces of healthy cats [75-77].    
Capsules are polymers, usually composed of repeating carbohydrate subunits 
that coat the bacterial cell and protect it from host defense mechanisms.  More than 
80 antigenic types of capsular polysaccharides have been described in E. coli [67].  
The K1 capsule is the most common capsule overall and in UPEC.  The K1 capsule is 
often found concurrently with P fimbriae, while the K5 capsule is commonly found 
with hemolysin [67].  Capsules have a negative charge and are hydrophilic, which 
help prevent phagocytosis [67].  They block opsonization, interfere with activation of 
the complementation cascade, and contribute to serum resistance [67].  K1 capsules 
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are expressed more often in E. coli isolated from the urinary tract than from the GI 
tract.  Within the urinary tract, K1 capsules are more prevalent in isolates from 
pyelonephritis than cystitis [7].   
Serum Resistance refers to E. coli’s ability to avoid being killed by serum 
complement.  The property of serum resistance stems from a combination of factors, 
such as capsular polysaccharides, O-polysaccharide side chains, and various surface 
proteins that block the membrane attack complex of serum complement from binding 
to the outer membrane of E. coli [7].  E. coli isolates from urine of patients with 
cystitis and pyelonephritis are often serum resistant, while similar isolates from 
patients with asymptomatic bacteriuria and isolates from feces are most commonly 
serum sensitive [7]. 
 Studies involving UPEC isolates from human beings and dogs with UTI have 
identified virulence characteristics that occur in both species, and dogs have been 
considered a possible reservoir for UPEC in human beings [57, 58, 66, 78].  The most 
frequently identified urovirulence factor genes in UPEC isolates from dogs with UTI, 
are pap, sfa, hly, aer, and cnf [69, 75, 79].  These same virulence factors play an 
important role in the pathogenesis of human UTI, and the prevalence of these 
virulence genes in E. coli isolates from urine of human beings and dogs with UTI are 
comparable [74, 80].  Surprisingly, two studies have shown that isolates from feces of 
healthy cats have these same urovirulence genes in high frequency, suggesting cats 
may be reservoirs of UPEC for dogs and human beings [74, 77].   
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 Although evidence of similar virulence factor patterns between species is 
suggestive of transmission of clonal E. coli between species, this could also be from 
concurrent acquisition from a common source in the environment; therefore, 
multiplex PCR for virulence factor patterns is not useful for determining clonal 
relatedness between human and canine strains.  Such comparisons require DNA 
analysis (fingerprinting or sequencing) that includes broader and more conserved 
portions of the bacterial genome.  In the future, virotyping of E. coli isolates from 
canine UTI may be of prognostic value to help determine likelihood of ascension to 
pyelonephritis or persistence of recurrence of infection.  Urovirulence factors may 
also provide new targets for treating or preventing UTI [81]. 
 
Antimicrobial Resistance 
 Prescription of antimicrobial therapy for treatment of pathogenic E. coli 
infections can be either empirical or based on susceptibility testing.  Traditionally, 
physicians have chosen empirical therapy for UTIs because E. coli isolates have been 
predictably susceptible to common antimicrobial drug choices.  Empirical therapy is 
economical, saving the cost of culture and susceptibility testing.  The empirical 
antimicrobial drug of choice for UTIs in women has been trimethoprim-
sulfamethoxazole, but antimicrobial resistance has become a problem, with 18% of 
human UTI isolates resistant to this drug [82, 83].  Resistance is also increasing to 
other antimicrobial agents commonly used for UTIs, such as ampicillin and 
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cephalothin, and for this reason, newer antimicrobial agents such as fluoroquinolones 
are being prescribed with increased frequency [46, 83].  As a consequence of this 
shift in antimicrobial choice, resistance to fluoroquinolones is now emerging, 
especially within UPEC [84-86].  Because of this emerging antimicrobial resistance, 
clinicians should no longer rely on empirical treatment to be effective, but instead 
should determine the susceptibility pattern for each isolate from patients with UTI 
and treat accordingly [51].  
 Antimicrobial resistance can either develop from a mutation within the 
bacterial genome or be acquired from other bacteria through genetic transfer.  Certain 
mutations enhance survival when exposed to a specific antimicrobial agent.  Clonal 
replication then creates an entire population of resistant bacteria.  In the mixed flora 
of the GI tract, selection pressure occurs as a response to antimicrobial treatment, 
whereby susceptible bacteria die, while mutated, resistant clones survive and flourish.  
This increases the proportion of resistant bacteria within the GI tract that are shed into 
the environment and can potentially spread to the urinary tract.  
 General categories of mutations that have been identified and linked with 
resistance to antimicrobial agents include: decreased uptake or increased efflux of the 
drug, alteration or destruction of the drug, modification of the drug’s target, or 
bypassing the drug’s mechanism of action.  Decreased uptake via alteration in porin 
expression and pumping the drug out of the bacterium via efflux mechanisms have a 
role in development of resistance to fluoroquinolones by E. coli and other 
Enterobacteriaceae [87].  Common examples of bacterial products that alter and 
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destroy antimicrobial drugs are beta-lactamase and extended spectrum beta-
lactamases.  Many strains of E. coli produce beta-lactamases, and E. coli strains able 
to produce extended-spectrum beta-lactamases are relatively common in healthcare 
settings [87].  Other enzymatic alterations that can render antimicrobials ineffective 
are acetylation of aminoglycosides and phosphorylation of chloramphenicol [88].  
Modifying the drugs’ target can occur by mutations in the penicillin-binding protein 
for beta-lactam drugs, the ribosome binding sites for tetracyclines and macrolides, or 
the DNA gyrase or topoisomerase IV for fluoroquinolones.  By preventing binding of 
antimicrobial agents to their receptor and site of action, these mutations protect the 
bacteria from the actions of these drugs.  Finally, some bacteria have developed ways 
to survive even when the antimicrobial agent reaches sufficient concentrations, is not 
inactivated, and successfully binds to its target.  An example of this bypass 
mechanism is bacteria that have developed an alternate mechanism for folic acid 
synthesis in the face of trimethoprim-sulfamethoxazole, an antimicrobial drug that 
interferes with folic acid metabolism [89].  
 Once genetic mutations occur within bacteria and are selected for, mutated 
genetic material can be transferred between commensal and pathogenic bacteria 
within host species and in the environment.  There are three main mechanisms of 
genetic transfer of antimicrobial resistance: transformation, transduction, and 
conjugation.  These mechanisms have already been discussed at length in the section 
on acquisition of virulence, and mechanisms of horizontal genetic transfer are the 
same for virulence factors as for antimicrobial resistance genes.  Conjugation is 
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responsible for the majority of genetic transfer of antimicrobial resistance, and it has 
been estimated that approximately 85% of therapy failure in treating 
Enterobacteriaceae with ampicillin, trimethoprim-sulfamethoxazole, gentamicin, and 
chloramphenicol is due to conjugation-induced resistance [90].   
 Concern regarding emerging antimicrobial resistance often centers on 
antimicrobial use in livestock and transfer of resistance through the food chain.  
Antimicrobial therapy is used in livestock for both therapeutic purposes and growth 
promotion.  Bacteria within the GI tracts of livestock may develop mutations causing 
primary resistance, or livestock may acquire resistant bacteria from the environment, 
other animals on the farm, or human beings with whom they are in contact.  
Antimicrobial therapy creates selective pressure within the livestock’s GI tract, 
increasing number and proportion of resistant bacteria [91].  This selective pressure 
disturbs the host’s normal flora and colonization resistance, lowering the minimal 
infectious dose of further resistant or pathogenic bacteria, and increasing shedding 
dose and duration of resistant bacteria [92].  By horizontal gene transfer, resistant 
genes from commensal bacteria can be spread to zoonotic pathogenic bacteria within 
the GI tract.  Resistant commensal and pathogenic bacteria can be shed into the 
environment and act as a fecal reservoir of resistant genes.  
 Ultimately, shedding resistant bacteria can result in indirect fecal-oral 
transmission to other animals on the farm, farmers, slaughterhouse workers, and 
consumers.  Accepting sick animals for slaughter and entry into the food chain, and 
poor hygiene at slaughterhouses allowing GI contents to spill and contaminate meat 
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may increase the risk of propagating resistant bacteria.  The US Department of 
Agriculture (USDA) regulations and surveillance have minimized contamination of 
meat, but ground beef contaminated with E. coli continues to reach consumers.  
Irradiation is highly effective at destroying bacteria within contaminated meat prior to 
commercial sales without altering flavor or appearance; however, until irradiation 
becomes routinely performed for ground beef, consumers should take precautions by 
cooking meat thoroughly and avoiding cross-contamination within the kitchen.   
 Fresh produce can be a source of resistant bacteria spread from animals to 
human beings.  Produce can be contaminated with E. coli on the farm by fertilizing 
with contaminated animal feces, allowing wild pigs to defecate on crops, and by not 
providing sufficient restrooms, sanitary sewage disposal, or hand-washing facilities 
for farm workers resulting in crops contaminated with human fecal material.  Other 
potential routes include contaminated irrigation water or aerosolized bacteria spread 
by wind, insects, or birds.  Although recommendations can be made for proper human 
hygiene, fertilization, water testing, and fences to minimize wild animals, not all 
potential sources of contamination can be prevented.  It is inevitable that 
contaminated produce will continue to enter the food supply.  As with meat, 
precautions must be taken by consumers to minimize risk of ingesting contaminated 
produce, including: washing produce with warm water, scrubbing outer surfaces of 
produce, discarding outer leaves of lettuce and washing inner leaves carefully, good 
general kitchen hygiene, and caution to avoid cross-contamination of knives, cutting 
boards, countertops, and other kitchen areas [93].   
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 A method to monitor and survey antimicrobial resistance in healthy 
populations of livestock, companion animals, and human communities is to routinely 
collect and test fecal samples from these hosts.  Indicator bacteria, such as E. coli and 
Enterococcus faecalis, represent commensal GI bacteria within fecal flora.  
Antimicrobial use within a host results in increased resistance among these indicator 
bacteria, and susceptibility patterns give an objective prevalence of resistance.  This 
information helps predict the risk of resistance within pathogenic or zoonotic bacteria 
within the same host, and the degree to which the host may be a reservoir for cross-
species transmission [92].  A study of fecal indicator bacteria from healthy dogs 
found that multiple drug resistant (MDR) E. coli strains were rarely isolated from 
individually owned dogs compared with strains from kennel dogs [94].  In a separate 
study, each day of hospitalization in the intensive care unit (ICU) increased a dog’s 
odds of being colonized by an ampicillin-resistant E. coli by a factor of 2.6, by an 
amoxicillin-clavulanate-resistant E. coli by a factor of 1.6, or by a strain of E. coli 
resistant to both ampicillin and cephalothin by a factor of 1.5 [95].  There was no 
significant association between concurrent beta-lactam treatment and development of 
antimicrobial resistant fecal E. coli found in this study; however, dogs that were 
treated with enrofloxacin were 25.6 times more likely to have fluoroquinolone-
resistant fecal E. coli than dogs that did not receive any antimicrobial treatment [95].  
Similarly, comparison of fecal indicator bacteria from different groups of cats has 
determined that hospitalized and cattery cats have more resistant indicator bacteria 
than individually owned cats [96].  These studies help to determine potential risk 
 35
factors for development of resistance within the GI tract and document that the flora 
of healthy dogs and cats can act as reservoirs of resistant genes.  Surveys of 
antimicrobial resistance trends in indicator bacteria also provide objective measures 
to evaluate efforts to control resistance.   
 Although antimicrobial use in livestock has been implicated in increasing 
antimicrobial resistance in human beings, strategies to control this potential problem 
are widely debated.  Swedish legislation now prohibits antimicrobial use for growth 
promotion and strictly regulates sales of antimicrobial drugs, which has led to a 
decrease in overall antimicrobial resistance in animals [97].  Similar legislation with 
strict control and limitation of antimicrobial use in animals has been proposed in the 
United States, and in 1995 the Food and Drug Administration (FDA) banned the use 
of enrofloxacin in poultry [98].  The American Veterinary Medical Association 
Legislative Advisory Committee has opposed further legislation in the United States 
because banning antimicrobial use for therapeutic purposes presents risk to animals’ 
health and welfare without evidence of protecting or improving human health [99]. 
 In addition to concern about misuse of antimicrobial agents in livestock, 
misuse of antimicrobial therapy in human beings and companion animals is also 
recognized.  Physicians and small animal veterinarians often prescribe antimicrobial 
therapy indiscriminately and empirically and often select broad-spectrum rather than 
narrow-spectrum therapy.  Incorrect dose, interval, and duration allow selection 
pressure and promotion of resistant bacteria.  In veterinary medicine, off-label use of 
antimicrobial agents and over-the-counter purchase and use of antimicrobial agents 
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are additional methods that contribute to emerging antimicrobial resistance.  Finally, 
pharmaceutical companies may contribute to emerging resistance via marketing 
pressure of new, expensive, broad-spectrum antimicrobial drugs for infections that 
may respond equally well to older, less-expensive, narrow spectrum drugs [100].  In 
light of this problem, many human and veterinary hospitals have developed 
antimicrobial use guidelines, and while some have seen positive effects including 
decreased overall antimicrobial therapy and decreased antimicrobial resistance, 
continued monitoring, analysis, and improvement of protocols will be essential in the 
future to control emerging resistance [101]. 
 
Cross-Species Bacterial Transmission 
 Although the role of livestock as a reservoir of antimicrobial resistant bacteria 
has been the subject of extensive research, the role of companion animals and human 
beings as potential reservoirs is less understood and overlooked [100, 102].  In the 
United States, 58.3% of all households own pets, with 36% owning dogs and 31% 
owning cats [103].  The human-animal bond is an important phenomenon, with 99% 
of dog and cat owners considering their pets to be part of the family [104].  With this 
relationship between pets and human beings comes the possibility and concern of 
sharing or transmitting resistant bacteria during daily activities including petting, 
feeding, grooming, sleeping, and disposal of feces.   
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 Numerous studies have implicated dogs as reservoirs for ExPEC [57, 58, 66, 
78, 105].  In the late 1980s, E. coli causing UTI in dogs were found to carry similar 
virulence factors such as P fimbriae, hemolysin, and the O4 and O6 somatic antigens, 
as UPEC in women, suggesting that canine ExPEC strains may pose an infectious 
threat to human beings [105].  PCR studies have shown that canine urinary and fecal 
E. coli can possess many urovirulence factors similar to UPEC in women, including 
papGIII, sfa, cnf, capsular antigens, and serum resistance [66].  Molecular 
fingerprinting using PFGE and RAPD has shown indistinguishable commonality 
between E. coli isolates from fecal and urinary specimens from dogs with UTIs and 
human urosepsis E. coli isolates [66].  A study specifically testing the canine 
reservoir hypothesis collected environmental canine fecal samples from an urban 
sidewalk and found papGIII-positive E. coli in 30%, and over half of these samples 
showed similar phylogenetic characteristics to human ExPEC strains based on RAPD 
testing [58].  This study concluded that even healthy dogs in urban environments can 
carry highly virulent strains of E. coli that may pose a human public health risk [58].   
 These collective data show that dogs and human beings have similar E. coli 
strains in the GI tract and causing UTI, and the potential for cross-species 
transmission does exist.  While most studies implicate dogs as a source or reservoir 
for human beings, others have found that human beings are the more likely reservoir, 
and that dogs may acquire antimicrobial resistant and virulent bacteria from human 
beings [106].  One study comparing prevalence and resistance patterns of E. coli 
isolates from urine of women with cystitis and pyelonephritis with isolates from feces 
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of healthy women and dogs, found that canine isolates had the least amount of 
antimicrobial resistance, suggesting that dogs were not a likely reservoir for resistant 
genes [106].  It is possible that both human beings and dogs are potential reservoirs 
for pathogenic, virulent, and resistant E. coli. 
 Rather than direct transmission, dogs and human beings could acquire the 
same strain of bacteria from an environmental reservoir.  These sources could include 
contaminated food, water, or exposure to wildlife.  From these potential reservoirs, 
fomites within the kitchen, household, and yard can become contaminated, providing 
additional opportunity for transmission to dogs and human beings.  Furthermore, 
conjugation can occur within the environment.  Some plasmids and other mobile 
genetic elements are not highly specific to one bacterial genera or species, thus 
conjugation can cross bacterial species, carrying antimicrobial resistance and 
virulence factors to otherwise benign bacteria within the environment.   
 With many potential reservoirs including environmental sources, animals, and 
human beings, there is ample opportunity for transmission of resistant and virulent 
bacteria.  Improving our understanding of common routes of transmission and risk 
factors is warranted.  The most common route of bacterial transmission of E. coli is 
fecal-oral transmission.  Fecal-oral transmission can occur by accidental ingestion of 
feces during bathing, grooming, sexual intercourse, diaper changing, or disposal of 
feces from pets or livestock.  Human contact with animal feces has been recognized 
as a risk factor for infection with E. coli 0157 and other enteric pathogenic bacteria 
[107].  Children may be at greater risk, because they have increased direct contact 
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with pets, they are physically closer to floors and carpets that may be contaminated 
by pet feces, and they have less stringent hygiene habits than adults [100, 108].   
Good personal hygiene minimizes risk of fecal-oral transmission of bacteria and 
include frequent hand-washing and discouraging hand-to-mouth activities such as 
smoking, eating, drinking, or using pacifiers in the presence of animals [109].   
 Other routes of transmission include indirect fecal-oral transmission, sexual 
activity, aerosolization, and cutaneous transmission.  Indirect fecal-oral transmission, 
as discussed before with regard to ingesting fecal-contaminated meat and produce, is 
a common cause of outbreaks of gastroenteritis jeopardizing public health.  Direct 
contact through sexual activity has been associated with concurrent fecal colonization 
of the same strain of E. coli implying transmission between sexually active 
heterosexual and homosexual partners [110-112].  Aerosolization of urine or fecal 
material followed by inhalation or ingestion is also a potential route of transmission 
of UPEC.  Other routes of bacterial transmission between species are through skin 
contact, bite wounds, and from bites from ticks or other insects.  These routes can be 
significant for bacteria such as Staphylococcus aureus (S. aureus), Bartonella, and 
rickettsial organisms such as Rickettsia rickettsii, respectively, but they are not 
significant routes of transmission for E. coli [113-115].   
 Although the concept of cross-species transmission is a major public health 
concern, it is very difficult to prove transmission of bacteria between two individuals 
and to determine direction of transmission.  Comparing genetic makeup of bacterial 
strains from two individuals and finding a high percentage of clonality (genetic 
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relatedness) is supportive of transmission, especially if the individuals have 
opportunity for bacterial sharing.  DNA fingerprinting with PFGE is one method to 
compare clonal relatedness, through % PFGE profile similarity and via dendrograms.  
DNA sequencing can also be used to compare bacterial strains and to confirm two 
strains of E. coli are related.  Because of increased sensitivity, DNA sequencing may 
replace fingerprinting for comparing relatedness of bacterial strains for transmission 
studies in the future.  
 In observational studies, directionality of transmission can only be speculated 
through understanding the epidemiology of bacteria and behavior of populations 
being studied.  Comparing antimicrobial drug usage and fecal resistance patterns 
between species is a useful way to hypothesize directionality of cross-species 
transmission.  A study in western Uganda isolated fecal E. coli from chimpanzees, 
from human beings employed in chimpanzee-directed research and tourism, and from 
local villagers with no chimpanzee contact [116].  Results confirmed that 
chimpanzees had fecal E. coli genetically more similar to those of human beings who 
worked in chimpanzee-directed research and tourism than local villagers, suggesting 
sharing of bacteria via either direct contact or indirect contact through ecological 
overlap and contact with environmental reservoirs [116].  Although chimpanzees in 
this national park had never been treated with antimicrobial therapy, 4.4% of 
chimpanzee E. coli isolates were resistant to at least one locally-available 
antimicrobial drug, suggesting that cross-species transmission, directly or indirectly, 
was occurring from human beings to chimpanzees [116].    
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 Similarly, genetically related S. aureus has been identified from domestic 
animals and human beings within households and veterinary clinics, and transmission 
was believed to have occurred [113, 117, 118].  Some argue that pets may be the 
underlying reservoir of methicillin-resistant S. aureus (MRSA), infecting their human 
housemates; however, since cases of MRSA have a higher prevalence in people who 
are hospitalized or work in healthcare professions than in the general canine 
population, these bacteria are more likely transmitted from infected human beings to 
their pets, rather than from pets to owners [100].                                                                                           
 There are only sporadic cases that document sharing of E. coli clones between 
companion animals and human beings within a household, supporting potential cross-
species transmission [119-121].  A case report documented a single EPEC E. coli 
clone from the feces of a 3-year-old healthy child and a 3-month-old diarrheic dog in 
her household [108].  The source and direction of transmission of EPEC in this report 
remained unknown [108]. 
 A separate case report documented extensive sharing of virulent E. coli strains 
within a household between a heterosexual couple and their cat, based on biweekly 
fecal, urine, and vaginal cultures over a 4-month period and again a year later [119].  
PFGE showed that the strain isolated from the woman’s UTI was found repeatedly in 
the man and cat, and PCR showed that presence of the virulence factors pap, hly, and 
cnf was associated with persistent, multiple-site, and multiple-host isolation [119].  
Based on this finding, it was speculated that these virulence factors may promote 
colonization and transmission in addition to virulence [119].   
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 A similar longitudinal study followed a woman with a UTI along with 4 
household family members and their pet dog, isolating fecal and urine E. coli and 
comparing them with PFGE and RAPD [120].  Three clones were found extensively 
among multiple human beings and the dog, including the woman’s UPEC clone 
which had the highest overall prevalence and persistence [120].  Both clones isolated 
from the pet dog were also isolated from multiple human beings in the household 
[120].  Epidemiologic study of temporal patterns of isolation of these clones and 
reported physical contact of the family members led to the conclusion that nonsexual 
host-to-host transmission of E. coli was more likely than acquisition of clonal E. coli 
from an environmental common point source [120].  The woman’s UPEC clone was 
not isolated from her again after fluoroquinolone therapy; however it continued to be 
isolated in fecal samples from her family members and dog, supporting the theory 
that housemates and pets can be reservoirs for UPEC [120].   
 A cross-sectional study evaluated fecal samples from human beings and pets 
from 5 families and used electrophoresis to determine the extent of strain sharing 
within households.  Eleven percent of strains isolated from a household were shared 
by two or more family members, with 1 strain found in a mother, father, and dog, and 
a second strain isolated from a son and his cat [121].   
 Although these case reports and small cross-sectional study have documented 
sharing of clonal E. coli between human beings and companion animals, prevalence 
of E. coli sharing among healthy dogs and human beings within households remains 
unknown.  The objective of the current study was to determine the extent to which 
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clonally similar E. coli isolates are detected in feces from in healthy dogs and human 
beings living in the same household.  Fecal E. coli isolates were compared by genetic 
fingerprints, presence of virulence factors, and antimicrobial susceptibility patterns.  
An epidemiologic analysis was performed to identify potential risk factors for cross-
species sharing of fecal E. coli.  Results from this study will help veterinarians, 
medical doctors, and public health authorities make appropriate husbandry and 
hygiene recommendations to pet owners to minimize cross-species bacterial sharing 




Materials and Methods 
Study Design and Participants 
 This was a cross-sectional study evaluating fecal E. coli isolates collected 
from participants at one point in time.  Study participants included 61 pairs of human 
beings and their dogs.  Participants were recruited from the faculty, staff, and student 
body of the University of Tennessee, College of Veterinary Medicine (UTCVM) and 
the Department of Medical Genetics.  Recruitment was done by word of mouth, an 
internet posting, and Email notifications.  Inclusion criteria specified that all human 
participants must be generally healthy and over 18 years of age to participate.  
Inclusion criteria specified that the dog must be owned by and have lived in the same 
household as the human participant for at least 6 months, and only one dog and 
human per household could participate.  Exclusion criteria specified that no human or 
canine participants could have received oral, topical, or parenteral antimicrobial 
therapy within two weeks of enrollment.  
 A control population was recruited and included 34 human beings who did not 
own a dog or cat, nor had more than 1-hour contact per week with a dog.  No 
restrictions were made on contact with other species of non-human animals.  Controls 
were recruited from the faculty, staff, and student body of the UTCVM, the 
Department of Medical Genetics at the University of Tennessee, and employees from 
a local business, GI Associates.  Recruitment was done by word of mouth, an internet 
posting, and Email notifications.  Inclusion criteria specified that all human 
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participants must be healthy and at least 18 years of age.  Exclusion criteria specified 
that no controls could have received oral, topical, or parenteral antimicrobial therapy 
within two weeks of enrollment.  
 
Compliance 
 This study was granted approval by both the Institutional Review Board 
(#6910B) and Institutional Animal Care and Use Committee (#1492) of the 
University of Tennessee to ensure appropriate treatment of all participants.  All 
human participants were informed of potential risks and benefits of participation as 
well as confidentiality of participation.  Each human participant signed a standardized 
informed consent form.  All human participants received a $20 stipend once 
participation was complete.  
 
Sample Size Calculation 
 A sample size of 61 pairs of dogs and owners was calculated based on a 
McNemar’s Chi-Square statistical analysis for paired samples with alpha 0.05, effect 
size 0.30, and 98% power.  The test was two-tailed, which means that an effect in 
either direction was considered important; thus 98% of studies performed would be 
expected to yield a significant effect, rejecting the null hypothesis that E. coli isolates 
from dogs and their owners would be equally likely to have a particular variable.  
Sample size for the control population was calculated based on a Chi-Square analysis 
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for independent samples with alpha 0.05, effect size 0.30, and power 85% and was 
determined to require 34 control participants.  At the time this study was designed, 
data were not available for % PFGE similarity of E. coli between dogs and owners 
within households from which to extrapolate an appropriate effect size.  Previous 
prevalence studies have shown that between 0.9-31% of fecal E. coli from dogs and 
owners have virulence factors to be tested in this study; however no previous studies 
compared virulence factors between isolates from dogs and owners in the same 
households [74, 122].  Similarly, no data was known for susceptibility results 
between dogs and owners.  Therefore, a conservative effect size was chosen at 0.30, 
which is Cohen’s convention for a medium effect size when using Chi-Square 
analyses [123].  
 
Sample Collection 
 Participants were given a packet of materials for the study including 
confidential identification numbers for each participant, a standard questionnaire, and 
instructions for sample collection, gloves, disposable plastic bag, a bubble envelope, 
and sterile culture swabs.  A key that associated the identification number of each 
fecal sample with the appropriate dog or human source was kept strictly confidential 
in a locked cabinet only accessible to the investigators and was destroyed at the end 
of this study in August 2008.  The investigator performing the laboratory work was 
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blinded from this information, preventing any potential bias of results due to 
knowledge of which samples were paired.   
 Samples collected for this study included one fecal BBL CultureSwab Plus 
Collection and Transport System (Becton Dickinson and Company, Sparks, MD) 
from each human and dog participant.  Paired samples from dogs and owners were 
collected from the same 12-hour period and submitted together.  Human being 
participants were asked to submit a swab of their own feces.  This was collected by 
defecating in their home toilet and inserting the culture swab deep into the fecal 
material to generously soil the swab.  The soiled swab was then returned to the 
transport medium tube.  Toilets should not have been cleaned or disinfected 
immediately prior to sample collection, nor should a continuous-release sanitizer have 
been used within the toilet bowl.  Owners were also asked to bring in a swab of their 
dog’s feces.  This sample was taken from an outdoor site shortly after the dog 
defecated, and the swab was to be inserted into the center of the fecal material to 
allow for generous soiling of the swab.  All samples were collected within 24 hours of 
when they were submitted for the study and refrigerated if collected more than an 
hour before submission.  They were labeled with the confidential identification 
numbers provided and stored in a disposable plastic bag inside a bubble envelope 
until submission.   
 Each human participant answered a questionnaire.  The questionnaire was 
developed in a focus group of dog owners and was piloted prior to use in the study.  
Questions were designed to identify demographics, medical and medication histories, 
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and relationship between dog and owner.  The questionnaire aimed to determine 
history of infection or immunosuppression, antimicrobial usage, and extent of dog-
owner interaction.  The questionnaire is included as Appendix A. 
 
Questionnaire Analysis 
 Descriptive statistics were used to summarize demographic data, medical 
history, medication history, and behaviors between dogs and owners.  An independent 
t-test was used to compare age of owners and controls.  Chi-Square analysis was used 
to compare gender distribution between owners and controls.  Chi-Square analyses 
were used to compare history of antimicrobial therapy in participants prior to 
enrollment in the study.  Chi-Square analysis was used to compare history of UTI 
with gender of participants.  Chi-Square analysis was also used to compare owners’ 
reported disposal of dog’s fecal material with gender and with hours spent at dog 
parks per week. 
 
E. coli Isolation 
 Fecal swabs were processed within 6 hours of submission, and original swabs 
were discarded immediately.  Fecal samples were diluted in 3ml of 0.1% Peptone 
(Fisher Scientific, Fair Lawn, NJ), vortexed, and 20μl of diluted feces was streaked 
for isolation onto two separate plates containing: BBL Eosin Methylene Blue Agar 
Modified (EMB) (Becton Dickinson and Company, Sparks, MD) with added 0.1g/L 
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MUG fluorescence crystals (HACH Company, Loveland, CO), and Bacto EC 
Medium with MUG (Becton Dickinson and Company, Sparks, MD).  Eosin and 
methylene blue are toxic to Gram-positive bacteria, but Gram-negative bacteria are 
protected by their LPS layer and grow well; thus, this medium selects for Gram-
negative bacteria.  Bacto EC Medium with MUG (Becton Dickinson and Company, 
Sparks, MD) contains bile salts that are toxic to Gram-positive bacteria, allowing 
selection for Gram-negative bacteria.   
 Four-methylumbelliferyl-β-D-glucuronide (MUG) was used as a differential 
agent to identify E. coli colonies.  Most strains of E. coli possess the enzyme β-
glucuronidase, which hydrolyzes MUG to 4-methylumbelliferone, causing colonies to 
fluoresce under 366nm ultraviolet light.  An exception is E. coli 0157 which does not 
possess β-glucuronidase and does not fluoresce; thus florescence was a way to select 
against E. coli 0157 strains.  Although rare, other bacteria can produce β-
glucuronidase, including strains of Shigella, Salmonella, and Yersinia [124, 125].   
 Plates were incubated at 44C for 18-24 hours; incubation at this temperature 
provides additional selectivity for E. coli.  Plates were examined under 366nm 
ultraviolet light for blue-fluorescing colonies.  Not all green metallic colonies that 
were later proven to be E. coli on EMB plates fluoresced under ultraviolet light; 
however all colonies that were later proven to be E. coli on EC plates fluoresced 
under ultraviolet light.  Presumptive colonies were counted and their appearance 
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described.  Three presumptive E. coli colonies were selected from each sample for 
further testing.   
Presumptive E. coli colonies were each separately inoculated into 5 ml BBL 
Brain Heart Infusion Broth, Modified (BHI) (Becton Dickinson and Company, 
Sparks, MD), vortexed, and incubated at 44C for 18-24 hours.  After incubation, 
samples were vortexed, and 20μl was streaked for isolation onto an EC plate.  Plates 
were incubated at 44C for 18-24 hours and examined under an ultraviolet light for 
blue-fluorescing colonies that were presumed to be E. coli.   
API-20E biochemical test kits (bioMerieux, Inc., Durham, NC) were used to 
confirm E. coli colonies.  This test utilizes 20 biochemical reactions in parallel.  
Isolated colonies presumed to be pure E. coli were mixed with 5 ml sterile distilled 
water and tested with a turbidometer (Oxoid, Hampshire, England), which was 
calibrated daily, until consistent with the 0.5 McFarland turbidity standard.  This 
dilution was used to inoculate API-20E biochemical test kits according to the 
manufacturer’s instructions followed by incubation, addition of reagents, and 
interpretation of individual test reactions.  Results were entered into the bioMerieux 
API website (http://apiweb.biomerieux.com) to identify the genus and species and 
confirm each isolate as E. coli.  Quality control was performed for the API-20E test 
strips using E. coli reference ATCC 25922. 
 Due to difficulty interpreting citrate results on the API-20E test, slants 
containing Simmons Citrate Agar (Becton Dickinson and Company, Sparks, MD) 
were also inoculated and incubated for each isolate.  Slants were inoculated by 
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stabbing the butt of the media and then inoculating the surface with a serpentine 
pattern.  Slants were incubated at 44C for 3 days.  Slants that turned blue were 
considered positive, demonstrating that the bacteria used citrate as the sole carbon 
source for growth.  Slants that remained green were considered negative and 
consistent with E. coli.   
All confirmed pure E. coli colonies were grown in 5ml BHI broth at 44C 
overnight and stored long-term in a refrigerator and freezer.  Three refrigerator vials, 
each containing 1ml vortexed BHI mixture and 1ml Difco Stock Culture Agar 
(Becton Dickinson and Company, Sparks, MD), were stored at 4C.  Two freezer 
vials, each containing 1ml vortexed BHI mixture and 1ml of 20% Glycerol (Fisher 
Scientific, Fair Lawn, NJ), were stored in two separate freezers at -85C.  Glycerol 
protects E. coli from freezer injury and crystallization. 
 
Antimicrobial Susceptibility Testing 
 E. coli isolates were tested for susceptibility to 17 antimicrobial agents.  
Sixteen antimicrobial agents were chosen because enteric bacteria of human beings 
and animals are routinely monitored through passive surveillance by the National 
Antimicrobial Resistance Monitoring System (NARMS) for susceptibility to these 
antimicrobial agents.  These antimicrobial agents include amikacin, amoxicillin-
clavulanic acid, ampicillin, cefoxitin, ceftiofur, ceftriaxone, cephalothin, 
chloramphenicol, ciprofloxacin, gentamicin, imipenem, kanamycin, nalidixic acid, 
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streptomycin, tetracycline, and trimethoprim-sulfamethoxazole.  Although an 
additional two antimicrobial agents, apramycin and sulfamethoxazole, are also 
considered standard antimicrobial drugs monitored by NARMS, susceptibility test 
discs were not commercially available, and these antimicrobial agents were excluded 
from this study.  Alternatively, susceptibility was determined for cefpodoxime, a third 
generation cephalosporin that had recently been introduced to the veterinary market.  
Susceptibility testing of E. coli isolates was performed with the Kirby-Bauer 
disk diffusion method, in accordance with the guidelines of the Clinical and 
Laboratory Standards Institute (CLSI), formerly known as the National Committee 
for Clinical Laboratory Standards (NCCLS) [126].  Approximately 0.2ml of E. coli 
from a 2-6-hr-old culture in BHI broth was diluted in 5ml sterile distilled water until 
its turbidity was consistent with the 0.5 McFarland standard, using a turbidometer to 
ensure accuracy.  A cotton swab was used to inoculate two 150mm Mueller Hinton II 
agar plates per isolate.  A BBL Sensi-Disc 12-Place Dispenser (Becton Dickinson and 
Company, Sparks, MD) was used to apply antimicrobial discs onto inoculated plates.  
Since 17 antimicrobials were tested, 9 discs were dispensed onto one plate, and 8 
discs were dispensed onto the second plate for each isolate.  Standard antimicrobial 
disc potencies were used: amikacin (30μg), amoxicillin-clavulanic acid (30μg), 
ampicillin (10μg), cefoxitin (30μg), ceftiofur (30μg), cefpodoxime (10μg),  
ceftriaxone (30μg), cephalothin (30μg), chloramphenicol (30μg), ciprofloxacin (5μg), 
gentamicin (10μg), imipenem (10μg),  kanamycin (30μg), nalidixic acid (30μg), 
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streptomycin (10μg), tetracycline (30μg), and trimethoprim-sulfamethoxazole (30μg) 
(BD BBL Sensi-Disc, Becton Dickinson and Company, Sparks, MD).  Plates were 
incubated inverted at 35C for 18-24 hours.   
An electronic digital caliper (Control Company model 14-648-17, 
Friendswood, TX) was used to measure zones of inhibition for each antimicrobial 
agent.  Diameter measurements were taken of zones of complete inhibition, with the 
exception of trimethoprim-sulfamethoxazole.  Antagonists to trimethoprim-
sulfamethoxazole in the Mueller Hinton medium may allow slight growth of E. coli, 
therefore CLSI recommends measuring trimethoprim-sulfamethoxazole zones at 80% 
inhibition, or where there is an obvious margin [126].  Zones were measured to the 
hundredth of a millimeter, but were rounded to the nearest millimeter for 
interpretation, in accordance with CLSI recommendations.  Diameters of zones of 
inhibition were interpreted in accordance with current guidelines of CLSI and 
NCCLS for E. coli isolated from human beings and animals, allowing classification 
of each E. coli isolate as susceptible, intermediate or resistant to each of the 17 
antimicrobial agents, as illustrated in Appendix B [127, 128].  When interpretive 
recommendations were not available from CLSI for canine isolates, recommendations 
were followed for E. coli isolates from other animal species (ceftiofur) or human 
beings (cefoxitin, ceftriaxone, ciprofloxacin, nalidixic acid, and streptomycin) [127, 
128].  Plates that had one or more intermediate or resistant zones of inhibition were 
incubated an additional 48 hours and interpreted daily; however, in all of these cases, 
zones of inhibition did not change enough daily to alter the original determination of 
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intermediate or resistant.  Quality control was performed prior to the study on each 
package of antimicrobial discs using E. coli American Type Culture Collection 
(ATCC) 25922 and Staphylococcus aureus ATCC 25923 to ensure quality of the 
antimicrobial discs; acceptable quality control ranges and results appear in Appendix 
C [127, 128]. 
Susceptibility was reported as a percentage of participants with isolates that 
were susceptible, intermediate, and resistant to each antimicrobial agent.  
Susceptibility was also reported as a percentage of total isolates from each participant 
that was susceptible, intermediate, and resistant to each antimicrobial agent.  These 
results differed because 3 isolates were taken from each participant and frequently 
had different susceptibility patterns.  A participant was considered resistant to an 
antimicrobial if any of their 3 fecal isolates was resistant to that antimicrobial agent.  
The Wilcoxon Signed Ranks test was performed to compare susceptibility between 
paired dogs and owners, using susceptible, intermediate, and resistant as ordinal data.   
Data were collapsed, so that intermediate results were considered susceptible, and a 
McNemar Chi-Square test was used to compare paired dog and owner susceptibility 
results.  Similarly, data were collapsed so that intermediate results were considered 
resistant, and a McNemar Chi-Square test was used to compare paired dog and owner 
results.  Mann-Whitney tests were used to compare susceptibility results, as ordinal 
data, between independent dogs and controls, and between owners and controls.  
Mann-Whitney and Chi-Square analyses were used to compare susceptibility results 
to variables such as history of antimicrobial therapy.  A commercial statistical 
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software program was used to compute all statistics (SPSS 15.0 for Windows, SPSS 
Inc, Chicago, IL).  The original threshold for significance was set at p≤0.05.  The 
Bonferroni correction for multiple comparisons (17 antimicrobial agents) was 
applied, lowering the threshold for significance to p≤0.05/17 or p≤0.003, and 
decreasing the power of the study to 84%.   
 
Pulse Field Gel Electrophoresis 
 Pulse field gel electrophoresis was performed on 2 E. coli isolates from each 
participant.  Frozen E. coli isolates were grown on Columbia Agar with 5% Sheep 
Blood (Fisher Scientific, Fair Lawn, NJ) and MacConkey Agar plates (Fisher 
Scientific, Fair Lawn, NJ) overnight at 35C.  Blood agar is a non-selective medium, 
and E. coli colonies appear grey and moist.  E. coli α-hemolysin produces large, clear 
zones of hemolysis around colonies on blood agar plates, and phenotypic presence of 
hemolysis was recorded.  MacConkey agar contains bile salts and crystal violet, 
which are selective against Gram-positive bacteria, as well as a pH indicator that 
responds to the acidic environment created by lactose fermentation.  Thus using 
MacConkey agar differentiates lactose-fermenting bacteria such as E. coli, because 
the medium turns red, and the colonies are pink.  Lactose negative colonies were 
streaked onto Triple Sugar Iron (TSI) Agar slants, Urea agar slants, and used to 
inoculate Motility Indole Ornithine medium (Becton Dickinson and Company, 
Sparks, MD).   Isolates biochemically consistent with E. coli were acidic throughout 
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the TSI slant with hydrogen sulfide gas production, were negative for urease 
production, had positive motility, were positive for indole production, and were 
positive for ornithine decarboxylase.  Any isolate that did not fit these characteristics 
was confirmed to be E. coli with an API-20E biochemical test kit (bioMerieux, Inc., 
Durham, NC).  A Gram stain was performed on a colony from each blood agar plate 
to confirm the presence of a pure culture of small gram-negative coccobacilli.  One 
colony was then transferred from each blood agar plate to Luria-Bertani broth (LB) 
(Fisher Scientific, Fair Lawn, NJ) and incubated overnight at 35C.  Pure E. coli 
cultures in overnight LB broth were used for PFGE.    
 Cultures were concentrated and washed in phosphate buffered saline (PBS) 
(Fisher Scientific, Fair Lawn, NJ), to remove any potential inhibitors of enzymes 
required for PFGE.  From each 10ml LB broth culture, 2ml were dispensed into each 
of 4 microcentrifuge tubes and centrifuged at 4C for 10 minutes at 8000 x gravity (G).  
The supernatant was removed from all 4 tubes.  The first pellet was suspended in 1ml 
PBS, and this mixture was used to suspend the second pellet, then third, and fourth 
pellets, so that all 4 pellets from the same isolate were combined, concentrating the 
culture.  This culture was centrifuged at 4C for 10 minutes at 8000G.  The 
supernatant was removed, and 1ml of PBS was added to suspend and continue 
washing the pellet, and the sample was again centrifuged at 4C for 10 minutes at 
8000G.  Finally, the supernatant was removed, and 0.8ml PBS was added to suspend 
the pellet.   
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 Washed E. coli cultures were used to make plugs for PFGE.  First 25μl 
protease K (Qiagen Inc., Valencia, CA) was added to each E. coli sample.  2% 
agarose gel was prepared by combining 1g pulse-field certified agarose (BioRad 
Laboratories, Richmond, CA) with 50ml 1x Tris-EDTA buffer (Fisher Scientific, Fair 
Lawn, NJ), and this mixture was tempered to 55C before use.  Then 0.5ml of the E. 
coli sample was mixed with 0.5ml of 2% agarose gel in 1x Tris-EDTA buffer (Fisher 
Scientific, Fair Lawn, NJ).  Quickly, 100μl of the E. coli agarose mixture was 
dispensed into each plug mold.  Two plugs were made per E. coli isolate.  Plugs were 
refrigerated for 10-15 minutes to allow solidification. 
 Lysis buffer was made fresh before each use and contained 2.25ml 1M Tris 
HCl (Fisher Scientific, Fair Lawn, NJ), 4.5ml 0.5M EDTA (Fisher Scientific, Fair 
Lawn, NJ), 4.5ml 10% sarcosine (Teknova, Hollister, CA), 225μl protease K (Qiagen 
Inc., Valencia, CA), and 18.5ml sterile distilled water.  Protease K is responsible for 
breaking down the bacterial cell wall.  The solidified plug and 5ml of lysis buffer 
were dispensed into a sterile labeled 50ml tube.  The plug and lysis solution were 
incubated in a 54C water bath overnight (IsoTemp 120 by Fisher Scientific, Fair 
Lawn, NJ).  Before leaving for the day, an additional 15μl protease K (Qiagen Inc., 
Valencia, CA), was added to each tube containing plugs and lysis buffer. 
 After incubation in lysis buffer, plugs were washed to remove any remaining 
lysis buffer and the majority of cellular debris so only DNA remained.  Lysis buffer 
was removed from each 50ml tube, 5ml warmed sterile distilled water was added to 
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the plugs, and the tube was placed in the 54C water bath for 15 minutes.  The water 
was removed, and 5ml warmed 1x Tris-EDTA buffer (Fisher Scientific, Fair Lawn, 
NJ) was added, and the tube was placed in the 54C water bath for 15 minutes.  This 
1x Tris-EDTA buffer (Fisher Scientific, Fair Lawn, NJ) washing was repeated an 
additional two times.  Then 1x Tris-EDTA buffer (Fisher Scientific, Fair Lawn, NJ) 
was removed from each tube and 5ml room-temperature 1x Tris-EDTA buffer (Fisher 
Scientific, Fair Lawn, NJ) was added, completing the plug washing procedure.  The 
50ml tubes containing plugs with 1x Tris-EDTA buffer (Fisher Scientific, Fair Lawn, 
NJ) could be stored at 4C for up to 2 weeks before restriction digestion. 
 Prior to restriction, plugs were removed from the 1x Tris-EDTA buffer 
solution (Fisher Scientific, Fair Lawn, NJ), dried, and halved with a straightedge 
razor blade.  Both plugs were transferred into a 1.5ml microcentrifuge tube containing 
200μl pre-restriction buffer and incubated at room temperature for 5 minutes.  Pre-
restriction buffer contained 20μl 10x buffer D (Promega, Madison, WI) and 180μl 
Nuclease-Free Water (Ambion, Inc., Austin, TX).  After 5 minutes of pre-restriction, 
plugs were removed, dried, placed in a restriction enzyme solution, and stored in a 
37C water bath (Isotemp 202S, Fisher Scientific, Fair Lawn, NJ) for at least 8 hours 
or overnight.  Restriction enzyme solution contained 40μl 10x buffer D (Promega, 
Madison, WI), 5μl BSA (10mg/ml) (Promega, Madison, WI), 5μl restriction 
endonuclease XbaI 12u/μl (Promega, Madison, WI), and 351μl Nuclease-Free Water 
(Ambion, Inc., Austin, TX). 
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 Electrophoresis gels (1%) were made with 400ml 0.5x tris-borate-EDTA 
(Fisher Scientific, Fair Lawn, NJ) and 4g PFGE agarose (BioRad Laboratories, 
Richmond, CA).  Plugs were removed from restriction enzyme buffer and placed in 
200μl 0.5x tris-borate-EDTA (Fisher Scientific, Fair Lawn, NJ) for 5 minutes at room 
temperature before being loaded into the gel wells.  Duplicate plugs of each isolate 
were run on each gel.  Plugs from paired dog and human isolates were run on the 
same gel to minimize effects of gel-to-gel variability on interpretation of similarity 
between paired isolates.  Low range PFG markers (New England BioLabs Inc., 
Ipswich, MA), comprised of a mixture of lambda DNA-Hind III fragments and 
lambda concatemers embedded in 1% LMP agarose, were loaded into wells 1, 8, and 
15 of each gel.  Plugs were sealed into the gel with additional 1% PFGE agarose 
(BioRad Laboratories, Richmond, CA).   
 Gels were electrophoresed in 3L of 0.5x tris-borate-EDTA buffer solution 
(Fisher Scientific, Fair Lawn, NJ).  Electrophoresis was performed with the CHEF-
Mapper (BioRad Laboratories, Richmond, CA) with initial switch time 6s, final 
switch time 40s, gradient 6V/cm, included angle 120°, linear ramping, a run time of 
24h, and cooling temperature of 14C.  Gels were stained with of 400ml sterile 
distilled water and 1μl ethidium bromide (10mg/ml) for 30 minutes with shaking, and 
destained with sterile distilled water for 75 minutes with shaking.  Gels were 
visualized by photographing them with a GelDocXR camera using Quantity One 
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Software 4.6.3 (BioRad Laboratories, Richmond, CA), and saved as tagged image file 
format (TIFF) images.   
 FPQuest Software Version 4.5 (BioRad Laboratories, Richmond, CA) was 
used to analyze bands from electrophoresis gels, as well as to compare, correlate, and 
generate similarity indices (cluster analysis) among E. coli isolates.  A matrix of 
coefficients was generated, and a correlation analysis was conducted by using the 
unweighted-pair group method with averaging (UPGMA) based on Dice similarity 
coefficients and the clustering algorithm to create dendrograms.  One percent 
optimization and 2% position tolerance were used.  Genomic fingerprints were 
compared between each dog-owner pair using similarity matrices.   
 When comparing E. coli isolates by PFGE fingerprint similarity, a variety of 
definitions have been used for clonal sharing, including % PFGE similarity based on 
similarity matrices and comparing number of bands in common on DNA fingerprint 
[84, 120, 129].  To remain most consistent with the current literature in this area of 
research, E. coli isolates with >94% PFGE similarly were considered shared strains or 
clones.  In this study, groups were defined as a cluster of 4 or more E. coli isolates 
with >90% PFGE profile similarity.  
 Chi-Square analysis was used to compare percent of participants sharing 
clones with other participants, and demographics of those participants sharing clones.  
Total number of potential clone-sharing pairs was calculated as the overall number of 
pair-wise combinations of participants, n(n-1)/2, where n is the total number of 
participants [129].  The number of potential within-household sharing pairs was the 
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number of dog-owner pairs enrolled in the study.  The number of potential across-
household sharing pairs was the difference between the two values.  Chi-Square 
analysis was used to compare within-household versus across-household sharing.  
Chi-Square, Mann-Whitney U, and Kruskal-Wallis analyses were used to compare 
demographics and dog-owner behaviors to within-household % PFGE similarity, and 
the threshold for significance was p ≤ 0.05.   
 
Virulence Factor Multiplex PCR 
 Multiplex PCR to test for virulence factors was performed on all 3 E. coli 
isolates per participant.  Frozen E. coli isolates were grown on Columbia Agar with 
5% Sheep Blood (Becton Dickinson and Company, Sparks, MD) overnight at 35C.  
One colony was transferred from each blood agar plate to LB broth (Fisher Scientific, 
Fair Lawn, NJ) and incubated overnight at 35C.  To remove inhibitors, 1ml of each 
culture was centrifuged for 1 minute at 14,000rpm at 20C, the supernatant was 
discarded, and the pellet was suspended in 200ul sterile Nuclease-Free Water 
(Ambion, Austin, TX).   A boiled preparation was used for DNA extraction.  
Suspensions were boiled at 100C for 5 minutes, vortexed to mechanically disrupt the 
cell membrane, and then boiled for another 5 minutes.  After boiling, suspensions 
were centrifuged for 1 minute at 14,000rpm at 20C.  DNA lysate supernatant was 
transferred to 2ml storage vials and stored at -80C for future use for PCR. 
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 Spectrophotometry was used to determine nucleic acid concentration and 
quality in DNA lysate from each E. coli isolate (NanoDrop ND-1000, NanoDrop 
Technologies Inc, Wilmington, DE).  This ensured enough DNA was included in 
each sample to provide a positive PCR result if the isolate was truly positive.  Two 
microliters of DNA lysate from each E. coli isolate were sampled.  An arbitrary cutoff 
for minimum DNA concentration was set at 400ng/µl.  Established guidelines for 
DNA purity use the ratio of absorption of UV light at 260nm to absorption at 280nm 
(260:280), based on the knowledge that DNA absorbs light at 260nm and proteins 
absorbs light at 280nm.  Pure DNA samples have a 260:280 ratio of 1.8; a ratio 
considerably lower than 1.8 suggests presence of proteins, phenols, or other 
contaminants that absorb light near 280nm [130]. 
 Multiplex PCR was developed to determine presence or absence of 4 
urovirulence factors: cytotoxic necrotizing factor (cnf), hemolysin (hlyD), S fimbriae 
adhesin (sfa), and pilus associated with pyelonephritis G allele III (papGIII).  Table 1 
lists the primer sequences and base pair sizes of each of the four virulence factors 
tested in this multiplex PCR assay (all Tables are listed in the Appendix).  Positive 
(J96) and negative (JJ055) control strains for these virulence factors were obtained 
from Dr. James R. Johnson from the University of Minnesota.  E. coli strain J96 is 
positive for all 4 virulence factors in this study, as well as numerous other 
urovirulence factors.  E. coli strain JJ055 is negative for all 4 virulence factors in this 
study.   Sterile water was also used as a non-nucleic acid negative control.    
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 A master mix was prepared under a biosafety hood to minimize contamination 
and kept frozen until use.  The master mix included (per reaction): 2.5μl 10x buffer 
(Applied Biosystems, Foster City, CA), 4μl 25mM magnesium chloride (Applied 
Biosystems, Foster City, CA), 0.25μl Amplitaq Gold polymerase (Applied 
Biosystems, Foster City, CA), 2μl 2.5mM mixed deoxyribonucleotide triphosphates 
(dNTPs) (Bioline, Taunton, MA), 0.075μl of each primer (Invitrogen, Carlsbad, CA), 
and 13.65μl sterile Nuclease-Free Water (Ambion, Austin, TX).  Ninety-six-well 
PCR plates (BioRad, Richmond, CA) were used, and each well was loaded with 23μl 
of master mix, followed by 2μl of sample DNA lysate.  Plates were sealed with 
microseal film (BioRad Laboratories, Richmond, CA). 
 Each sample was run in triplicate to ensure accuracy.  Each PCR plate 
contained positive control strain J96 as well as negative control strain JJ055 and 
sterile nuclease free water (Ambion, Austin, TX).  All plates were loaded under a 
biosafety hood to minimize contamination, in a room separate from any other DNA or 
RNA research.  Study samples were loaded into the plates first, followed by negative 
controls and water, followed last by the positive control strain. 
PCR plates were run on an iCycler (BioRad, Richmond, CA), and conditions 
were based on a protocol obtained from Dr. James R. Johnson (personal 
communication 9/18/2007).  Activation was performed at 95C for 12 minutes.  
Twenty-five cycles were performed of denaturation, annealing, extension.  
Denaturation was set at 94C for 30 seconds, annealing was set at 63C for 30 seconds, 
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and extension was set at 68C for 3 minutes.  A final extension was performed at 72C 
for 10 minutes.   
 Twenty-five μl of each PCR sample was analyzed by electrophoresis using a 
2% agarose gel (Promega, Madison, WI).  Five μl blue/orange loading dye (Promega, 
Madison, WI) was added to each 25μl sample prior to loading.  A 100bp DNA ladder 
(Promega, Madison, WI) was used as a standard to control the size of the amplified 
product, and 1.5μl blue/orange dye was added to 7.5μl DNA ladder prior to loading.  
Positive and negative controls were included on each gel.  Gels were run at 150 volts 
for 3 hours, with 1x tris-acetate EDTA buffer (Promega, Madison, WI).  Gels were 
stained with ethidium bromide (1μl per 500ml water) for 15 minutes, and destained 
with water for an additional 15 minutes.  Images were photographed using a 
GelDocXR camera (BioRad, Richmond, CA) with Quantity One Software 4.6.3 
(BioRad, Richmond, CA), and saved as tagged image file format (TIFF) images.   
 FPQuest Software Version 4.5 (BioRad, Richmond, CA) was used to analyze 
band size and to verify presence or absence of virulence factors.  McNemar and Chi-
Square tests were used to analyze paired dog-owner and independent dichotomous 
data, respectively.  Kappa measure of agreement was used as a comparison of 
agreement between virulence factors; a Kappa value of 1 implies perfect agreement, 
and a Kappa value of 0.8-1 implies very good agreement [131].  Chi-Square analysis 
was also used to measure associations between virulence factors, between virulence 
factors and susceptibility results, between virulence factors and hand-washing, and 
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between virulence factors and history of UTI.  The original threshold for significance 
was set at p ≤ 0.05.  A Bonferroni adjustment was made for multiple comparisons.  
The original p-value (0.05) was divided by the number virulence factors (4), resulting 








 Sixty-one dog and owner pairs and 34 controls that fit the inclusion criteria 
volunteered to participate from September to December 2006.  Forty-three owners 
were recruited from the UTCVM.  Seven dog owners were recruited from the 
University of Tennessee, Department of Medical Genetics, and 11 owners 
volunteered from various other departments in the University of Tennessee 
Department of Agriculture.  Twenty controls were recruited from the UTCVM, 4 
from Gastrointestinal Associates, 3 from the University of Tennessee, Department of 
Medical Genetics, and 7 from various other departments within the University of 
Tennessee.  Owner ages ranged from 21 to 76-years-old, with a mean of 34.3 and a 
median of 28-years-old.  Fifty-one owners were women, and 10 were men.  Control 
ages ranged from 21 to 70-years-old, with a mean of 38.5 and a median of 31.5-years-
old.  Twenty-three controls were women and 11 were men.  There was no difference 
between age (p=0.168) or gender (p=0.133) of enrolled owners and controls. 
 Dogs enrolled in this study varied in age from 6-months-old to 18-years-old, 
with a mean age of 5.5-years-old, and a median age of 5-years-old.  Twenty-nine 
female spayed dogs, 24 male neutered dogs, 4 intact female dogs and 4 intact male 
dogs were enrolled.  Twenty-three purebred dog breeds were represented, but mixed 
breed dogs (24/61, 39.3%) were more common than any one breed.   The most 
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common pure breed was Labrador retrievers (6/61, 9.8%), followed by boxer dogs 
(3/61, 4.9%).  Twenty-five dogs (41%) were acquired from breeders, 13 dogs (21.3%) 
were acquired from shelters, 11 dogs (18%) were previously strays, 5 dogs (8.2%) 
were acquired from family or friends, 2 dogs (3.3%) were acquired from pet stores, 
and 5 (8.2%) dogs were acquired from other sources.  
 
Canine Medical Histories 
 One dog in the study had well-controlled diabetes mellitus, and 4/61 dogs had 
previously been diagnosed with cancer.  Three dogs had a history of cutaneous mast 
cell tumors.  The fourth dog was receiving chemotherapy and was in remission from 
lymphosarcoma.  Eight dogs had a history of UTI, including 6 female dogs and 2 
male dogs.  One dog had received cephalexin 30 days prior to enrollment for a 
pyoderma and prednisone for atopy.  A second dog had received cyclosporine 
ophthalmic drops in the past month.  Eighteen dogs (29.5%) had received 
antimicrobial therapy within the year prior to enrollment.  
  
Owner Medical Histories 
 One owner had well-controlled diabetes mellitus, and 27 owners had a history 
of UTI.  All owners with history of UTI were women.  Number of UTI per female 
owner ranged from 0-10, with a mean of 1.55 and a median of 1.  Three owners had 
each taken 1 course of antimicrobial therapy in the 30 days prior to enrollment: 
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amoxicillin-clavulanic acid for an unreported infection, ciprofloxacin for otitis, and 
penicillin for a dental procedure.  All antimicrobial therapy had been discontinued 2 
weeks prior to enrollment.   Twenty-two owners (36%) had received antimicrobial 
therapy within the year prior to enrollment. 
 
Control Medical Histories 
 One control had an immunosuppressive disease (skin cancer), and one control 
was receiving a topical immunosuppressive therapy.  Ten controls had a history of 
UTI, all women, with a range of 0-10 lifetime UTIs and a mean of 0.97 lifetime UTIs 
per individual.  Two controls had taken antimicrobial therapy within 30 days prior to 
enrollment but had finished two weeks prior to enrollment; one received a sulfa 
antimicrobial for acne, and one received both nitrofurantoin for a UTI and 
azithromycin for an upper respiratory infection.  Nine controls had received 
antimicrobial therapy within the year prior to enrollment.  
 
History of Antimicrobial Therapy 
 Dogs (1/61, 1.6%), owners (3/61, 4.9%), and controls (2/30, 6.7%) were 
equally likely to have received antimicrobial therapy in the 30 days prior to 
enrollment (p=0.453).  Similarly, dogs (18/61, 30%), owners (22/61, 36%), and 
controls (9/30, 30%) were equally likely to have received antimicrobial therapy in the 
year prior to enrollment (p=0.711).  There was no difference in the number of courses 
 69
of antimicrobial therapy taken by participants within each population within the year 
prior to enrollment (p=0.885).    
 Of 18 dogs (29.5%) with a history of receiving antimicrobials within a year of 
enrollment into the study, 13 dogs had received 1 course, and 5 dogs had received 2 
courses of antimicrobial therapy.  Of the 22 owners (36.1%) with a history of 
receiving antimicrobial therapy within a year of enrollment into the study, 18 owners 
had received 1 course, 3 owners had received 2 courses of antimicrobial therapy, and 
1 owner had received 1 course of amoxicillin-clavulanic acid and intermittent courses 
of minocycline throughout the year.  Of the 9 controls (30%) with a history of 
receiving antimicrobial therapy within a year of enrollment into the study, 6 controls 
had received 1 course, 2 controls had received 2 courses, and 1 control had received 
intermittent courses of sulfa therapy throughout the year (at least 4 courses).   
 Grouping all human participants together, 15 courses of antimicrobial therapy 
had been prescribed over the previous year for respiratory disease (mostly sinus 
infections), 13 for skin infections, 6 for UTIs, and 5 courses prophylactically.  The 
most common antimicrobial agents prescribed were beta-lactams (penicillin, 
amoxicillin, amoxicillin-clavulanic acid, and cephalexin) and fluoroquinolones (see 
Figure 1, all Figures are listed in the Appendix).  Of the 6 courses of 
fluoroquinolones, 5 were ciprofloxacin received by owners, and 1 was levofloxacin 
received by a control participant.  Antimicrobial agents prescribed for human UTIs in 
the study population included ciprofloxacin, cephalexin, and an unknown agent.   
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 In the canine population, amoxicillin-clavulanic acid was the most commonly 
prescribed antimicrobial in the year prior to enrollment, and it was prescribed for skin 
infections, respiratory infections, and a UTI (see Figure 2).  Cephalexin and an 
unknown antimicrobial agent were also reportedly used to treat UTIs in dogs within 
the year prior to enrollment.  Only one owner reported administering a 
fluoroquinolone, enrofloxacin, to their dog in the previous year, for a UTI. 
 
History of Urinary Tract Infections 
 Of the 91 human participants, 37 reported having a history of UTI at some 
point during their lifetime.  All 37 were women, making up 52.1% of the total female 
population in this study, see Figure 3.  Women were significantly more likely to have 
a history of UTI than men (p<0.001).  Of the dogs in the study, 6/33 (18.2%) female 
dogs and 2/28 (7.1%) male dogs had a history of UTI, but the difference was not 
significant (p=0.203).   
 Nine women (25%) had a UTI only once during their lifetime, while 28/37 
(75%) had multiple UTIs.  Fourteen women (37.8%) reported 2 UTIs, 8/37 (21.6%) 
women reported 3 UTIs, and 6/37 (16.2%) women reported 4+ UTIs (see Figure 4).  
Four dogs (50%) had a UTI only once during their lifetime, and 4 dogs (50%) had 
multiple UTIs, with 3/8 dogs (37.5%) having 3 or more lifetime UTIs (see Figure 5).   
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Exposure to Other Animals, Children, and Human Hospitals 
 Of the 43 faculty, staff, and student owners recruited from the UTCVM, 9 had 
handled canine patients in the 7 days prior to enrollment.  Four owners worked at 
veterinary clinics other than the UTCVM; 3 had 0-10 hours contact with dogs per 
week, and 1 had 21-30 hours contact with dogs per week.  Six controls worked at 
veterinary clinics, but none had more than 1 hour of direct contact with dogs per 
week.   
 Fifty dog-owner households (82%) had pets in addition to the dog enrolled in 
the study living in their households (see Figure 6).  Twenty-seven households (44%) 
contained only dogs, while 23/61 (38%) households contained other pets including 
cats, birds, rabbits, and reptiles.  The average household contained a mean of 3.23 
pets (including the dog enrolled in the study), with a median of 3 pets.  One dog, not 
enrolled, had diarrhea at the time of the study, and 7 unenrolled pets, from 6 different 
households, had taken antimicrobial therapy in the 30 days prior to their housemates 
enrolling in this study.  Antimicrobial agents recently administered to pets in 
households of volunteers included cefazolin, cefpodoxime, ciprofloxacin, 
clindamycin, metronidazole, and trimethoprim-sulfamethoxazole.  Nine dog owners 
(14.7%) reported spending 3 or more hours a week at a dog park.   Owners and their 
dogs may also have had exposure to other dogs, and potentially their fecal material, 
when visiting dog parks.  Three controls had pets in their household; one control had 
2 tree frogs, and 2 controls each had 2 cockatiel birds.  None of these pets had 
diarrhea nor had received antimicrobial therapy within the past 30 days. 
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 Ten owners had children living in their house; one child had diarrhea at the 
time of the parent’s enrollment, but no children were receiving antimicrobial therapy.  
Seven controls had children in their households.  None of these children had diarrhea 
at the time of the study, but 2 children in the same household had received topical 
ophthalmic ciprofloxacin 5 days prior to their parent’s enrollment.   
 Eleven owners had household members who worked in human hospitals or 
medical offices.  Nine controls worked at human hospitals or medical offices, but 
none had occupational exposure to human fecal or urine samples.   
 
Relationship with Dog Results 
 Several questions addressed the amount of direct contact owners had with 
their dogs.  Fifty-four percent of owners spent more than 30 hours per week of 
awake-time with their dogs, while 9.8% spent 0-10 hours with their dog per week (see 
Figure 7).  Male owners spent more awake-time with their dogs than female owners 
(p=0.036), although there were only 10 male owners and 51 female owners.  Fifty-
four percent of owners slept in the same bed with their dogs, and seventy percent of 
owners allowed their dog to kiss or lick them on the face.  There was no difference 
between male or female owners allowing either of these behaviors.  Twenty-five 
percent of owners reported washing their hands after petting their dog (see Figure 8). 
   Ninety percent of owners were the primary feeder in their household for their 
dog (see Figure 9).  Only 4/61 (6.6%) owners washed their hands before feeding their 
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dogs, but 47/61 (77%) washed their hands before eating their own meals.  The 
questionnaire inquired about feeding table scraps and raw food, and asked volunteers 
to list these foods if applicable.  There was considerable overlap in the responses.  For 
example, some owners considered carrots to be table scraps, while others considered 
carrots to be raw foods.  For consistency, results were recategorized into feeding of 
“people food” in general, feeding raw meat, and feeding raw vegetables.  Forty-one 
percent of owners fed their dogs “people food”, including table scraps (pizza crusts, 
cooked meat fat, licking plates and bowls), breads, crackers, pastas, rice, and fresh 
fruit and vegetables.  Eleven percent of owners reported sharing “everything they ate” 
with their dog.  Five owners (8.2%) fed their dogs raw meat, and 10 owners (16.4%) 
fed their dogs raw fruits and vegetables.  Of owners who fed their dog raw meat, 80% 
also allowed their dogs to kiss or lick them on the face.   
 Only 29/61 (47.5%) of owners reported disposing of their dog’s feces, while 
32/61 (52.5%) owners responded that they never disposed of their dog’s feces (see 
Figure 10).  A higher percentage of female (49%) than male (40%) owners reported 
disposing of their dog’s feces, but there was no significant association between owner 
gender and disposing of feces (p=0.602).  Of owners who disposed of their dog’s 
feces, 27/29 (93.1%) reported washing their hands afterwards.   
 Of dog-owner pairs who spent 3 or more hours a week at dog parks, only 6/9 
(67%) owners reported ever disposing of their dog’s feces.  Within this group, all 
three owners who spent 3 or more hours at dog parks and reported never disposing of 
their dog’s feces were veterinary students.  Owners who spent 3 or more hours a week 
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at dog parks were not more likely to dispose of feces than those who visited dog parks 
0-2 hours per week (p=0.213).   
 Thirteen percent of dogs were reported to drink water out of toilets, and 
therefore, had potential exposure to their owner’s urine and fecal material.  Within 
households reporting dogs drinking out of toilets, 75% of owners allowed their dogs 
to kiss or lick them on the face, and 50% of owners share their “people food” with 
their dogs.   
 
E. coli Isolation Results 
 E. coli was isolated from the feces of 91/95 (96%) human participants and 
61/61 (100%) dogs.  Enumeration of E. coli ranged from 3-1500 colonies per plate.  If 
all fecal culturettes had been soiled with a consistent amount of feces, extrapolation 
of E. coli colony enumeration to quantification of E. coli per gram feces may have 
been possible; however, there was a wide range of degree of soiling of fecal swabs by 
participants, making accurate extrapolation unrealistic.  On EC with MUG plates, 
most E. coli colonies were small smooth creamy white colonies, although rough 
colonies were also seen.  On EMB plates, all E. coli colonies were smooth, green, and 
metallic.  Three presumptive E. coli colonies were isolated from each fecal sample for 
further testing, and when possible, colonies with different morphologies were selected 
from the same participant.   
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 Biochemical testing with API-20E kits resulted in 32 different API-20E 
profiles confirmed as E. coli.  The most common profile, 5144572, seen in 141/456 
isolates, was characterized as β-galactosidase positive, arginine dihydrolase negative, 
lysine decarboxylase positive, ornithine decarboxylase positive, citrate utilization 
negative, H2S production negative, urease production negative, tryptophan deaminase 
negative, indole production positive, acetoin production negative, gelatinase negative, 
and had positive fermentation for glucose, mannitol, sorbitol, rhamnose, saccharose, 
melibiose, and arabinose, and negative fermentation for inositol and amygdalin.  An 
example of an API-20E original worksheet and web printout with this biochemical 
pattern is shown in Figure 11.  The next most common API-20E profile was 5144552, 
seen in 94/456 (20.6%) isolates, which had negative saccharose fermentation, 
followed by 5044572, seen in 51/456 (11.2%) isolates, which were ornithine 
decarboxylase negative.  Table 2 summarizes percentages of positive biochemical 
reactions for all E. coli isolates included in this study.   
 In 111 participants, all 3 E. coli isolates had the same API-20E profile.  In 31 
participants, 2 different API-20E profiles were seen among the 3 E. coli isolates, and 
in 10 participants each of the 3 E. coli isolates had a different API-20E biochemical 
profile.  The wide array of API-20E results demonstrates the variety of E. coli strains 
in the fecal flora of human and canine participants in this study. 
 Four human fecal samples provided by control participants did not yield E. 
coli isolates.  Repeat samples were requested from these participants, and instructions 
for proper collection, storage, and submission were reviewed.  Repeat samples were 
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processed within an hour of submission, but E. coli was not isolated from these 
specimens.  No additional enrichment procedures were attempted.  Three fecal 
samples yielded Klebsiella pneumoniae, and one yielded Serratia liquifaciens, see 
Figure 12.  Since no E. coli was isolated from these participants, they were excluded 
from the remainder of the study.  With a sample size of 30 for the control group 
instead of 34, and a continued alpha set at 0.05, effect size of 0.30, and two-tailed 
test, the power decreased from 85% to 82%.   
 
Antimicrobial Susceptibility Results 
Comparison of Antimicrobial Susceptibility within Groups   
 For each group, percentage of participants with E. coli susceptible to each of 
the 17 antimicrobial agents is shown in Table 3.  Similarly, for each group, 
percentage of E. coli isolates susceptible to each of the 17 antimicrobial agents is 
shown in Table 4.   
 Forty-one percent (75/183) of canine isolates were susceptible to all 17 
antimicrobial agents.  The remaining isolates had either intermediate susceptibility or 
resistance to at least one antimicrobial agent.  All canine isolates were susceptible to 
amikacin and imipenem, and 182/183 (99.5%) isolates and 180/183 (98.4%) isolates 
were susceptible to gentamicin and ciprofloxacin, respectively, see Figure 14.  
Intermediate susceptibility was seen to cephalothin (63/183, 34.4%), streptomycin 
(53/183, 29%), and ampicillin (24/183, 13.1%).  The greatest amount of resistance in 
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canine isolates was seen to ampicillin (23/183, 12.6%), followed by cephalothin 
(13/183, 7.1%).   
 Thirty-nine percent (71/183) owner isolates were susceptible to all 17 
antimicrobial agents.  All isolates from owners were susceptible to imipenem, while 
181/183 (98.9%) isolates were susceptible to amikacin and cefoxitin.  Intermediate 
susceptibility was seen to cephalothin (47/183, 25.7%) and streptomycin (40/183, 
21.9%).  The greatest amount of resistance was seen to ampicillin (43/183, 23.5%), 
followed by streptomycin (19/183, 10.4%) trimethoprim-sulfamethoxazole (19/183, 
10.4%), and tetracycline (17/183, 9.3%), see Figure 14.   
 Resistance to two 3rd generation cephalosporins, ceftiofur and cefpodoxime, 
was seen in dogs and owners but not in controls.  Ceftiofur-resistant isolates were 
seen in 3/61 (5%) of dogs, and 2/61 (3%) of owners.  Only Household #58 had 
ceftiofur-resistant E. coli isolated from both dog and owner.  There was overlap in 
resistance for ceftiofur and cefpodoxime.  Cefpodoxime-resistant isolates were seen 
in 4/61 (7%) dogs and 3/61 (5%) of owners.  Again, only Household #58 had 
cefpodoxime-resistant E. coli isolated from both dog and owner.  In Household #58, 
owner identification number (ID#)124 had received a course of amoxicillin-
clavulanic acid 30 days prior to enrollment, but dog ID#64 had no history of 
receiving antimicrobial therapy.  Of the other participants with isolates resistant to 
ceftiofur and cefpodoxime, one dog had received amoxicillin in the past year, and one 
dog had received cephalexin 4 years previously, while the remaining dogs and owners 
had no history of receiving antimicrobial therapy.  
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 Thirty-eight percent (34/90) control isolates were susceptible to all 17 
antimicrobial agents.  All control isolates were susceptible to amikacin, cefoxitin, 
ceftiofur, cefpodoxime, ceftriaxone, gentamicin, and imipenem.  Intermediate 
susceptibility was commonly seen to cephalothin (25/90, 27.8%) and streptomycin 
(23/90, 25.6%).  The greatest amount of resistance was seen to ampicillin (27/90, 
30%), followed by trimethoprim-sulfamethoxazole (13/90, 14.4%), streptomycin 
(9/90, 10%), and tetracycline (9/90, 10%), see Figure 15.    
 
Comparison of Antimicrobial Susceptibility between Groups 
 No differences were found with the Wilcoxon signed ranks tests for 
susceptibility comparisons of E. coli isolated from dog-owner pairs, to any of the 17 
antimicrobial agents, see Table 5.   When the data were collapsed so that intermediate 
results were considered susceptible, and a McNemar Chi-Square test was used, no 
differences were found between dog-owner pairs for any of the 17 antimicrobial 
agents.  Similarly, if the data were collapsed so that intermediate results were 
considered resistant, no differences were found between dog-owner pairs for any of 
the 17 antimicrobial agents.  For 6 pairs, both dog and owner had fecal E. coli that 
were susceptible to all 17 antimicrobial agents tested.   
 There were no differences in susceptibility results from owners and controls, 
see Table 6.   Differences were found when comparing susceptibility results of dogs 
and controls, see Table 7.  Control isolates were more resistant than canine isolates to 
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ampicillin (p<0.001), chloramphenicol (p=0.029), ciprofloxacin (p=0.029), 
tetracycline (p=0.024), and trimethoprim-sulfamethoxazole (p<0.001).  With the 
Bonferroni adjustment, control isolates were more likely resistant to only ampicillin 
and trimethoprim-sulfamethoxazole than canine isolates.  
  
Analysis of Antibiograms 
 Construction of antibiograms provides a way to analyze overall antimicrobial 
resistance patterns.  Antibiogram patterns included concurrent resistance to two or 
more antimicrobial agents, and prevalence for each pattern was calculated for the 
isolates in each population (see Table 8).  In the canine population, the most common 
antibiogram pattern of resistance was seen to ampicillin and cephalothin (8/183, 
4.4%).  In owners, the most common antibiogram pattern of resistance was seen to 
ampicillin and trimethoprim-sulfamethoxazole (13/183, 7.1%), followed by 
ampicillin and streptomycin (11/183, 6%).  Antibiogram results for controls were 
similar to owners, with highest resistance to ampicillin and trimethoprim-
sulfamethoxazole (10/90, 11.1%), followed by ampicillin and streptomycin (9/90, 
10%).  The combination of resistance to ampicillin, streptomycin, and trimethoprim-
sulfamethoxazole was seen in 7/90 (7.8%) of control isolates. 
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Multiple Drug Resistance 
 Multiple drug resistance (MDR) was defined as resistance to 3 or more 
antimicrobial agents, regardless of class.  Overall, 19/152 participants (12.5%) had 
MDR E. coli and 46/456 (10.1%) isolates were MDR.  Eight isolates (8/183, 4.4%) 
from 4/61 (6.6%) dogs were classified as having MDR.  Two dogs had 1 MDR isolate 
each, 1 dog had 3 different MDR isolates, and 1 dog had 3 isolates with the same 
MDR pattern (see Table 9).  Isolates from these 4 dogs were resistant to a range of 7-
14 antimicrobial agents.  One hundred percent were resistant to ampicillin, and 62.5% 
were resistant to amoxicillin-clavulanic acid, cefoxitin, ceftiofur, cefpodoxime, 
cephalothin, streptomycin, and trimethoprim-sulfamethoxazole. 
 Twenty-five isolates (25/183, 13.7%) from 10/61 (16.4%) owners were 
classified as having MDR.  These isolates were resistant to a range of 3-10 
antimicrobial agents, with a median of 4.5.  In 7/10 of these owners, all 3 fecal 
isolates were MDR.  Five of these owners had the same MDR susceptibility pattern in 
all 3 isolates, whereas 2 owners had multiple MDR profiles, see Table 10.  Ninety-
two percent were resistant to ampicillin, 52% were resistant to trimethoprim-
sulfamethoxazole, and 48% were resistant to streptomycin.  Percentages of resistance 
to amoxicillin-clavulanic acid and the cephalosporin antimicrobials was lower than in 
dogs and ranged from 8-36%.   
 Thirteen isolates (13/90, 14.4%) from 5/30 (16.7%) controls were classified as 
having MDR.  Isolates from these 5 individuals were resistant to a range of 3-9 
antimicrobials, with a mean of 4.2 and median of 3.  In 4/5 of these controls, all 3 
 81
fecal E. coli isolates were MDR, and in 3 of these controls all 3 isolates shared the 
same susceptibility pattern.  One control had 3 MDR isolates that each had different 
susceptibility patterns, see Table 11.  One hundred percent were resistant to 
trimethoprim-sulfamethoxazole, 79.6% were resistant to ampicillin, and 53.8% were 
resistant to streptomycin.  While 23.1% were resistant to cephalothin, all MDR 
isolates from controls were susceptible to the remaining cephalosporins. 
 The percentage of MDR E. coli varied between groups and was lowest among 
dogs, see Figure 16.  There was no difference between percentage of paired dogs 
versus their owners (p=0.109) who had MDR E. coli.  Controls had more MDR 
isolates (13/90, 14.4%) than dogs (8/183, 4.4%), (p=0.003).  There was no statistical 
difference between the number of owners and controls who had fecal MDR E. coli 
(p=0.974) or between the total number of MDR E. coli isolates from owners and 
controls (p=0.833).   
 Resistance patterns varied widely between MDR E. coli isolated from dogs 
versus human beings in this study, see Figure 17.  Canine MDR isolates were more 
resistant than owner and control MDR isolates to cefoxitin (p=0.001), and more 
resistant than control MDR isolates to ceftiofur (p=0.001), cefpodoxime (p=0.001), 
and ceftriaxone (p=0.002) see Table 12.  Control MDR isolates were more resistant 
than owner MDR isolates to trimethoprim-sulfamethoxazole (p=0.003).   
 Comparing history of antimicrobial therapy to MDR results, only 2/4 (50%) 
dogs with MDR isolates had received antimicrobial therapy: dog ID#6 had received a 
course of amoxicillin within 30 days of enrollment, and dog ID#19 had received a 
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course of amoxicillin-clavulanic acid within a year of enrollment.  Of the owners with 
MDR isolates, 2/10 (20%) had received antimicrobial therapy: owner ID#109 had 
received an unknown antimicrobial agent within a year of enrollment, and owner 
ID#124 had received a course of amoxicillin-clavulanic acid within 30 days of 
enrollment.  Of the controls with MDR isolates, 2/5 (40%) had received antimicrobial 
therapy: control ID#145 had received azithromycin and nitrofurantoin within 30 days 
of enrollment, and control ID#156 had received intermittent sulfa therapy throughout 
the year prior to enrollment. 
 For two dog-owner pairs, MDR E. coli was isolated from dog and owner, see 
Table 13.  One pair, from Household #2, included a dog ID#6 with E. coli resistant to 
7 antimicrobial agents and an owner ID#66 with E. coli resistant to 3 antimicrobial 
agents.  The dog in Household #2 was a 15yr-old female spayed Weimaraner with a 
history of 3-4 historical UTIs of unknown bacterial etiology, most recently in May 
2006 (3 months prior to enrollment).  Although the dog had not received 
antimicrobial therapy within the month prior to enrollment, she had previously 
received three courses of amoxicillin during 2005-2006.  This dog did not have 
diarrhea or known endocrine disease, and she was not currently receiving 
immunosuppressive therapy.  The owner in Household #2 was an adult female with 
no history of UTI, immunosuppressive disease or therapy, and no known 
antimicrobial history.  Both dog and owner had E. coli resistant to ampicillin.  There 
were 2 other dogs also living in the home at the time, neither of which had any history 
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of diarrhea or antimicrobial therapy.  There were no children or other family members 
living in this household.   
 The second pair, from Household #58, included dog ID#64 with E. coli 
resistant to 9 antimicrobial agents and owner ID#124 with E. coli resistant to 10 
antimicrobial agents.  The dog in Household #58 was a 5-year-old female spayed 
Labrador retriever with no history of UTI, diarrhea, known endocrine disease, or 
neither antimicrobial nor immunosuppressive therapy.  The owner in Household #58 
was a 29 year-old female with no history of UTI, diarrhea, or immunosuppressive 
disease or therapy.  This owner had received a 10-day course of amoxicillin-
clavulanic acid that was finished 24 days prior to entry into the study.  Both dog and 
owner had E. coli resistant to amoxicillin-clavulanic acid.  There were no other pets 
in this household.  There was a 13-year-old child in the household, but this child was 
healthy and had no antimicrobial history.   
 
Comparison of Antimicrobial Susceptibility to Demographics 
 There was no association between owners’ or controls’ gender and 
susceptibility results for any of the 17 antimicrobial agents.  An association was seen 
between dogs’ sex and susceptibility to tetracycline (p=0.003), with female dogs 
more likely to have tetracycline-resistant E. coli than male dogs.  Living in a multi-
pet vs. single pet household was not associated with susceptibility results of any of 
the 17 antimicrobial agents for dogs or owners.  Owner affiliation with the UTCVM 
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was associated with susceptibility results to kanamycin (p=0.002), streptomycin 
(p=0.003), tetracycline (p=0.001), and trimethoprim-sulfamethoxazole (p=0.001).  
Owners not affiliated with the UTCVM were more likely to have E. coli resistant to 
each of these antimicrobial agents than owners affiliated with the UTCVM.  Owner 
affiliation with human hospitals was not associated with susceptibility results to any 
of the 17 antimicrobial agents or to carriage of MDR E. coli. 
 
Comparison of Susceptibility to Antimicrobial Therapy within 30 Days 
 Participants who received antimicrobial therapy in the month prior to 
enrollment had more MDR fecal E. coli than those who did not (p=0.005).  Dog 
ID#28 had been administered cephalexin within one month of enrollment into this 
study, but all 3 fecal E. coli isolates were susceptible to all 17 antimicrobial agents; 
isolates from its owner ID#88 had intermediate susceptibility to cephalothin but were 
susceptible to the remaining antimicrobial agents.   
 Three owners had each taken 1 course of antimicrobial therapy in the past 30 
days.  Owner ID#69 had taken penicillin prophylactically for a dental procedure.  E. 
coli isolates from the feces of both owner ID#69 and his dog ID#9 had intermediate 
susceptibility to ampicillin and cephalothin.  Dog ID#9 also had E. coli that was 
resistant to nalidixic acid and intermediately susceptible to streptomycin, while the 
owner’s E. coli had intermediate susceptibility to nalidixic acid and was susceptible 
to streptomycin.  Owner ID#72 had received a course of topical ciprofloxacin for 
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otitis in the 30 days prior to enrollment.  This owner’s fecal E. coli had intermediate 
susceptibility to ampicillin, cephalothin, and streptomycin, and E. coli from his dog, 
ID#12, also had intermediate susceptibility to cephalothin and streptomycin, but E. 
coli from both were fully susceptible to ciprofloxacin.  Owner ID#124 (Household 
#58) had received amoxicillin-clavulanic acid in the 30 days prior to enrollment for 
an unspecified infection, and both dog and owner had MDR fecal E. coli that were 
resistant to amoxicillin-clavulanic acid, as well as other beta-lactam antimicrobial 
agents.   
 Two controls received antimicrobial therapy within the 30 days prior to 
enrollment.  Control ID#145 took nitrofurantoin for a UTI and azithromycin for an 
upper respiratory infection.  E. coli isolated from control ID#145 was MDR and 
resistant to ciprofloxacin, nalidixic acid, and trimethoprim-sulfamethoxazole, and had 
intermediate susceptibility to cephalothin and streptomycin.  Control ID#156 received 
sulfa drugs frequently for acne, and E. coli isolated from this participant was MDR 
and resistant to ampicillin, cephalothin, chloramphenicol, ciprofloxacin, kanamycin, 
nalidixic acid, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole, and 
had intermediate susceptibility to amoxicillin-clavulanic acid.    
 Five dog-owner households had pets, other than enrolled dogs, who had 
received antimicrobial therapy within 30 days of their housemate’s enrollment.  
Although the following descriptions suggest recent antimicrobial therapy in 
unenrolled household pets may be linked to carriage of MDR E. coli in enrolled 
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owners or dogs, no statistical association was found (p=0.137) and (p=0.205), 
respectively. 
 A cat in Household #7 received cefazolin 1 week prior to the dog and owner’s 
enrollment; neither the dog nor the owner had received any antimicrobials within the 
year prior to enrollment.  E. coli from the dog in Household #7 had intermediate 
susceptibility to amoxicillin-clavulanic acid, cephalothin, kanamycin, and 
streptomycin, but was susceptible to the remaining antimicrobials.  E. coli from the 
owner in Household #7 were MDR and resistant to amikacin, cefoxitin, ceftiofur, 
cefpodoxime, ceftriaxone, cephalothin, kanamycin, nalidixic acid, and streptomycin.     
 Household #28 had a second dog who had received a sulfa antimicrobial 
within 30 days.  While E. coli from the enrolled dog were susceptible to 
trimethoprim-sulfamethoxazole, E. coli from the owner were resistant to 
trimethoprim-sulfamethoxazole although that owner had not taken any antimicrobial 
agents in the past year.   
 Household #30 had 2 unenrolled dogs, one who had received cefpodoxime 
and one who had received ciprofloxacin in the month prior to the study.  Fecal E. coli 
from the enrolled dog in Household #30 (and who had not received any 
antimicrobials in the past 4 years) were MDR and resistant to 14 antimicrobials, had 
intermediate susceptibility to ceftriaxone, and were susceptible only to amikacin and 
imipenem.  Fecal E. coli from the owner in Household #30 were susceptible to all 17 
antimicrobial agents.   
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 Household #37 had one unenrolled dog who had diarrhea during the study and 
had received metronidazole 1 day prior to his housemates’ enrollment.  Neither the 
enrolled dog nor the owner had received antimicrobial therapy within the year prior to 
enrollment.  Fecal E. coli from the dog were susceptible to all 17 antimicrobials, and 
from the owner were resistant to ampicillin and had intermediate susceptibility to 
cephalothin.   
 Household #44 had two unenrolled dogs who had received clindamycin in the 
30 days prior to the study for dental purposes.  Fecal E. coli from the enrolled dog, 
who had not received antimicrobials in the past month, but had 1 course each of 
metronidazole and cefpodoxime over the past year, were resistant to chloramphenicol 
and had intermediate susceptibility to ampicillin, cephalothin, and streptomycin.  
Fecal E. coli from the owner in Household #44, who had not received antimicrobials 
in the past 30 days but had received an unknown antimicrobial within the year prior 
to enrollment for bronchitis, were MDR with resistance to ampicillin, streptomycin, 
and trimethoprim-sulfamethoxazole.   
 Although 16.4% of dog-owning households had children in the house, none of 
these children had received antimicrobial therapy in the 30 days prior to their parent’s 
and dog’s enrollment in the study.  Control ID#157 had 2 children in the house who 
received topical ciprofloxacin ophthalmic medication 5 days prior to their parent’s 
enrollment into the study, however E. coli from this participant was susceptible to all 
17 antimicrobial agents.  Unfortunately, it was not asked whether other family 
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members in the house, besides children, received antimicrobial therapy in the 30 days 
or year prior to the study; this was an oversight in the questionnaire design. 
 
Comparison of Susceptibility to Antimicrobial Therapy within a Year 
 Thirty-two percent (6/19) of participants with MDR isolates had a history of 
receiving antimicrobial therapy within a year prior to enrollment, but this was not 
associated with isolation of MDR E. coli (p=0.948).   Dogs, owners, and controls with 
MDR E. coli were equally likely to have taken antimicrobial therapy within the year 
prior to enrollment (p=0.512).  There was no association between taking 2 or more 
courses of antimicrobial therapy and having MDR E. coli (p=0.172).  Of participants 
who received 2 or more courses of antimicrobials within the previous year, 25% had 
MDR E. coli isolates, and 58% of volunteers had isolates that were not susceptible 
(intermediate or resistant) to at least one of the antimicrobials which they reported 
receiving.  Twenty-two percent of the paired housemates to a participant who 
received 2 or more courses of antimicrobials in the year prior to enrollment had MDR 
E. coli, and 33% were not susceptible to one of the antimicrobials their pair reported 
receiving.   
 Two participants reported receiving antimicrobial therapy, either in frequent 
courses intermittently or continuously throughout the year.  Owner ID#76, who 
reported taking a course of amoxicillin-clavulanic acid and intermittent minocycline 
throughout the year, had E. coli susceptible to all beta-lactams and tetracycline; 
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however dog ID#16 in the same household, who had no history of antimicrobial 
therapy reported in the past year, had E. coli resistant to ampicillin and cephalothin, 
and intermediate susceptibility to amoxicillin-clavulanic acid.  Control ID#156 
received continuous sulfa antimicrobial therapy from December 2005 through 
November 2006, prior to enrolling in late December 2006.  E. coli isolated from this 
participant was MDR and resistant to trimethoprim-sulfamethoxazole as well as 
amoxicillin, cephalothin, chloramphenicol, ciprofloxacin, kanamycin, nalidixic acid, 
streptomycin, and tetracycline.  
 
Comparison of Antimicrobial Susceptibility to History of UTI 
 Antimicrobial susceptibility results were compared with reported history of a 
UTI at any time in the participant’s lifetime.  In women, an association was found 
between history of UTI and ampicillin resistance in fecal E. coli (p=0.002); no 
associations were found when including male isolates.  In dogs, there was an 
association between history of UTI and harboring fecal E. coli with resistance to 
ciprofloxacin (p<0.001) and nalidixic acid (p=0.002).   History of recurrent UTIs was 
associated with isolates having increased ampicillin resistance in women (p=0.002), 
and increased cefoxitin (p=0.002), ceftiofur (p=0.002), ceftriaxone (p=0.002), 
ciprofloxacin (p<0.001), gentamicin (p<0.001), and nalidixic acid (p<0.001) 
resistance in dogs. 
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 History of reported UTI was associated with receiving antimicrobial therapy 
both 30 days (p<0.001) and 1 year (p<0.001) prior to enrollment into the study.  Nine 
percent of participants with reported UTI had received antimicrobial therapy in the 30 
days prior to enrollment, compared with only 1% of those without a history of UTI.  
Forty-four percent of participants with reported UTI had received antimicrobial 
therapy in the year prior to enrollment, compared with 27% of those without a history 
of UTI.   
 
Comparison of Antimicrobial Susceptibility to Dog-Owner Behaviors 
 Twenty-five percent of owners reported washing their hands after petting their 
dogs, and this behavior was associated with antimicrobial susceptibility results in the 
owners’ fecal E. coli to ampicillin (p=0.003), amoxicillin-clavulanic acid (p=0.009), 
cephalothin (p=0.033), and trimethoprim-sulfamethoxazole (p=0.009); only 
ampicillin is significant when using the Bonferroni corrected threshold.  Fifty percent 
of E. coli isolates from owners who did not wash their hands after petting their dogs 
were resistant to ampicillin, compared with only 4% resistance in isolates from 
owners who did wash their hands. 
 An association was found between cephalothin resistance and consumption of 
raw meat by dogs (p=0.021); however this result was not significant using the more 
rigid Bonferroni threshold of p≤0.003.  Eighty percent (4/5) of owners who fed raw 
meat also allowed their dogs to kiss or lick them on the face, but the power was too 
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low to find statistical differences between susceptibilities of fecal E. coli from these 
two subpopulations.  There were no associations between antimicrobial susceptibility 
results of dog’s fecal E. coli and consumption of raw fruits and vegetables. 
 An association was found between ciprofloxacin resistance and feeding 
“people food” to dogs (p=0.037); however this result was not significant using the 
more stringent Bonferroni corrected threshold of p≤0.003.  There was no association 
between feeding “people food” to dogs and the owners’ fecal E. coli susceptibility 
results. 
 Hand-washing before meals was associated with susceptibility results of fecal 
E. coli isolated from owners to chloramphenicol (p<0.001), ciprofloxacin (p<0.001), 
nalidixic acid (p<0.001).  Isolates from owners who did not wash their hands were 
more likely resistant than isolates from owners who did wash their hands to 
chloramphenicol (7.1% vs. 0%), ciprofloxacin (14.3% vs. 0.7%), and nalidixic acid 
(14.3% vs. 2.8%).   
 Washing hands before feeding their dogs was associated with susceptibility 
results to tetracycline in their dog’s fecal E. coli (p=0.002).  Tetracycline resistance in 
canine isolates was more common from dogs whose owners washed their hands 
before feeding them than from dogs whose owners did not wash their hands (25% vs. 
2.3%). 
 Washing hands after disposing of dog’s feces was associated with 
streptomycin susceptibility results in owner’s fecal E. coli (p=0.050); however this 
result would not be significant using the more stringent Bonferroni p-value threshold 
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of p≤0.003.  Streptomycin resistance was more common in isolates from owners who 
did wash their hands after disposing of their dog’s feces than in those who did not 
wash their hands (16% vs. 0%).   
 Drinking water out of the toilet was associated with susceptibility results in 
dogs’ fecal E. coli for ciprofloxacin (p<0.001) and nalidixic acid (p=0.002).  Dogs 
that drank water out of the toilet had E. coli isolates that were more likely resistant 
than those who did not to ciprofloxacin (12.5% vs. 0%) and nalidixic acid (12.5% vs. 
1.3%).   
 No associations were identified between susceptibility results and dog-owner 
pairs sleeping in the same bed, allowing the dog to kiss or lick the owner on the face, 
or awake time spent together per week.   
 
Pulse Field Gel Electrophoresis Results 
Gel Electrophoresis Image Results 
 An example of a gel’s image after running PFGE is shown as Figure 18.  Each 
gel contained 3 pairs of dog and owners, or 6 controls.  Lanes 1, 8, and 15 contained 
Low Range PFG markers with known base pair bands used for standardization of 
fingerprints within and between gels.  In gels representing dogs and owners, lanes 2, 
3 contained E. coli from the dog, and lanes 4, 5 contained E. coli from the owner in 
the same household.  Similarly, lanes 6, 7 contained with E. coli from the dog, and 
lanes 9, 10 contained E. coli from the owner in the same household.  Finally, lanes 
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11, 12 contained E. coli from the dog, and lanes 13, 14 contained E. coli from the 
owner in the same household.  All gel images were analyzed with FPQuest Software 
Version 4.5 (Bio-Rad, Richmond, CA), and similarity matrices were determined 
between each dog-owner pair.    
 
Distribution of Clones 
 Both E. coli isolates from 57/152 participants had >94% similarity.  Eleven 
isolates (3.6%) were untypeable due to degradation of the genomic DNA during 
preparation; of the untypeable isolates, 4 were canine isolates, 1 was an owner isolate, 
and 6 were control isolates.  Thus, 293 isolates with genomic patterns remained for 
comparison.   From these isolates, PFGE resolved 205 discrete genomic patterns or 
clones.  Of these 205 clones, 169 (82.4%) were isolated from only one participant.  
Thirty-six E. coli clones (17.6%) were shared between multiple participants. 
 Of the 36 shared clones, 3 clones were shared between 3 hosts, and 33 clones 
were shared between 2 hosts.  Six clones were shared between dogs and owners 
within households, while 30 clones were shared across households.  Seven clones 
were shared between dogs across households, 9 were shared between dogs and owner 
across households, 2 were shared between dogs and controls across households, 4 
were shared between owners across households, 5 were shared between owners and 
controls across households, and 3 were shared between controls across households 
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(see Figure 19).  A dendrogram showing the similarity between isolates from all dogs, 
owners, and controls is shown in Figure 20.   
 
Clonal Sharing By Individuals 
 Of the 152 total participants, 48 (31.6%) shared ≥ 1 clone with another 
participant (see Figure 21).  Twenty dogs (32.7%) shared a fecal E. coli clone with 
another individual in this study, although only 6/61 (9.8%) shared that clone with 
their owner as a within-household shared clone.  Similarly, 20/61 owners (32.7%) 
shared a fecal E. coli clone with another individual in this study, although only 6/61 
(9.8%) shared that clone with their dog as a within-household shared clone.  Eight 
control participants (26.7%) shared a fecal E. coli clone with another individual in 
this study, all across-household sharing.  
 There was no difference in percentage of individuals sharing ≥ 1 clone for 
each of the three groups (p=0.812).  Among human participants, clone sharing was 
not different between men (26.3%) and women (31.9%) (p=0.636).  Similarly, among 
dogs, clone sharing was not different between male (32.1%) and female (33.3%) dogs 
(p = 0.921).   
 
 95
Clonal Sharing Within Households 
 One dog-owner pair had isolates with 100% PFGE profile similarity, see 
Figure 22.  Six dog-owner pairs (9.8%) had isolates with >94% PFGE profile 
similarity, and 13 dog-owner pairs (21.3%) had isolates with >90% PFGE profile 
similarity.  Results of the remaining dog-owner pair similarity matrices are available 
in Table 14.   
 
Comparison of Within and Across-Household Sharing 
 There were 11,476 total potential clone-sharing pairs, 61 potential within-
household clone-sharing pairs, and 11,415 potential across-household clone-sharing 
pairs.  Clonal sharing was seen in 36/11,476 (0.3%) total potential clone-sharing 
pairs, 6/61 (9.8%) potential within-household clone-sharing pairs, and 30/11,415 
(0.26%) potential across-household clone-sharing pairs.  Within-household sharing 
was more prevalent than across-household sharing of fecal E. coli (p<0.001). 
 
Descriptive Analysis of Clone Sharing Across Households 
 Nine E. coli clones were shared between dogs and owners across households, 
with one clone sharing 100% PFGE profile similarity.  Five of these clones (55.6%) 
were shared by unpaired dogs and owners affiliated with the UTCVM, including the 
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clone with 100% similarity.  Four clones were shared across households with no 
known direct, occupational, or environmental contact.    
 Seven clones were each shared between 2 dogs that lived in separate 
households.  All of the dogs’ owners either worked or were students at the UTCVM.  
Twelve clones were shared between human participants living in separate households.  
Of these, 4 were shared by participants who worked or studied at the UTCVM, while 
the remaining 8 clones were shared by participants from a mix of UTCVM, GI 
Associates, and Department of Genetics.  Due to confidentiality limitations, further 
questioning of the owners regarding contact with each other or between their dogs 
was not permitted after the study was performed.   
   
Analysis of E. coli Groups of Isolates 
 Based on analysis of the dendrogram in Figure 20, no strains or groups of 
strains were identified more commonly in dogs, owners, or controls in this study.   
Instead, the dendrogram displays the genetic uniqueness of the clones isolated from 
these participants.  Of the 205 E. coli clones, seventeen groups of isolates were 
identified that each shared >90% PFGE profile similarity.  All groups contained 5 or 
fewer participants. 
Only 1 group included E. coli isolates from all 3 populations, dog ID#28, 
owner ID#112, owner ID#123, and control ID#146, see Figure 23.  The owner of dog 
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ID#28 was affiliated with the UTCVM, but participants ID#112, ID#123, and ID#146 
were not and had no known direct or occupational contact.   
 Six groups included participants from both the dog and owner population (see 
Figures 24-29).  Since the definition of a group required 4 or more isolates to have 
>90% PFGE similarity, none of the 6 dog-owner pairs that had 2 clones with >94% 
within-household sharing met this criteria; however, all 4 isolates from one additional 
dog-owner pair, dog ID#56 and owner ID#116, did have >90% PFGE similarity 
(Figure 29).  One other group included within-household sharing between dog ID#22 
and owner ID#82 (Figure 27).  All other groups identified were comprised of across-
household clonal sharing exclusively.  Three groups included hosts from the owner 
and control populations, 5 groups included just owners (2-3 owners per group), 1 
group included 3 controls, and 1 group included 4 isolates from 2 dogs.  
 
Comparison of PFGE Profile Similarity to Demographics 
 Percent PFGE similarity between isolates from dogs and owners was 
compared to demographic information, and no significant associations were found 
with owner gender (p=0.253), dog sex (p=0.282), dog’s age category (<2years, 2-
5yrs, 6-9yrs, and 10+) (p= 0.563), breed (purebred or mixed breed dog) (p=0.574), or 
dog source (breeder, shelter/stray, pet store, other) (p=0.123).  Living in a multi-pet 
vs. single pet household was not associated with % PFGE profile similarity, nor was 
total number of pets in the house (p=0.226), and (p=0.069), respectively.  Owner 
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affiliation with the UTCVM was not associated with increased E. coli clonal sharing 
based on % PFGE profile similarity (p=0.829). 
  
Comparison of PFGE Profile Similarity to Dog-Owner Behaviors 
 Percent PFGE profile similarity between isolates from dogs and owners were 
compared to the following dog-owner behaviors: amount of awake-time spent with 
dog, sleeping in the same bed, kissing on the face, washing hands after petting, being 
the primary feeder of the dog, feeding dog raw meat, feeding dog raw fruits and 
vegetables, feeding dog “all people-food,” washing hands before feeding dog, 
washing hands before eating, washing hands after disposing of dog’s feces, dog 
drinking from toilet, having other pets in household, and weekly time spent at dog 
parks.  No behaviors surveyed were found statistically more often in dog-owner pairs 
exhibiting within-household clonal sharing; however, disposing of dog’s feces was 
associated with lower % PFGE profile similarity (p=0.013).  Owners who disposed of 
their dog’s feces had E. coli with a mean % PFGE profile similarity with their dog of 
81.48%, while owners who did not dispose of their dog’s feces had E. coli with a 
mean % PFGE profile similarity with their dog of 85.78%.  Owners who disposed of 
their dog’s feces 5 or more times a week had E. coli with the lowest % PFGE profile 
similarity with their dog (mean 77.2%).  Times per week an owner disposed of feces 
was not associated with whether or not they washed their hands after disposing of 
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feces (p=0.429), but only 2/29 owners who did dispose of feces did not wash their 
hands.   
 
Virulence Factor Results 
Spectrophotometry Results 
 Nucleic acid concentration and quality results from spectrophotometry testing 
of DNA lysates to be used for PCR are in listed in Appendix D.  All E. coli lysates 
were found to have sufficient DNA (>400ng/µl), with a range of 454-2862ng/μl, 
mean of 920ng/μl, and a median of 874ng/μl.  Overall quality of DNA lysates was 
pure with a mean 260:280nm absorbance ratio of 1.81. 
 
Gel Electrophoresis Image Results 
 An example of a gel image from the multiplex PCR assay is shown in Figure 
30.  Each gel for PCR samples had two rows of 20 lanes, numbered from left to right 
starting with the top row.  Lanes 1, 20, 21, and 40 contained 100bp DNA ladder for 
standardization.  The largest band in this ladder was 1500bp, followed by 1000bp, 
and then each band decreased in size by 100bp.  Lanes 2, 19, 22, and 39 each 
contained E. coli strain J96, a known positive control for all 4 virulence factors.  Lane 
31 contained sterile water as a negative control.  Lane 32 contained E. coli strain 
JJ055, a known negative control for all 4 virulence factors.  The remaining lanes 
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contained PCR-amplified DNA from participant isolates.  Base pair sizes for each 
virulence factor were: cnf 974, hlyD 904, sfa 410, and papGIII 258.  Bands for cnf 
and hlyD were physically close together due to their similar base pair size.  All 
images were analyzed with FPQuest Software Version 4.5 (BioRad, Richmond, CA), 
to confirm base pair size of each band.  
 
Prevalence of Virulence Factors  
 Overall, 45/61 (73.7%) dogs, 50/61 (81.9%) owners, and 24/30 (80%) 
controls were negative for all 4 virulence factors in all 3 fecal E. coli isolates, see 
Tables 15 and 16.  Six dogs (9.8%), 4 owners (6.5%), and zero controls had presence 
of all 4 virulence factors in all 3 fecal E. coli isolates.  Figure 31 summarizes the 
percentage of dogs, owners, and controls that had fecal E. coli isolates with presence 
of each of the 4 virulence factors.   
 Ten dogs (16.4%), 10 owners (16.4%), and 5 controls (16.7%) had E. coli 
isolates positive for cnf.  Ten dogs (16.4%), 11 owners (18%), and 6 controls (20%) 
had E. coli isolates positive for hlyD.  Fifteen dogs (24.6%), 10 owners (16.4%), and 
3 controls (10%) had E. coli isolates positive for sfa.  Eight dogs (13.1%), 5 owners 
(8.2%), and 3 controls (10%) had E. coli isolates positive for papGIII.   
 Since not all individuals had similar virulence factor profiles among all 3 
isolates, prevalence data for total number isolates was different than prevalence per 
participant.  Figure 32 displays the prevalence of each virulence factor when 
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including all 3 fecal E. coli isolates from each participant.  Twenty-eight canine 
isolates (15.3%), 26 owner isolates (14.2%), and 12 control isolates (13.3%) were 
positive for cnf.  Twenty-eight canine isolates (15.3%), 29 owner isolates (15.8%), 
and 15 control isolates (16.7%) were positive for hlyD.  Forty canine isolates 
(21.9%), 26 owner isolates (14.2%), and 6 control isolates (6.7%) were positive for 
sfa.  Twenty-three canine isolates (12.6%), 14 owner isolates (7.7%), and 7 control 
isolates (7.8%) were positive for papGIII. 
 
Virulence Factor Patterns 
 In 142/152 (93.4%) of participants, all 3 E. coli isolates shared the same 
virulence factor profile.  The most common virulence factor pattern was negative for 
all 4 virulence factors, occurring in 78% (119/152) of participants.  The next most 
common was positive for all 4 virulence factors, occurring in 7/61 (11.5%) dogs and 
5/61 (8.2%) owners, followed by the combination of cnf, hlyD, and sfa, occurring in 
2/61 (3.3%) dogs, 5/61 (8.2%) owners, and 2/30 (6.7%) controls, see Table 17.  The 
only virulence factors that occurred alone were sfa in 6/61 (9.8%) dogs and 1/30 
(3.3%) controls, and hlyD in 1/61 (1.6%) owners. 
   
Comparison of Virulence Factors between Groups 
 There was no significant difference in presence or absence of each virulence 
factor between dog and owner pairs (see Table 18).  In 35/61 households, all isolates 
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from both dog and owner were negative for all 4 virulence factors.  Only Household 
#48 had a dog and owner who both had E. coli positive for virulence factors.  In this 
household all 3 isolates from both dog and owner were positive for cnf, hlyD, and sfa, 
but negative for papGIII.   In the remaining 25/61 households either the dog or the 
owner had E. coli isolates positive for one or more virulence factor.    
 There was no difference in presence or absence of any of the 4 virulence 
factors between owners and controls (see Table 19).  More canine isolates were 
positive for sfa than control isolates (p=0.002), (see Table 20). 
 
Agreement between Virulence Factors 
 Presence of phenotypic hemolysis, as determined by visualizing large zones of 
clearing around colonies on blood agar plates was compared with presence of hlyD 
genotypically in each E. coli isolate and found to have a high measure of agreement 
(Kappa = 0.884, p <0.001).  Thirteen isolates positive for hlyD on multiplex PCR did 
not show the hemolytic phenotype (13/72, 18%). 
 In the canine population, there was perfect agreement (Kappa=1, p<0.001) 
between presence of cnf and hlyD, and very good agreement (Kappa=0.886, p<0.001) 
between presence of cnf and papGIII and between hlyD and papGIII, (see Table 21).  
In the owner population, there was complete agreement between cnf and sfa 
(Kappa=1.000, p<0.001), and very good agreement between cnf and hlyD (K=0.936, 
p<0.001), and hlyD and sfa (Kappa=0.936, p<0.001).  Within the control population 
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there was very good agreement between presence of cnf and hlyD (Kappa=0.870, 
p<0.001).    
  
Comparison of Virulence Factor Results to Demographics 
 There were no differences in presence or absence of virulence factors based 
on dogs’ sex, but isolates from male human participants were more likely to have 
papGIII than isolates from female participants (p=0.010).  Presence or absence of 
virulence factors in canine and owner fecal E. coli was not associated with living in a 
single or multi-pet household, nor was it associated with owner’s affiliation with the 
UTCVM or working in a human hospital. 
 
Comparison of Virulence Factors Results to Dog-Owner Behaviors 
 No associations were found between presence or absence of virulence factors 
and amount of awake time spent together, sleeping in the same bed, kissing on the 
face, or dogs drinking from the toilet.  Hand-washing after petting their dogs, before 
eating their own meals, or before feeding their dogs, was not associated with presence 
or absence of any of the 4 virulence factors in owners’ fecal E. coli.  Hand-washing 
after petting their dogs was associated with papGIII in the feces of their dogs 
(p=0.003); in households where owners did not wash their hands after petting their 
dogs 16.7% of dogs’ fecal E. coli had papGIII, whereas in households where owners 
did wash their hands, 0% of dogs fecal E. coli had papGIII.  There was no association 
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between presence of virulence factors in dogs’ fecal E. coli and whether or not 
owners washed their hands prior to feeding the dogs.  In the subpopulation of owners 
who disposed of their dogs feces, hand-washing after disposal was not associated 
with presence or absence of virulence factors in either dog or owner’s feces. 
  
Comparison of Virulence Factor Results to UTI History 
 No association was found between having a history of UTI and presence or 
absence of any of the virulence factors in fecal E. coli for the human population as a 
whole.  For women alone, history of UTI was associated with presence of hlyD 
(p=0.048) and papGIII (p=0.026) in fecal E. coli; however these would not be 
significant using the more stringent Bonferroni corrected threshold of p≤0.0125.  No 
association was found between history of UTI and presence of any of the 4 virulence 
factors in fecal E. coli for either the entire dog population or the female dog 
subpopulation.  History of recurring UTIs (reporting 2 or more UTIs) was associated 
with presence of papGIII in women’s fecal E. coli (p= 0.008), but not in dogs’ or 
female dogs’ fecal E. coli.  There was no association between cnf, hlyD, or sfa, and 
recurrence of UTI in any subpopulation. 
  An association was found between women’s history of UTI and presence of 
virulence factors in their dogs’ feces: cnf (p<0.001), hlyD (p<0.001), sfa (p=0.007), 
and papGIII (p<0.001).  There was no association between a dog’s history of UTI and 
 105
presence or absence of cnf, hlyD, sfa, or papGIII in their owner’s fecal E. coli, 
whether including the entire dog population or just female dogs. 
  
Comparison of Susceptibility, Clonality, and Virulence Factors  
Comparison of Susceptibility and Virulence Factors  
 Mann-Whitney analysis was used to compare ordinal susceptibility results 
with presence or absence of virulence factors for 456 isolates, see Table 22.  
Resistance to cephalothin, kanamycin, nalidixic acid, streptomycin, tetracycline, and 
trimethoprim-sulfamethoxazole was associated with decreased presence of virulence 
factors if a p-value threshold of 0.05 was used; however with the Bonferroni 
adjustment for multiple comparisons to p≤[0.05/(17*4)], or p≤0.0007, the only 
remaining association was streptomycin resistance with reduction of sfa. 
 
Comparison of Virulence Factors to Percent PFGE Similarity 
 No significant associations were found between presence or absence of any of 
the 4 virulence factors in E. coli isolated from dogs and their owners and percent 
PFGE profile similarity.   Presence of papGIII was closest to a significant association 
with percent PFGE similarity (p=0.098). 
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Comparison of Susceptibility to Percent PFGE Similarity 
 No associations were found between antimicrobial susceptibility to any of the 
17 antimicrobial agents and percent PFGE similarity.  Susceptibility data were 
collapsed from intermediate to resistant to increase likelihood of detecting a 
significant difference, and both cephalothin (p=0.068) and ciprofloxacin (p=0.074) 
approached a p-value of 0.05, but no associations were found with p≤ 0.05 or the 
Bonferroni corrected threshold of p≤0.003. 
 
Comparison of Susceptibility within Shared E. coli Clones 
 Susceptibility patterns varied widely within a single clone of E. coli.  One 
clone contained isolates with MDR and isolates susceptible to all antimicrobial agents 
tested.  Isolates within 9/36 (25%) of shared E. coli clones had identical susceptibility 
patterns, while isolates within 27/36 (75%) of shared clones had different 
susceptibility patterns.   
 In 7/9 of the shared clones with isolates having identical susceptibility 
patterns, all isolates in the clones were susceptible to all 17 antimicrobial agents.  In 
one clone, both isolates had intermediate susceptibility to cephalothin and were 
susceptible to all other antimicrobial agents.  In the remaining clone, both isolates had 
identical MDR susceptibility patterns, with resistance to ampicillin, ciprofloxacin, 
and nalidixic acid.  Two of the shared clones with identical susceptibility patterns 
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were shared between dog-owner pairs within households, while 7 were shared across 
households (see Figure 33). 
 Out of the 27 clones whose isolates had different susceptibility patterns, 8 
clones contained an MDR isolate.  Three of these clones had one MDR isolate and 
one isolate susceptible to all 17 antimicrobial agents.  One across-household clone 
contained 5 isolates, with 2 canine isolates (ID#28A and ID#28B) susceptible to all 
17 antimicrobial agents, 2 owner isolates (ID#112A and ID#112B) that shared an 
MDR pattern resistant to ampicillin, streptomycin, tetracycline, and trimethoprim-
sulfamethoxazole, and 1 owner isolate (ID#123B) that was MDR with resistance to 
ampicillin, kanamycin, streptomycin, tetracycline, and trimethoprim-
sulfamethoxazole (see Figure 34 and Table 23).   
  
Comparison of Virulence Factors within 36 Shared E. coli Clones 
 Isolates within 28/36 (77.8%) shared E. coli clones had identical virulence 
factor patterns, while 8/36 (22.2%) clones had different virulence factor pattern 
results.  Twenty-six of these clones had all negative virulence factor results, while 2 
of these clones contained only E. coli isolates positive for all 4 virulence factors.  The 
remaining 8 clones had mixed virulence factor results.  Three of these clones had an 




Comparing Susceptibility and Virulence Factors within Shared Clones 
 Six of the 36 shared E. coli clones contained isolates that all had identical 
susceptibility patterns and identical virulence factor patterns within the clone.  The 
remaining 30 clones contained isolates with either different antimicrobial 
susceptibility patterns or different virulence factor patterns.  There was no agreement 
between having identical susceptibility patterns and having identical virulence factor 
patterns (Kappa = -0.087, p=0.355).  Five of the 36 shared E. coli clones contained 
isolates with neither identical antimicrobial susceptibility patterns nor identical 
virulence factor patterns.   
 Further analysis of the 6 clones with all isolates having both identical 
susceptibility and virulence factor patterns revealed that none of these clones carried 
both antimicrobial resistant phenotypes and genes for virulence factors (see Table 
24).   Of these 6 clones, 2 clones had isolates had 4/4 virulence factors present and 
were susceptible to all 17 antimicrobial agents.  Isolates in two clones had 0/4 
virulence factors and were susceptible to all 17 antimicrobial agents.  Isolates in 1 
remaining clone had 0/4 virulence factors and had intermediate susceptibility to 
cephalothin but were susceptible to the remaining 16 agents, while isolates in the 
other remaining clone had 0/4 virulence factors and were resistant to ampicillin, 
ciprofloxacin, and nalidixic acid but susceptible to the remaining 14 agents.  Of these 
6 clones, 2 clones were shared dog-dog, 2 clones were shared dog-owner (both 
across-households), 1 clone was shared owner-owner, and 1 clone was shared owner-
control.  None of the 6 clones were shared within-household.    
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Discussion 
E. coli Isolation 
 E. coli is one of the most common bacteria in the GI flora of human beings 
and dogs, and it was expected to be isolated from all fecal samples in this study; 
however E. coli was not isolated from 4/156 (2.6%) of the participants.  It has been 
reported that a small percentage of fecal samples from healthy human beings and 
dogs do not yield E. coli or any coliforms, and that Klebsiella may be the 
predominant coliform in some individuals [121, 132].  Rather than E. coli, Klebsiella 
pneumoniae was isolated from 3 participants and Serratia liquifaciens was isolated 
from 1 participant in our study. 
 Numerous variables affect bacterial composition of the GI tract, including 
recent exposure to antimicrobial agents or probiotics, altered GI pH, GI pathogens or 
inflammation, stress, and dietary choices [3].  Two of the 4 participants who did not 
have E. coli isolated from their feces had received beta-lactam antimicrobial therapy 
within the past year, but none reported routinely consuming yogurt or other probiotics 
or having a vegetarian lifestyle.  Although all reported to be healthy, stress or other 
physiologic changes may have altered their GI flora and decreased the prevalence of 
E. coli.  Other possibilities such as incorrect sample collection, storage, or submission 
were also considered, although repeat fecal samples also failed to yield E. coli.  Using 
microbiology techniques with increased sensitivity for detecting E. coli such as pre-




Susceptibility to Individual Antimicrobial Agents 
 In canine and human participants, susceptibility of fecal E. coli was lowest to 
ampicillin, cephalothin, and streptomycin.  Our results were consistent with a large 
study by Srinivasan of phenotypic and genotypic antimicrobial resistance patterns in 
E. coli from many species of animals and human beings that found high resistance to 
ampicillin, cephalothin, and streptomycin, but susceptibility to amikacin, gentamicin, 
ceftriaxone, ciprofloxacin, and trimethoprim in isolates from both animals and human 
beings [133].   
 In the Srinivasan study, all ampicillin resistant strains carried the gene ampC, 
encoding a beta-lactamase [133].  Genotypic resistance testing was not performed in 
our study, but presence of ampC or an ampC-like gene encoding for extended 
spectrum beta-lactamase production, and spread via plasmids, could explain low 
ampicillin susceptibility.  Beta-lactam therapy may have allowed selection pressure 
and cross-resistance to other beta-lactam antimicrobial agents as well.  In total, 10 
courses of penicillin, amoxicillin, and amoxicillin-clavulanic acid were received by 
human participants, and 7 courses of amoxicillin and amoxicillin-clavulanic acid 
were received by canine participants in the year prior to the study.  Resistant E. coli 
from these participants may have contaminated and acted as a reservoir in the 
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environment and shared plasmids with genes for resistance with other pathogenic 
bacteria and normal flora, contributing to overall beta-lactam resistance.   
 As a first generation cephalosporin, cephalothin is susceptible to most beta-
lactamases produced by E. coli strains and shared via plasmids; therefore, resistance 
is expected to be higher than for newer cephalosporins.  Ceftiofur is the only 
extended spectrum cephalosporin approved for use in food animals in the US, and is 
approved for dogs but is not routinely used in this species; however ceftiofur is not 
approved for use in human beings.  Resistance to ceftiofur was seen in 3/61 (5%) 
canine isolates and 2/61 (3%) owner isolates, but 0% control isolates.  This suggests 
that transmission of ceftiofur-resistant E. coli may have occurred directly from dogs 
to owners, but only Household #58 had ceftiofur-resistant E. coli isolated from both 
dog and owner.  Both owners with ceftiofur resistance had MDR E. coli, with 
concurrent resistance to other beta-lactam antimicrobial agents, suggesting that 
ceftiofur resistance was more likely due to selection pressure from beta-lactam 
exposure and extended spectrum beta-lactamases. 
 Cefpodoxime is a third generation cephalosporin that was new on the 
veterinary market at the time of the current study, and only 1 dog was reported to 
have taken a course of cefpodoxime prior to enrollment.  Cefpodoxime has been 
available for use in human beings for a longer period, but no human participant 
reported receiving cefpodoxime therapy.  Cefpodoxime-resistant E. coli isolates were 
found in 4/61 (7%) dogs and 3/61 (5%) owners, but in no controls.  Although this 
suggests spread of cefpodoxime resistance between owner and dog, only Household 
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#58 had cefpodoxime-resistant E. coli isolated from both dog and owner.  
Cefpodoxime resistance is less likely due to selection pressure from specific 
cefpodoxime therapy or direct transmission, and more likely due to other beta-lactam 
use and acquired cross-resistance from mobile genetic units such as plasmids and 
transposons. 
Imipenem was the only antimicrobial agent in the present study to which all E. 
coli isolates were susceptible.  No canine or human participants were reported to have 
received imipenem prior to enrollment in this study.  As a carbapenem, imipenem is a 
beta-lactam antimicrobial agent, but it is stable to most beta-lactamases and extended-
spectrum beta-lactamases.  Resistance to carbapenems occurs by mutations or 
acquired structural changes in penicillin binding proteins, metallo-beta-lactamases 
that can degrade carbapenems, and loss of outer membrane porins allowing changes 
in membrane permeability [134].  Its use is limited by bioavailability (requires 
parenteral administration), expense, and potential side effect of renal dysfunction and 
seizures.  Although guidelines in both veterinary and human medicine suggest 
judicial use of carbapenems to minimize selection pressure, the author’s clinical 
impression is that imipenem and meropenem are being prescribed with increasing 
frequency for resistant infections in dogs and cats.  Resistance to imipenem will need 
to be monitored in the future if therapeutic use increases. 
 Although streptomycin is no longer widely used in clinical medicine, it is a 
naturally produced antibiotic, and natural exposure may maintain selection pressure 
and resistance.  In the Srinivasan study, the genes strA and strB, encoding for 
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streptomycin phosphotransferase, and aadA, encoding for aminoglycoside 
adenyltransferase, were found in nearly all streptomycin resistant strains of E. coli 
[133].  Another study found a significant proportion of streptomycin resistant isolates 
carry the integrase gene intI for class-1 integrons [135].  Researchers at the University 
of Tennessee found that 50% of streptomycin resistance is plasmid-borne in E. coli  
(personal communication with Dr. Ann Draughon).  Although molecular testing for 
presence of these genes was not performed in our study, low streptomycin 
susceptibility suggests presence of class-1 integrons as well as plasmids carrying 
genes for streptomycin resistance [136, 137].   
Resistance to other aminoglycosides, including amikacin, gentamicin, and 
kanamycin, was less common in this study.   No canine or human participant reported 
having received aminoglycoside therapy, suggesting selection pressure did not 
contribute to resistance.  Lower kanamycin susceptibility (92-96%) may have been 
due to use of kanamycin resistance genes as selection markers in molecular genetics 
testing, which may increase the number of kanamycin-resistant E. coli in the 
environment. 
Tetracycline resistance is a well-recognized problem in E. coli isolated from 
farm animals, and was seen in 3.8% of canine isolates and 9.3% and 10% of owner 
and control isolates in this study [138, 139].  Tetracycline resistance may be high in 
farm animals due to use for disease prevention, and because it has been shown that 
bacteria in soil can acquire tetracycline resistance from environmental exposure, 
possibly creating a reservoir [140].  No owners reported administering tetracycline or 
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doxycycline to their dogs within the year prior to enrollment.  One owner received 
minocycline intermittently throughout the year for acne, and one control received a 
course of doxycycline 5 months prior to enrollment.  Tetracycline resistance occurs 
by efflux pumps or alteration of the 50S ribosome to prevent binding, and resistance 
is often plasmid-mediated.  Tetracycline resistance may also be carried on class-1 
integrons, genetically linked to streptomycin and trimethoprim-sulfamethoxazole 
resistance genes, with selection pressure from sulfa antimicrobial use causing cross-
resistance to tetracyclines.  Other possible routes for acquiring tetracycline resistance 
could be resistant bacterial spreading through the food chain, contact through 
occupational exposure at the veterinary or human hospitals, or exposure to waste 
runoff from a food-producing facility. 
 Susceptibility to trimethoprim-sulfamethoxazole was highest for canine 
isolates (97.3%) and lowest for control isolates (85.6%).  Although sulfa drugs have 
been available for a long time, are inexpensive, and have often been the first-line 
empirical choice for treatment of infections, no dog or owner had a history of 
receiving sulfa therapy, and only 1 control had received intermittent sulfa treatment 
over the year prior to enrollment.  Veterinarians have become cautious with 
prescribing sulfa antimicrobials due to side effects including immune-mediated 
diseases.  Resistance to sulfa drugs has increased within human UTI isolates, up to 
34% of UPEC, making it less desirable as a first-line empirical choice [82, 83, 141].  
Resistance to sulfa drugs can be carried on plasmids or class-1 integrons and spread 
horizontally through populations of E. coli and potentially other bacteria.  The higher 
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resistance rate in control participants may be due to cross-resistance from plasmids or 
class-1 integrons carrying genes for resistance to other antimicrobial agents.  
Decreased sulfa use over time may result in decreased selection pressure and 
resistance.   
 Chloramphenicol is an older but effective antimicrobial agent that is not used 
frequently in veterinary medicine and was not reportedly received by any participants 
in this study.  Resistance occurs by reduced membrane permeability, inactivation via 
an acetyltransferase cat gene, and less commonly by mutation of the 50S ribosome to 
decrease or prevent chloramphenicol binding.  Chloramphenicol resistance is usually 
chromosomal but plasmids can concurrently carry resistance genes for 
chloramphenicol, ampicillin, co-trimoxazole, and tetracycline.  
In the present study, susceptibility remained high (>92%) in all 3 populations 
for both nalidixic acid and ciprofloxacin.  Nalidixic acid is the parent quinolone, 
active mainly against gram-negative bacteria, from which modifications were made to 
increase the antimicrobial spectrum creating fluoroquinolones such as enrofloxacin 
and ciprofloxacin.  Enrofloxacin was created specifically for veterinary use and is 
metabolized to ciprofloxacin in dogs.  Only one dog had a history of receiving a 
fluoroquinolone, enrofloxacin, for a UTI; omitting enrofloxacin from the panel of 
antimicrobial agents tested was a limitation of the study from a veterinary 
perspective, but it is not routinely monitored by NARMS.  Six human participants 
had received a course of fluoroquinolones, each receiving ciprofloxacin, over the year 
prior to enrollment.  As may also be true in human medicine, a recent epidemiologic 
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review has shown that increases in fluoroquinolone resistance among canine UTI 
isolates correlates with the increase in fluoroquinolone usage in veterinary medicine 
[84]. 
Fluoroquinolone resistance can occur by efflux pump (AcrAB) and 
chromosomal mutations in gyrase (gyrA) and topoisomerase IV (parC and parE).  
Plasmid-mediated conjugation plays a small role in spreading fluoroquinolone 
resistance, although qnr genes encoding fluoroquinolone resistance can be transferred 
on plasmids with extended-spectrum beta-lactamase-encoding genes, allowing for 
cross-resistance and selection pressure during administration of beta-lactams or 
fluoroquinolones [142].  Most fluoroquinolone resistance is from chromosomal 
mutations, and selection pressure plays an important role in maintaining this 
resistance.   
Fluoroquinolones are being increasingly used as resistance has developed to 
more traditional antimicrobial agents, and ciprofloxacin is now reported to be the 
most used antibiotic in the world [86, 143].  In both dogs and human beings, 
treatment with fluoroquinolones has a profound effect of suppressing the normal 
aerobic flora, specifically eliminating coliforms [144, 145].  Gupta and colleagues 
showed that treatment with ciprofloxacin decreased prevalence of rectal colonization 
of E. coli in women treated for cystitis from 94% to <10% [146].  One study showed 
that with selection pressure from fluoroquinolones, but not without, introduced MDR 
E. coli can persist and shed for long periods in the GI tract of treated dogs [144].  
Trott and colleagues suggest this may be one explanation for the occurrence of MDR 
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E. coli nosocomial infections in veterinary hospitals, because hospitalized dogs 
carrying MDR E. coli shed large numbers of drug-resistant fecal E. coli following 
treatment with fluoroquinolones and contaminate the hospital environment [144].   
In this study, prior fluoroquinolone use by participants was unlikely to have 
affected their susceptibility directly.  Only 1 participant had received a 
fluoroquinolone in the month prior to enrollment, an owner received topical 
ciprofloxacin for otitis, and neither that owner nor his dog had fecal E. coli resistant 
to ciprofloxacin or nalidixic acid.  Although other participants had received 
fluoroquinolones in the past year, the effects of these antimicrobial agents are 
transient, and participants’ normal GI flora would have returned within two weeks or 
certainly by the time of study enrollment [147].  Rather than direct selection pressure 
from individuals receiving fluoroquinolone treatment, fluoroquinolone resistance seen 
in this study may result from increasing trends of fluoroquinolone treatment in 
veterinary and human medicine causing increased shedding of fluoroquinolone-
resistant E. coli into the environment allowing for community-acquired sharing. 
 
Mobile Genetic Elements 
 Multiple antimicrobial resistance genes can be genetically linked on plasmids, 
integrons, or transposons, which can be spread and integrated between bacteria and 
various hosts.  Although not completely understood, these genetic linkages may help 
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explain commonalities found in antibiogram patterns, within-household vs. across-
household susceptibility comparisons, and multiple drug resistance. 
Plasmids carrying genes for resistance to multiple antimicrobial agents have 
been identified in fecal E. coli from human beings, dogs, and food-producing animals, 
and plasmids can transfer resistance between bacteria either within a host’s GI flora 
or in the environment [136, 137].  Conjugation studies have found that 60-64% of 
fecal E. coli isolates from dogs were able to transfer resistance on plasmids, and that 
transfer of ampicillin, streptomycin, and tetracycline occur readily, but transfer of 
chloramphenicol and fluoroquinolones occur less frequently [136, 137]. 
 The most commonly recognized reservoir for plasmids is bacteria within the 
GI tracts of food-producing animals [137].  E. coli and plasmids may spread from this 
reservoir to other hosts by direct spread to human beings and animals on the farm, 
environmental contamination and spread through using fecal material as fertilizer, or 
by contamination of the food supply.  Companion animals and human beings may 
share plasmids due to close association with each other.  Within-household sharing of 
plasmids is a possible explanation for why no differences were found between dog 
and owner susceptibility results in this study, whereas dog and control participants 
had significant differences, with control isolates more resistant than canine isolates. 
  In addition to plasmids, integrons play a major role in the epidemiology of 
resistance to antimicrobial agents, especially streptomycin and sulfonamides [135].  A 
study compared antimicrobial resistance patterns and prevalence of integrons in feces 
of animals with varying degrees of contact with human beings [148].  Isolates from 
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animals free of human exposure had no antimicrobial resistance, and there was a 
steady increase in resistance seen as exposure to human beings increased [148].  
Class-1 integrons were not seen in isolates from wild animals but were seen in 
isolates from farm animals (7% prevalence), pet dogs (16% prevalence), and people 
(16% prevalence) [148].  Lack of a control group of wild dogs without exposure to 
human beings and not testing for presence of integrons were limitations of the present 
study.  Regardless, this suggests that finding no differences in the susceptibility 
results from dogs and owners may be due to sharing of integrons or other resistant 
genetic material in the direction of human beings to dogs, rather than dogs to human 
beings.  This would also be consistent with finding that human beings had more 
overall MDR isolates than dogs, and that risk of potential transfer would therefore be 
in the direction of human being to dog more so than dog to human being.  
 
Analysis of Antibiograms 
 The most common antibiograms for concurrent resistance in human being E. 
coli isolates were to ampicillin and trimethoprim-sulfamethoxazole, followed by 
ampicillin and streptomycin, ampicillin and tetracycline, and then ampicillin, 
streptomycin, and trimethoprim-sulfamethoxazole.  Ampicillin, tetracycline, and 
streptomycin are known to be spread via plasmids, while tetracycline, streptomycin, 
and trimethoprim-sulfamethoxazole may be linked genetically on class-1 integrons.   
Six control isolates also had concurrent resistance to ciprofloxacin, nalidixic acid, and 
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trimethoprim-sulfamethoxazole.  Genes for fluoroquinolone resistance are usually 
chromosomal mutations (gyrA) rather than acquired by a mobile genetic element, so 
this finding may be caused by coincidental mutations concurrent with a class-1 
integron carrying sulfa resistance. 
Antibiogram analysis showed the most common concurrent resistance in dogs 
was to ampicillin and cephalothin; however this occurred in only 4.4% of all canine 
isolates.  There was a large number of isolates with intermediate susceptibility to both 
ampicillin and cephalothin, explaining the low susceptibilities yet infrequent 
resistance patterns for these antimicrobial agents.  Many canine isolates were fully 
susceptible or were only resistant to one antimicrobial agent, which is why 
antibiogram patterns had low prevalence in canine isolates.  A similar study of fecal 
E. coli in dogs found the most common antibiogram for concurrent resistance was to 
ampicillin, streptomycin, and tetracycline; however no cephalosporins were included 
in that study [136].  These data are consistent with suspected genetic linkage of 
ampicillin, streptomycin, and tetracycline on plasmids, providing cross-resistance to 
all 3 antimicrobial agents [136, 137]. 
 
Comparison of Susceptibility between Dogs and Owners 
 No differences were found in antimicrobial susceptibility results of E. coli 
isolated from dog and their owners to any of the 17 antimicrobial agents, even when 
data was collapsed to eliminate intermediate results.  These results could be from a 
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small sample size and low power in the study; increasing the number of participants 
or number of isolates per participant may have identified significant differences if 
they existed.  Another explanation would be that dogs and owners directly share E. 
coli strains or mobile genetic elements with genes for antimicrobial resistance, 
leading to similar susceptibility profiles within households.  Alternatively, 
conjugation may occur in reservoirs within their households, and both dog and owner 
may be exposed to similar plasmids carrying genes for resistance.   
 In contrast, a study comparing fecal E. coli from pig farmers and their pigs 
found the prevalence of antimicrobial resistance to be significantly lower in E. coli 
from farmers than from their pigs [149].  Swine isolates were more resistant to 
chloramphenicol, nitrofurantoin, oxytetracycline, streptomycin, and sulfamethoxazole 
than isolates from farmers [149].  Pigs may have E. coli with more resistance due to 
greater selection pressure from prophylactic antimicrobial use and from living in 
fecal-contaminated barns where opportunity for environmental plasmid-conjugation 
is high.  Pigs and farmers may have fecal E. coli with different susceptibility results 
compared to dogs and owners due to the differences in their human-animal 
relationship and opportunity for sharing bacteria and mobile genetic elements.   
 
Comparison of Susceptibility between Owners and Controls  
 No differences were found in the susceptibility results of E. coli isolates from 
owners and controls.  This could be a result of a small sample size and power.  
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Alternatively, it suggests that ownership of a healthy dog does not increase 
antimicrobial resistance of a human being’s fecal E. coli, nor does living with a 
human being increase the antimicrobial resistance of a dog’s fecal E. coli.  This 
finding would have important public health implications, especially as concerns arise 
regarding antimicrobial-resistant bacteria being isolated from pets [95, 100, 106, 120, 
136].   Dogs provide psychological and physiological benefits to their owners, 
especially the elderly and immunosuppressed, and these results may help support the 
claim that the risk of zoonotic transmission of bacterial disease is minimal [150].  
Regardless, proper hygiene recommendations such as washing hands should be 
followed by all pet owners, especially in households with young children, elderly, or 
immunosuppressed adults.   
 
Comparison of Susceptibility between Dogs and Controls 
 Although canine and owner isolates had similar susceptibility profiles, control 
isolates were more resistant than canine isolates to ampicillin and trimethoprim-
sulfamethoxazole.  One theory to explain this is differences in antimicrobial 
prescription selection in veterinary medicine versus human medicine.  Veterinarians 
rely on beta-lactam antimicrobials such as ampicillin but are cautious with sulfa drugs 
due to side effects of immune-mediated disease.  There was no difference in 
ampicillin prescribed to dogs versus controls in this study, but one control had 
received numerous courses of sulfa therapy throughout the year (including during the 
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month prior to enrollment) whereas no dog had received sulfa therapy.  Although 
selection pressure was likely a factor in this control who did have MDR E. coli 
resistant to trimethoprim-sulfamethoxazole, there were also 4 other controls (total 
5/30, 17%) with E. coli isolates resistant to trimethoprim-sulfamethoxazole, whereas 
only 3/61 (5%) of dogs had E. coli isolates resistant to this agent. 
 A second theory to explain more resistance in control isolates compared with 
canine isolates is that enrolled dogs are younger than the control population and likely 
had been exposed to fewer antimicrobial agents over their lifespan.  While this may 
be true, review of antimicrobial history within a month or year of enrollment could 
not link antimicrobial exposure and selection pressure to differences in resistance 
between species.  This theory does not explain why dogs and their owners had no 
differences in susceptibility results, since owners were also older than their dogs and 
had opportunity for more lifetime exposure to antimicrobial agents and environmental 
reservoirs.  A third theory is that there was sampling bias from the small number of 
controls enrolled in the study (N=30).  It remains unclear why control isolates were 
more resistant than canine isolates.   
 
Multiple Drug Resistance  
 Both owners and controls had significantly more MDR E. coli isolates than 
dogs in this study.  One potential bias is that 27.8% (17/61) of owners and 20% (6/30) 
of controls worked in veterinary clinics, and 18% (11/61) of owners and 30% (9/30) 
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of controls worked in human hospitals, allowing for possible occupational exposure 
to MDR strains.  It is unknown whether sampling the general public would have 
yielded the same results.  Risk factors for carrying MDR isolates include 
immunosuppression and treatment with broad-spectrum antimicrobials, but there 
were no differences between the 3 groups for history of immunosuppressive disease 
or antimicrobial treatment history during the past year [151].  Human beings in this 
study may have carried more MDR E. coli because of differences in selection 
pressure from antimicrobial therapy or environmental exposure.  
 Among MDR isolates, resistance patterns varied between species, with canine 
MDR isolates showing significantly more resistance than human being MDR isolates 
to beta-lactam antimicrobial agents.  This may reflect veterinarians’ tendencies to 
choose beta-lactams as first-line treatments for antimicrobial therapy [100].  Twenty-
five percent of dogs with MDR E. coli received a beta-lactam, amoxicillin-clavulanic 
acid, in the month prior to enrollment, compared with 6.7% of human beings with 
MDR E. coli that received a beta-lactam, also amoxicillin-clavulanic acid, in the 
month prior to enrollment.  Canine MDR E. coli isolates were more resistant to 
amoxicillin-clavulanic acid than human being MDR isolates.  These data support 
previous studies suggesting use of beta-lactam antimicrobial agents is one 
contributing factor in the emergence of antimicrobial-resistant E. coli [138, 139].   
 MDR isolates from human beings had highest resistance to ampicillin and 
trimethoprim-sulfamethoxazole, with 100% of control MDR isolates showing 
trimethoprim-sulfamethoxazole resistance.  This may have been selection error due to 
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a relatively small sample size, but only 20% of controls with MDR E. coli received 
sulfa therapy in the month or year prior to enrollment, compared with none of the 
dogs or owners.    
 Prevalence of MDR E. coli in fecal flora of dogs varies with sample 
population and stress level of dogs.  A study sampling healthy dogs from a humane 
society found 79% of fecal E. coli had MDR; dogs were not receiving antimicrobial 
therapy, and MDR was defined as resistance to 3 or more antimicrobial agents [136].  
In another study, healthy dogs living in breeding kennels had 13% MDR fecal E. coli 
isolates, whereas healthy dogs living with individual owners had only 2% MDR fecal 
E. coli isolates [94].  These data are consistent with our finding of 4% of canine fecal 
E. coli isolates having MDR.  Dense living conditions in shelters and breeding 
facilities may increase fecal sharing of bacteria and genes for resistance, via exposure 
to feces and grooming.  Stress also plays a role in increasing shedding of resistant 
fecal E. coli [89].  This may explain the higher prevalence of MDR in these 
populations compared to individually owned dogs.  Good hygiene, separation of 
animals, and stress reduction in kennels and shelters may help minimize further 
spread of antimicrobial resistance in these locations. 
 MDR E. coli was isolated from both dog and owner from two separate 
households.  Household #2 had a dog ID#6 with a history of UTI and frequent 
amoxicillin use; selection pressure and extended-spectrum beta-lactamases may 
explain cross-resistance to all beta-lactams tested except imipenem in this dog.  The 
dog shedding resistant E. coli into the household environment could explain MDR 
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isolates found in its owner ID#66, however the MDR isolate from the owner was 
clonally different (77% PFGE similarity) than the dog’s and had a different 
susceptibility pattern, with resistance to ampicillin, ciprofloxacin, and nalidixic acid 
but susceptibility or intermediate susceptibility to all other beta-lactams.  There was 
no reported fluoroquinolone use by the owner or any household dogs, making direct 
selection pressure less likely to explain fluoroquinolone resistance.  Alternatively, 
cross-resistance would be possible through transmission of a plasmid carrying both 
the qnr genes encoding fluoroquinolone resistance and extended-spectrum beta-
lactamase-encoding genes, allowing selection pressure during administration of beta-
lactams [142]. 
 Household #58 involved a dog ID#64 and owner ID#124 with MDR E. coli 
isolates resistant to 9 and 10 antimicrobial agents.  The owner had finished an 
empirical course of amoxicillin-clavulanic acid 24 days prior to enrollment, but 
neither dog nor owner had any further antimicrobial treatment history.  Both the dog 
and owner MDR isolates in this household had cross-resistance to beta-lactams 
(except imipenem).  The canine E. coli was also resistant to streptomycin and 
trimethoprim-sulfamethoxazole, while the owner’s E. coli had additional resistance to 
aminoglycosides (gentamicin and kanamycin), and both ciprofloxacin and nalidixic 
acid.  Increased fecal shedding of resistant strains of E. coli during treatment with 
beta-lactams, followed by contaminating the household and fecal-oral exposure is one 
mechanism to explain the dog’s acquisition of MDR E. coli.  This should result in 
identical clones of E. coli isolated from both owner and dog, as measured by PFGE 
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and susceptibility testing.  Since these isolates shared only 80% PFGE profile 
similarity, direct transmission of E. coli was less likely.  Alternatively, plasmids 
containing genes for beta-lactamases and extended-spectrum beta-lactamases may 
have been transmitted between dog and owner explaining the common cross-
resistance to beta-lactam antimicrobial agents.   
 
Selection Pressure and MDR Isolation 
The association found between a participant’s history of receiving 
antimicrobial therapy within 30 days of enrollment and isolation of fecal MDR E. coli 
supports the theory of selection pressure leading to resistance.  Antimicrobial use is 
considered by some to be the most important factor in the emergence, selection, and 
dissemination of antibiotic-resistant bacteria [152].  This includes antimicrobial use 
for treatment of infections in human beings, companion animals, or livestock, or for 
growth promotion or disease prevention in livestock.  A study in Mexico found 20% 
of fecal E. coli isolates from children were resistant to 5 or more antimicrobial agents, 
and resistance rate was higher in children who had received antimicrobial therapy 
within 60 days of enrollment [153].   In healthy swine, herds that receive the most 
antimicrobial therapy also had the highest number of resistant fecal nonpathogenic E. 
coli [154].  Schroeder suggests using tetracycline derivatives, sulfa drugs, 
cephalosporins, and penicillins, either therapeutically or preventatively, may be a key 
driving force in the selection of antimicrobial resistance in E. coli [138, 139].  
 128
Without antimicrobial selection pressure, MDR E. coli do not compete well with 
resident coliforms; MDR isolates are less prevalent and are shed for briefer periods 
from dogs without antimicrobial treatment than from treated dogs [144]. 
 In this study, no significant associations were found between history of recent 
antimicrobial therapy in other pets or children and isolation of MDR E. coli from 
participants.  Isolates that have undergone selection pressure due to antimicrobial 
therapy in these housemates’ GI tracts may become resistant, shed, and pose a public 
health risk to others.  Further investigation in this area is needed.   
 
Summary of Antimicrobial Susceptibility of Dogs, Owners, and Controls 
 No differences were found between the susceptibility results of dogs and their 
owners, suggesting they may share genes for antimicrobial resistance.  An obvious 
manifestation of this occurred in the two households with MDR E. coli isolated from 
both dog and owner.  In these households, PFGE profiling proved the isolates were 
not clonal, suggesting that plasmids or other mobile genetic elements were 
responsible for spreading resistant genes between the two hosts.   
 Overall, dogs had fewer MDR isolates than human beings.  Not all households 
with MDR isolates from owners had MDR isolates from dogs, so horizontal gene 
transfer within the household environment is not 100% efficient.  Owners had a 
similar number of MDR isolates to controls, suggesting that dog ownership did not 
increase risk of harboring resistant E. coli.  Alternatively, as has been suggested by 
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Sannes, human beings may be more likely to spread MDR E. coli to dogs than dogs 
are to spread MDR E. coli to human beings [106].  
 
Comparison of Antimicrobial Susceptibility to History of UTI 
 Fifty-two percent of women participants reported being treated for at least one 
UTI in their past, and 75% reported multiple episodes of UTI.  Thirteen percent of 
dogs had a history of UTI with a 50% recurrence rate.  History of UTI was positively 
associated with antimicrobial therapy within 30 days and 1 year prior to enrollment 
into the study.  UTI is a common indication for prescribing antimicrobial therapy, 
which may cause selection pressure allowing survival of resistant E. coli in the GI 
tract.  Women with a history of UTI had fecal E. coli with increased resistance to 
ampicillin, but dogs with UTI history had fecal E. coli with increased resistance to 
ciprofloxacin and nalidixic acid.  This may reflect antimicrobial therapy choices by 
physicians and veterinarians, however both beta-lactams and fluoroquinolones are 
prescribed commonly by both types of clinicians [84, 143, 146].  Cooke’s study of 
enrofloxacin resistance in canine UPEC found the increase in resistance paralleled 
increase in fluoroquinolone prescriptions from their pharmacy during the same time 
period [84].  A study of UPEC from dogs with indwelling catheters by Ogeer-Gyles 
found resistance to ampicillin and cephalothin was most common and may be related 
to antimicrobial use both within the ICU and prior to admission [95].  Although beta-
lactams and fluoroquinolones continue to be used for treating UTIs and other 
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infections, clinicians should recognize the selection pressure these antimicrobial 
agents may induce and prescribe them judiciously [144]. 
 
Comparison of Antimicrobial Susceptibility to Dog-Owner Behaviors 
 An association was found between feeding dogs raw meat and isolation of 
cephalothin-resistant E. coli from dogs.  Commercial raw diets designed for dogs and 
cats can contain zoonotic pathogens including E. coli, Salmonella, and Clostridium, 
but feeding bones and raw meat can also contain E. coli 0157:H7 and Campylobacter 
[155].  These bacteria may be resistant to various antimicrobial agents or contain 
plasmids with genes for resistance.  Raw diets not intended for human consumption 
may also contain antimicrobial residues that could induce selection pressures within 
the dogs’ GI tracts.  Food-producing animals most often carry E. coli resistant to 
sulfamethoxazole, tetracycline, and streptomycin, but resistance to beta-lactam 
antimicrobials is less consistent [133, 138, 139].  One study found 54% of E. coli 
isolates from swine were resistant to cephalothin; therefore, if contamination of pork 
with GI contents occurred during processing, feeding a dog raw bacon or other pork 
products may increase risk of cephalothin-resistant E. coli [138].   
 In this study, several dogs reportedly ate raw deer meat.  One study found 
11.8% of fecal E. coli isolated from farmed deer were resistant to cephalothin [152].  
It is unclear how deer have acquired cephalothin-resistant E. coli.  Explanations 
include contact with natural Cephalosporium molds in the wild, or contact with feces 
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of livestock containing resistant E. coli.  Dogs who eat raw deer meat and their GI 
contents may consume cephalothin-resistant E. coli, thus influencing their own fecal 
flora.   
 Feeding “people food” to dogs may involve hand-feeding dogs, sharing plates 
or utensils, or placing food normally intended for human consumption into dog 
bowls.  Hand-feeding or sharing plates or utensils may increase risk of sharing 
bacteria or mobile gene elements between species.  Paired dogs and owners had 
similar susceptibility results to ciprofloxacin (overall susceptibility was 98.4% in 
dogs vs. 96.2% in owners), but dogs who were fed “people food” had fecal E. coli 
with more resistance to ciprofloxacin than those not fed “people food” (4% vs. 0%).  
Susceptibility results of owners’ fecal E. coli were not associated with feeding or 
sharing “people food” with their dogs.  The association between ciprofloxacin-
resistant E. coli in dog’s fecal samples and consuming people food may be due to 
sharing of ciprofloxacin-resistant E. coli from owner to dog during these behaviors.   
 Hand-washing is an important way to minimize potential spread of bacteria.  
An association was found between owners who did not wash their hands after petting 
their dogs and increased owners’ fecal E. coli resistance to ampicillin.  Petting dogs 
provides direct contact between two individuals and provides a mechanism for 
transfer of bacteria or mobile genetic elements from one host to the other, in either 
direction.  During grooming, dogs may spread fecal E. coli throughout their hair, 
exposing owners to fecal E. coli while petting them.  In this study, canine fecal E. coli 
had lowest susceptibility to cephalothin, streptomycin, ampicillin, and amoxicillin-
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clavulanic acid; sharing genes for resistance for these antimicrobials through petting 
is a plausible explanation for this finding.   
 Hand-washing before meals may reduce transmission of resistant bacteria or 
mobile gene elements acquired from contact with dogs or other environmental 
sources and spread via hands to the owner’s oral cavity and GI tract.  Owners who did 
not wash before meals had E. coli isolates with increased resistance to 
chloramphenicol, ciprofloxacin, and nalidixic acid.  Although these resistant-E. coli 
could have been acquired from multiple environmental sources, it is possible this 
increased resistance was acquired through contact with their dogs and may have been 
avoided by washing their hands after contact with their dogs and before meals.  
Similarly, owners washing their hands prior to feeding their dogs may decrease 
transmission of resistant bacteria or resistance genes from owners to dogs.    
 Toilets may be a reservoir for resistant bacteria and genes for antimicrobial 
resistance originating from the feces of human beings.  Dogs that drank out of the 
toilet had E. coli with increased resistance to ciprofloxacin and nalidixic acid.  This 
suggests fecal-oral transmission of ciprofloxacin-resistant E. coli from owners’ feces 
to their dogs, via toilet water.  Fluoroquinolone resistance is usually chromosomal, 
suggesting that dogs may be exposed to resistant bacteria, rather than plasmids or 
transposons, while drinking toilet water.  In this study, owners were asked not to 
clean toilets prior to sample collection, so that a sample representative of a typical 
day could be acquired.  It is unknown if the cleanliness of household toilets of 
participants in this study are representative of the general public.  Regardless, these 
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results suggest that dogs may be at risk of acquiring fluoroquinolone-resistant E. coli 
from drinking toilet water, and we recommend owners discourage their dogs from 
drinking from toilets. 
 
Environmental Reservoirs for Resistant E. coli and Resistance Genes 
 Outside of the household, resistant E. coli have been isolated from many 
environmental sources such as human septage, rivers, wildlife, and farm 
environments [152, 156-158].  Spread of resistance genes via plasmids in a fecal-
infested environment and fecal-oral ingestion may be as important as conjugation 
occurring within the GI tract [90].  Similar to our findings, highest resistance in these 
environmental E. coli was to cephalothin, streptomycin, tetracycline, and 
sulfisoxazole [152].  In one study, cephalothin resistance was higher in isolates from 
farm environments (manure storage facilities and animal housing areas) than from 
livestock fecal isolates, and water samples were only resistant to cephalothin [152].  
Exposure to rivers, wildlife, and farm animals was not asked on our questionnaire, but 
it is known that some participants and their dogs spent time in the Smoky Mountains 
near streams and wildlife, and some participants affiliated with the UTCVM may 
have had exposure to livestock or live on farms.  These environmental areas may 
have been a common source of exposure for shared E. coli strains or mobile genetic 
elements between participants in this study. 
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 Contaminated water supplies may be an important reservoir and source of 
common exposure to resistant E. coli.  Specifically, 18% of E. coli isolates from 
irrigation water and sediments were resistant to cephalothin, and 16-96% of gram-
negative bacteria from water samples across 22 US rivers were resistant to cefotaxime 
[156, 157].  Integrons have been identified in E. coli isolated from irrigation water 
and sediments and likely play an important role in maintaining and spreading 
resistance in the environment [157].  In our study, potential sites of contaminated 
water supplies could have included the Tennessee River or the Veterinary Teaching 
Hospital bathroom sinks.  One caveat is that if a contaminated water supply was a 
major reservoir for our participants, we would expect to see one or few common 
clones shared by many participants rather than a wide array of clones in the 
population. 
 The human food chain could be a source of common exposure for resistant E. 
coli strains or plasmids.  Antimicrobial agents are used in food-producing animals for 
growth promotion, prophylaxis, and treatment of infections.  Strict regulations are 
enforced by the USDA requiring antimicrobial withdrawal prior to slaughter to 
prevent antimicrobial residues from entering the human food chain.  Contamination 
has been minimized by improving hygiene at slaughterhouses and ensuring that GI 
contents do not mix with meat.  This study did not inquire about human being dietary 




Future Strategies for Minimizing Resistance 
 Our results show that antimicrobial resistance occurred even in fecal E. coli 
from healthy human beings and dogs.  Supporting existing programs and 
implementing new strategies may help slow the progression of antimicrobial 
resistance.  On the national level, in 2001 the Center for Disease Control (CDC) 
organized the Public Health Action Plan as a task force of 11 governmental agencies, 
with a goal of decreasing unnecessary antimicrobial prescriptions, to decrease 
selection pressure and development of resistance in both the medical and veterinary 
professions (www.cdc.gov/drugresistance).  On the local level, many human hospitals 
and some veterinary hospitals have developed antimicrobial use guidelines, both to 
help clinicians select appropriate antimicrobials and to restrict use of certain 
antimicrobials such as vancomycin [101].  These guidelines are only as effective as 
they are appropriately developed and followed.  Each hospital should create a 
committee to keep up-to-date with the Public Health Action Plan recommendations 
and current literature, to amend the hospital’s antimicrobial use guidelines as needed, 
and to be available to clinicians for consultation on antimicrobial selection. 
 
Clonal Analysis of E. coli Isolates 
Distribution of Clones  
A wide array of 205 E. coli strains was isolated from participants enrolled in 
this study.  Eighty-two percent of these clones were identified from only 1 host.  
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These findings agree with results from a similar study performed concurrently by 
Johnson et al. which enrolled 63 households with a total of 152 human beings and 76 
pets (mainly dogs and cats) [159].  In their study, 335 unique fecal E. coli clones were 
identified, 73% were identified from 1 host only [159].  These data suggest there is a 
great variety of E. coli strains shed in the feces of healthy human beings and dogs, as 
well as other pets, into the environment.  This diversity of clones may be beneficial 
allowing immunity to form to E. coli strains in both animals and human beings. 
Thirty-six clones (17.6%) were shared between hosts either within or across-
households, but prevalence data showed within-household sharing occurred more 
often (9.8%) than across-household sharing (0.26%).  In Johnson’s study, 27% of 
clones were identified from 2-11 (median 2) hosts, and they too found significantly 
more within-household sharing (27%) than across-household sharing (0.8%) [159].  
Johnson’s study included more isolates (up to 20) from each participant, as well as 
including multiple human beings and pets from one household, allowing higher 
sensitivity for finding bacterial sharing; this may explain the higher within-household 
prevalence found in their study [159].  Despite this difference, both studies provide 
evidence that bacterial sharing was more a household-specific occurrence than an 
across-household phenomenon. 
In our study, 31.6% of participants shared an E. coli clone with another 
participant, but human beings were as likely as dogs to share an E. coli clone with 
another participant.  This occurred within households between dogs and their owners, 
and across households between participants with no known contact.  Of across-
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household clonal sharing pairs in our study, sharing occurred most often between 
unpaired dogs and owners (30%) followed by sharing between 2 dogs in separate 
households (23%).  Johnson’s study found 52% of participants shared a clone with 
another participant, and his data corroborated that strain sharing was statistically no 
more frequent for pets (52%) than for human beings (53%) [159].   
Despite nearly 1/3 of participants sharing a clone with another participant, no 
clone was shared by more than 3 participants.  Rather than one or several clones of E. 
coli being shared between the majority of participants, there were many unique clones 
being shared by 2-3 participants each.  Many of the participants sharing E. coli clones 
came from different households, and the route of bacterial sharing for these 
participants remains unknown.  Although participants’ occupations may provide 
exposure to common environmental reservoirs of E. coli, no one clone was seen in a 
large proportion of participants as would be expected from a point source, such as a 
specific location from within the UTCVM.  
Analysis of dendrograms did not identify any large clusters of related E. coli 
strains that could be traced to one species (dogs vs. human beings) or occupational 
exposure (UTCVM vs. Department of Genetics).  When the dendrogram was 
analyzed for groups with 4 or more isolates having >90% PFGE similarity, 17 groups 
of E. coli were identified with 2-5 hosts each (median 3 hosts).  These groups 
included mixed participants from all 3 populations of dogs, owners, and controls, 
with mostly across-household sharing of similar E. coli strains.  The dendrogram and 
group analysis suggest that while there is a very large variety of E. coli found in the 
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feces of human beings and dogs, some genetically similar strains of E. coli are shared 
by individuals with no known contact.  Further investigation into how this sharing 
occurs and how to minimize its occurrence is warranted. 
 
Across-Household Sharing 
 Thirty clones were identified that represented across-household sharing, 
occurring between all combinations of unpaired participants.  Occupational contact 
may be a contributing factor, but only 1/3 of the human-human sharing occurred 
between people working in the same location.  The majority (5/9) of unpaired dog 
and owner sharing occurred between participants associated with the UTCVM, 
including the unpaired dog-owner clone with 100% PFGE profile similarity.   Many 
staff and students bring their dogs to the UTCVM for medical care, dog baths, and 
boarding.  It is possible that either direct contact may have occurred between 
participants during these visits, or indirect contact through exposure to common 
reservoirs within the college such as cages or bathtubs.  Common exposure may also 
occur between unpaired dogs and human being participants outside of the UTCVM if 
their owners socialize at dog parks or other community locations.  Other environment 
sources such as water supply, the food chain, or spreading of E. coli strains 
throughout the community by birds or insects may also play a role in the 





 Only one dog-owner pair in this study shared E. coli with 100% PFGE profile 
similarity, but within-household clonal sharing was found with 9.8% prevalence when 
defined as two strains sharing >94% PFGE profile similarity.  Clones are defined in 
the literature in various ways, including % PFGE profile similarity calculated by 
similarity matrices as was performed here, or by number of bands in common 
between strains [84, 159, 160].  For this study, visually comparing differences in 
number and location of bands between each profile would have been very subjective 
and time-consuming with the number of PFGE samples included; this technique is 
more practical for studies with few samples.  Comparing samples by similarity 
matrices was more objective for this study, and the 94% cutoff was chosen to be 
conservative and consistent with current literature in this field [159].   Interestingly, 
when the more liberal definition of >90% PFGE profile similarity was used to 
identify similar strains, 21.3% of dog-owner pairs had similar E. coli strains, 
suggesting that definition of sharing is an important factor, and that by increasing the 
number of participants and power in the study a higher prevalence of sharing may be 
found. 
Although our study only evaluated within-household fecal E. coli sharing 
between dog and owner, Johnson’s study included all household family members and 
pets and found that within-household sharing was highest between pet-pet (22/38, 
58%), followed by human-human (47/154, 31%), and pet-human (31/179, 17%) 
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(Johnson).   The highest sharing prevalence was between cat-cat (82%), followed by 
dog-dog (79%), adult-child (34%), child-child (33%), and adult sexual partners (31%) 
(Johnson).  These results support within-household bacterial transmission more so 
than point source acquisition from an environmental reservoir in the household.  
Sharing of strains between similar species of pets most likely occurs during fecal-oral 
spread of bacteria during grooming.  Sharing of bacteria between adults and children 
may occur during diaper changes, assisting with bathroom visits, or laundry, and 
sharing between children most likely occurs due to poor hygiene habits.  Sexual 
activity between heterosexual or homosexual adults has been recognized as a 
potential route of transmission or sharing of E. coli clones [110-112].  Further 
investigation of bacterial sharing including all household members, human beings and 
pets, will be important to develop recommendations for minimizing bacterial 
transmission. 
In Johnson’s study, pet-human sharing was more common with cats (12/47, 
26%) than with dogs (19/115, 17%) [159].  Indoor cats can spend many contact hours 
with owners each week, including sleeping in the same bed.  Cat hair could be 
contaminated with fecal bacteria after grooming, and shedding could spread it 
throughout the household.  Petting could directly transfer contaminated hair to human 
beings.   Cleaning of the litter box would also be a potential source of bacterial 
sharing.  A limitation of our study was not including cats; however, a similar study 
investigating cross-species sharing of bacteria between cats and owners is proposed.  
A detailed questionnaire would help to determine the differences in the relationships 
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and human-animal bond between cat and owner versus dog and owner and how this 
may relate to cross-species bacterial sharing. 
Age of owner also was a factor in cross-species sharing in the Johnson study, 
with a higher prevalence of sharing between cats and adult human beings (12/36, 
33%) than cats sharing with children (0/11, 0%) [159].  Children are closer to the 
ground and tend to have less stringent hygiene habits, and so it is expected that they 
would have increased bacterial sharing with pets.  However, while children may have 
increased direct contact with dogs, they may have less direct contact with cats that 
can be more aloof.   
 
  
Human-Animal Bond and Within-Household E. coli Sharing  
 Dog ownership continues to increase nationally, with 37.2% of US-
households owning at least one dog in 2006, compared with 31.6% in 1996 [161, 
162].  With this increase in ownership is a concurrent increase in the perceived 
strength of the human-animal bond, with 99% of owners considering the pets to be 
part of the family [104].  Increased dog ownership and closeness of relationship 
between dogs and owners creates concern of risk of bacterial sharing. 
 Dog owners in this study were more likely to purchase their dogs from a 
breeder (41%) than the average US dog owner (27%) [163].  One study showed that 
owners who purchased their dogs had stronger bonds with their dogs than owners 
who acquired their dogs at no cost from family or friends [163].  This increase in 
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bond may translate to increased direct contact and potential for bacterial sharing; 
however dog owners in this study who purchased their dogs from breeders did not 
have significantly more sharing of fecal E. coli based on % PFGE similarity than 
owners who acquired their dogs from other sources.   
 Based on a national survey, dog owners spend an average of 45.3 hours per 
week with their dog, and 40% of dog owners spent >30 hours per week with their 
dogs [163].  Results of this study were slightly higher, with 54% of owners spending 
>30 hours of awake-time with their dog per week and 9.8% of owners spending ≤10 
hours of awake-time per week with their dog; however, awake-time spent with dog 
was not associated with sharing of fecal E. coli based on % PFGE similarity 
(p=0.779). 
 That same study showed that female owners were more bonded with their 
dogs than male owners [163].  Our study had an uneven distribution of female (51) 
and male (10) owners, which reflects the general population of veterinary students, 
who made up 60% of the human participants in this study.  Although many indicators 
of strength of the human-animal bond used in their study were different than the 
behaviors asked in our relationship, time spent awake with dog was assessed in both 
studies.  In the general population survey, women were found to spend more time 
with their dogs, while in our study, male owners spent significantly more awake-time 
with their dogs than female owners (p=0.036).  Other behaviors suggesting a strong 
human-animal bond, such as sleeping in the same bed and kissing on the face were 
not different between male and female owners in our study. 
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 Fifty-nine percent of US pet-owning households own >1 pet, and households 
with dog, cats, or both, own on average 2.48 pets [163], while in this study 82% of 
dog-owning households had >1 pet, with an average of 3.23 pets per household.  This 
high percentage of multi-pet households would be expected for the population of 
veterinary students, staff, and faculty that were recruited from for this study, and our 
study did find more multi-pet households from participants working or studying at the 
UTCVM than those participants recruited outside of the college (p=0.044).  However, 
neither number of pets in household nor affiliation with the UTCVM was associated 
with within-household sharing of fecal E. coli between enrolled dogs and owners 
based on % PFGE profile similarity.   
 Johnson’s study enrolled all members from 63 households, isolating fecal E. 
coli from 152 human beings and 76 pets, and found that within-household sharing of 
E. coli increased linearly with household size [159].  Households with 6 or more 
individuals (including human beings and pets) had 100% probability of clonal sharing 
of fecal E. coli [159].  In that study, pet-pet sharing (58%) of fecal E. coli occurred 
more commonly than human-human (31%) sharing or human-pet (17%) sharing, and 
72% of households with ≥1 pet had evidence of pet-pet sharing of clonal E. coli 
[159].   
 Increased household size may result in increased direct contact between 
individuals, as well as common exposure to potential environmental reservoirs of E. 
coli such as bathrooms.  High prevalence of pet-pet sharing of E. coli clones is likely 
from fecal oral ingestion after sniffing rectums, grooming, and coprophagy.  
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Alternatively, human-human sharing is most associated with sexual active adults, but 
may also occur as fecal-oral spread during diaper changes, and between kids or adults 
who do not wash their hands after using the restroom and proceed to contaminate 
their environment [110, 111].   
 Sharing of bacteria between dogs and owners within households may occur by 
direct contact or contaminated environment reservoirs, and certain behaviors 
hypothesized to pose increase risk included: sleeping in the same bed, kissing on the 
face, sharing of food, handling dog’s feces, and dogs drinking from toilets.  Although 
sharing food, handling feces, and drinking from the toilet were associated with 
susceptibility results, none of these behaviors was associated with increased within-
household sharing of fecal E. coli based on PFGE profiling.  There may be no true 
association present or these results may be from low sample size and low number of 
isolates sampled per participant.   
 The risk of cross-species bacterial transmission during sleeping in the same 
bed may be low under most circumstances, but risk may increase if the owner or dog 
has diarrhea, if bedding is not routinely cleaned, or if the owner maintains poor 
hygiene.  Allowing a dog to kiss or lick an owner on the face also has potential for 
cross-species bacterial sharing and zoonotic spread, especially if the dog grooms 
other dogs, drinks from toilets, and eats raw foods.  The risk of disease transmission 
from dogs drinking from toilets would depend on the cleanliness of the toilet and 
frequency of drinking from it.  Most water dogs drink from flushed toilets where 
water is only very dilutely contaminated with fecal material or urine, but risk of fecal-
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oral transmission is possible.  A dog kissing or licking an owner right after drinking 
from the toilet could also cause fecal-oral transmission to the owner, with bacteria 
either from the owner’s own feces or from another human being in the household.  
Likewise, sharing table scraps and eating together after a dog drinks from the toilet 
could contaminate the owner’s mouth with dog’s saliva and cause fecal-oral 
transmission by that mechanism as well. 
 Forty-one percent of dog owners reported sharing “people food” with their 
dogs, which is consistent with a recent survey of dogs in the US and Australia that 
found 45.4% of dog and cat owner feed their pets table foods at least 1 or more times 
a week [164].  Although no association was found in this study, behaviors such as 
hand-feeding dogs and allowing dogs to lick plates or utensils intended for human use 
could in theory pose a higher risk for zoonotic or anthropozoonotic transmission of 
bacteria than placing “people food” into a dog bowl.  Further investigation into the 
risk of these specific behaviors may be warranted.  
 Raw meat was fed by 8.2% of dog owners in this study, which was consistent 
with the recent survey finding in the US and Australia that 7.4% of dogs received raw 
meat or bones as a treat or snack at least weekly [164].  The motivation behind 
feeding raw meat was not asked in our questionnaire, but pet owners may feed bones 
and raw meat for various reasons including perceived health benefits, because they 
are a more natural and less processed food, or as a special treat for their pets.  Several 
owners provided information that they fed their dogs raw deer meat scraps while 
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hunting and this may have been a bonding or rewarding behavior for these 
participants.   
 Although feeding raw meat was associated with cephalothin resistance, it was 
not associated with increased clonal sharing by PFGE profiling in this study.  Eighty 
percent of owners who fed their dogs raw meat allowed their dogs to kiss or lick them 
on the face, but this behavior too was not associated with increased clonal sharing.  
Despite these findings, raw meat can be contaminated with bacteria and parasites that 
can make both dog and owner sick, and so proper hygiene measures should be 
followed when handling raw meat, and behaviors such as eating or feeding raw meat 
to dogs is not advised.   
Hand-washing is often overlooked by owners of companion animals, perhaps 
because they are considered members of the family [104].  In this study, only 25% of 
owners reported washing their hands after petting their dogs, but this behavior was 
not associated with sharing of E. coli clones.  Washing their hands before meals has 
become routine for many human beings, with 77% of owners washed their hands 
before eating their own meals, but only 6.6% of owners reported washing their hands 
before feeding their dogs.  Hand-washing by owners prior to their own meals may 
minimize spread of bacteria from dogs to human beings but not washing prior to 
feeding the dogs leaves opportunity for spread of bacteria from human beings to dogs 
through contact with their food.  It is also recommended that owners wash their hands 
after feeding their dogs, because contaminated dry dog food has now been identified 
as a source of human Salmonella infections [165].  According to the CDC, dog 
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owners should wash their hands for 20 seconds in warm water with soap after 
handling dry pet food, treats, and supplements, before eating their own food, and they 
should keep children under the age of 5 away from all pet food and treats [165]. 
 Forty-eight percent of dog owners reported disposing of their dog’s feces, 
while 52% of owners never disposed of their dogs feces.  One possibility for the low 
number of dog owners who disposed of feces may be due to assigned chores in 
households, with another household member carrying primary responsibility for this 
chore.  Interestingly, an association was found between disposing of dog’s feces and 
% PFGE similarity, with those owners who disposed of their dog’s feces 5+ times a 
week having the lowest % PFGE similarity between dog and owner fecal E. coli 
compared with owners who disposed of their dog’s feces less frequently or never.  
One explanation for this finding may be that owners who handle their dog’s feces 
more frequently also are more careful about personal hygiene and wash their hands 
more consistently than other owners, but this association was not proven statistically.  
Despite these results, it would be irresponsible to suggest that handling canine feces is 
protective against cross-species bacterial sharing.  Good hygiene with hand-washing 
after disposing of feces is recommended. 
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Virulence Factor Results Discussion 
 Prevalence of Virulence Factors 
 Twenty-two percent of participants harbored E. coli with one or more 
virulence factors, while the majority of participants (118/152, 78%) carried E. coli 
negative for all four virulence factors.  Low prevalence of virulence factors in fecal E. 
coli was not unexpected, because these virulence factors were chosen for their 
urovirulence but were tested in isolates from feces of healthy participants.  A study by 
Usein et al. found carriage of urovirulence factors, including cnf, hly, sfa, and pap, 
was only 35% in E. coli from fecal flora of healthy adults compared with 70% in 
UPEC strains [166].  Finding urovirulence factors in 22-35% of fecal strains from 
healthy adults supports the hypothesis that intestinal E. coli serve as reservoirs for 
UTIs.   
 Cytotoxic necrotizing factor (cnf) was present in 15.3% of canine isolates, 
14.2% of owner isolates, and 13.3% of control isolates.  Other studies have found a 
prevalence of 12-30% in healthy canine fecal E. coli isolates and 0.9-10% in healthy 
human being fecal isolates [55, 74, 122, 167].  In uropathogenic E. coli strains, 
prevalence of cnf is higher, ranging from 41-45% in canine isolates, and between 
39% (cystitis), 47% (pyelonephritis), and 78% (prostatitis) in human being isolates 
[55, 75, 168].  
 Hemolysin (hlyD) was present in 15.3% of canine isolates, 15.8% of owner 
isolates, and 16.7% of control isolates.  HlyD is one gene in the operon, hlyCABD, 
 149
encoding alpha-hemolysin.  Other studies have found hly prevalence of 6-31% in 
healthy canine fecal E. coli isolates and 2.7-20% in healthy human being fecal 
isolates [55, 74, 122, 169].  In uropathogenic E. coli strains, prevalence of hly ranges 
from 44-50% in canine isolates [55, 75], and from 43% (cystitis), 47% 
(pyelonephritis), and 78% (prostatitis) in human being isolates [168].  Genes for 
hemolysin are included in most PAIs identified thus far in E. coli [10]. 
 S fimbriae adhesin (sfa) was present in 21.9% of canine isolates, 14.2% of 
owner isolates, and 6.7% of control isolates.  Other studies have found sfa prevalence 
of 6-27% in healthy canine fecal E. coli isolates and 14% in healthy human being 
fecal E. coli isolates [55, 74].  In uropathogenic E. coli strains, prevalence of sfa 
ranges from 57-60% in canine cases [55, 75], and from 61% (cystitis), 53% 
(pyelonephritis), and 83% (prostatitis) in human being isolates [168]. 
 Pilus-associated with pyelonephritis G allele III (papGIII) was present in 
12.6% of canine isolates, 7.7% of owner isolates, and 7.8% of control isolates.  Other 
studies have found papGIII prevalence of 6-30% in healthy canine fecal E. coli 
isolates and 4-8.2% in healthy human being fecal E. coli isolates [55, 58, 160].  In 
uropathogenic E. coli strains, prevalence of papGIII ranges from 22% (cystitis), 35% 
(pyelonephritis), and 34% (prostatitis) in human being isolates [168]. 
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Virulence Factor Patterns 
 The most common virulence factor pattern was the presence of all 4 virulence 
factors (cnf, hlyD, sfa, and papGIII) in isolates from 7/61 (11.5%) dogs and 5/61 
(8.2%) owners.  This virulence factor pattern has also been noted by Feria et al. from 
60% of canine UPEC isolates and 68% of feline UPEC isolates [75].  In 
Drazenovich’s study, 70% of UPEC clones isolated from dogs with persistent UTIs 
were positive for one or more virulence factors, with cnf, hly, and sfa occurring most 
often [79].  The pap gene was present less commonly but was always present in 
combination with cnf, hly, and sfa [79].   Usein et al. compared healthy human adults’ 
fecal E. coli isolates with clinical UPEC strains and found the combination of cnf, hly, 
sfa, and pap in 5% fecal strains but 55% UPEC strains [166].  E. coli with concurrent 
presence of all 4 virulence factors in ours and other studies suggests genetic linkage 
on a PAI, but this has not been conclusively proven at this time; PAIs have been 
identified with cnf and hlyD, and cnf, hlyD, and papGIII, but not all 4 [65, 170].  
Higher prevalence of these virulence factors from UPEC than from fecal samples 
supports association of these particular genes with urovirulence.   
 
Comparison of Virulence Factors between Groups 
 There was no difference in presence or absence of any of the four virulence 
factors between paired dogs and owners.  The low overall prevalence of virulence 
factors in this population influenced this comparison.  Lack of significant difference 
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cannot be explained by cross-species sharing of bacteria or mobile genetic elements, 
since only 1 household with positive results had a similar virulence factor pattern 
between dog and owner.  Although not significant, there may be clinical importance 
to the 25/61 households containing either a dog or owner (but not both) with E. coli 
positive for at least one virulence factor.  This suggests that even if E. coli are 
carrying PAIs with virulence factors, these PAIs are not being shared routinely 
between dog and owner.   
 There was also no significant difference in virulence factor results between 
owners and controls, suggesting that dog ownership did not affect presence or 
absence of virulence factors in a human being’s fecal E. coli.  On the contrary, more 
canine isolates (21.9%) were positive for sfa than control isolates (6.7%).  Yuri et al. 
study’s included healthy dogs and human beings in separate households, and also 
found a higher prevalence of sfa in fecal isolates from dogs (27%) than human beings 
(14%), but no p-value was provided [74].   It is possible sfa is transferred on 
plasmids, transposons, or phages more frequently among the canine population than 
human population, although within-household sharing would be expected if this were 
the case.  Many plasmids and PAIs also contain other virulence factors, such as cnf, 




Agreement between Virulence Factors 
 The hemolytic phenotype of E. coli isolates on blood agar plates agreed 
significantly with the hemolytic genotype, or presence of hlyD.  Eighteen percent of 
isolates had negative phenotypes but positive genotypes.  The absence of a hemolytic 
phenotype in the presence of hlyD can be due to defects in the hemolysin operon 
including the hlyBCD genes or to defects in the transcriptional activator rfaH [171].    
 Results of this study were consistent with previous findings of a close 
association between the two toxins encoded by hlyD and cnf [122].  Cnf was found in 
approximately 92% of hemolytic isolates in our study, but never in non-hemolytic 
isolates; only 2 participants had isolates that were cnf-negative but hlyD-positive.  
HlyD can be located either on the chromosome or on a transmissible plasmid, 
whereas, cnf is only a chromosomally-inherited gene [122].  Therefore, perfect 
agreement between these two virulence factors is best explained by linkage in a 
chromosomal gene cluster, such as a PAI, that concurrently governs the synthesis of 
both toxins [122].  Blum et al. have documented the presence of both cnf and hly on 
chromosomal PAI II on UPEC strain J96 [170].  Bingen-Bidois et al. have also shown 
genetic linkage between papGIII, hly, and cnf [65]. 
 The strong agreement between cnf and sfa and other combinations of 
virulence factors in this study provides further support for genetic linkage of these 
virulence factors, whether on a chromosome and controlled by the same promoter or 
on mobile genetic elements such as PAIs or plasmids.  No isolated association 
between cnf and sfa was found in the literature, although they are recognized to occur 
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in combination with other virulence factors with high frequency and are suspected to 
be included in PAIs [75, 166].  Johnson et al. identified an association between 
papGIII, hly, and sfa but did not assess cnf prevalence in their study [64].  
Alternatively, Hilali et al. found associations between papC, hlyC, and cnf and 
believed them to be associated on a PAI, perhaps PAI V [167].  In theory, housing 
virulence genes together in the same chromosomal cluster or mobile genetic elements 
may allow coordinated expression of different toxins and adhesins and more efficient 
establishment of extraintestinal infection. 
 
Virulence Factor Association with Hand-Washing  
 One would expect the effect of owners not washing their hands to be on their 
own fecal flora, so the association between their hand-washing and virulence factors 
in their dog’s fecal E. coli is difficult to explain.  Since prevalence of virulence 
factors was low overall in the population studied here, these associations may have 
been found by chance alone.  All dogs with papGIII in fecal E. coli lived with owners 
who did not wash their hands after petting their dogs.  This may suggest that these 
owners have poor hygiene, and perhaps the owners are transmitting the papGIII gene 
to the dogs.   
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Urinary Tract Infection History and Urovirulence Factors 
Although self-reporting of UTI has inherent potential for error, the high 
prevalence of women participants in this study with a history of UTI  (52.1%) is 
consistent with national data that approximately 50% of all women will have a UTI 
during their lifetimes [50].   Only14% of all dogs develop a UTI at some point during 
their lifetime, and our canine population had a similar overall prevalence (13%) 
[172].  Aerobic urine culture is the gold standard for diagnosing a UTI, but physicians 
and veterinarians may treat empirically based on clinical signs [6, 46, 173].  Although 
self-reporting was a limitation of the study, without reviewing medical records, the 
authors had no way to verify whether reported UTIs were confirmed by culture.   
The sex predilection for UTIs seen in our participants (100% women vs. 0% 
men, and 18.2% female dogs vs. 7.1% male dogs) was consistent with females being 
more susceptible than males to UTIs [50].  This may in part be due to anatomical 
differences; compared with females, the male urethral opening is located 
anatomically distant from the rectum and is longer, forcing bacteria to travel farther to 
reach the bladder and before establishing an infection.  Specific risk factors for 
women to develop UTIs include sexual intercourse, spermicidal use, urinary 
incontinence, and diabetes mellitus, which are similar to risk factors in dogs including 
underlying urinary anatomical defects, uroliths, incontinence, indwelling urinary 
catheters, and endocrine disorders [6, 174].  Men are at increased risk of UTI if 
homosexually active, sexually active with an infected woman, or if not circumcised, 
whereas male dogs are at increased risk if they are sexually intact [6, 46]. 
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In women, there is a high recurrence rate of UTIs, with >25% recurring within 
the first 6 months [52].  In our subpopulation of women with history of UTI, 75% 
reported more than 1 UTI in their lifetimes, while 50% of our dogs with a UTI history 
had more than 1 UTI.  It is unclear how many of these were relapses of the same 
strain of E. coli vs. reinfections with a new strain or new bacterium.  Up to 68% of 
UTI recurrences in women are caused by E. coli identical to the original strain [52].   
Results of this study confirmed previous studies’ results that antimicrobial patterns 
can differ extensively within a single PFGE clone; therefore, determination of relapse 
vs. reinfection should be based on PFGE profile similarity instead of antimicrobial 
susceptibility patterns [79, 84, 175].  This information may prove useful in 
determining the underlying cause of the UTI and preventing future recurrence. 
Numerous virulence factors have been associated with UTI in women and 
dogs in previous studies [53, 56, 66].  Without enrolling participants with active 
UTIs, our questionnaire enabled us to compare history of UTI in our participants with 
presence or absence of virulence factors in fecal E. coli.  We recognize the potential 
for error that exists because E. coli in the fecal flora at the time of sampling for the 
study may not represent what was present in the flora at the time of the UTI.   
For women, having a history of UTI was associated with presence of hlyD and 
papGIII in fecal E. coli, and having a history of recurrent UTIs was associated with 
presence of papGIII in fecal E. coli.  Of the 4 virulence factors analyzed in this study, 
hlyD and papGIII were the most specific to the urogenital tract [7].  It is possible that 
significant associations were not found in the canine population due to small number 
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of enrolled dogs with a history of UTI; a future study could be designed to further 
investigate the role of these virulence factors in dogs. 
The association found between presence of all 4 virulence factors in a dog’s 
fecal E. coli and an owner’s history of UTI has not been reported in the literature.  
One interpretation of these results is that dogs may harbor E. coli with urovirulence 
factors that may be shared with their human housemates, thus increasing the owner’s 
risk of developing UPEC UTIs.  Two longitudinal studies found extensive within-
household sharing of UPEC among family members and pets [119, 120].  Presence of 
virulence factors pap, hly, and cnf, were associated with persistence of these strains 
[119].  In both studies the women’s UPEC isolates persisted in the feces of the family 
members and pets once the woman’s UTI was treated and cleared, indicating that 
both other housemates and pets could be reservoirs for reinfecting the women in the 
future [119, 120].  We recognize associations found between historical UTIs and 
dog’s fecal virulence factors identified in our study, but we caution against over 
interpreting these data since owners did not have active UTIs during fecal sample 
collection.  Further investigation is needed enrolling owners with current UTIs and 
testing fecal samples from both human beings and dogs in the households to 
determine true association between owners UTIs and virulence factors in canine fecal 




Comparison of Susceptibility, Clonality, and Virulence Factors 
Comparison of Susceptibility and Virulence Factors 
 Our study found that streptomycin resistance was associated with presence of 
fewer virulence factors in fecal E. coli.  These data correspond with other studies that 
have shown that resistance to quinolones, fluoroquinolones, and trimethoprim-
sulfamethoxazole was associated with reduced virulence traits in UPEC [176, 177].  It 
has also been shown that quinolone-resistance can induce loss of PAIs containing 
virulence factors from E. coli strains [176].  Without the Bonferroni adjustment, both 
the quinolone in our study, nalidixic acid, and trimethoprim-sulfamethoxazole were 
associated with decreased virulence factors but the fluoroquinolone, ciprofloxacin, 
was not associated with any virulence factor.  
 One potential explanation for our finding is therapeutic use of antimicrobial 
agents causing selection pressure and allowing for survival of resistant commensal 
strains within the GI tract which are then isolated from fecal samples of healthy 
individuals or are able to migrate to the urinary tract and cause infection due to 
decreased host defenses rather than increased bacterial virulence.   Soto et al 
demonstrated one mechanism for quinolone-induced PAI loss is by induction of the 
error-prone SOS pathway of DNA repair and suggested that this deletion may be an 
adaptation of UPEC strains to gain selective advantages over less flexible organisms 
[176]. 
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The potential association between quinolones and fluoroquinolones with 
urovirulence factors is important as guidelines now recommend fluoroquinolones as 
first-line empirical treatment for UTIs in women in regions where trimethoprim-
sulfamethoxazole resistance is >10-20% [178].   Enrofloxacin usage has increased in 
veterinary medicine as well, and enrofloxacin one of the most commonly used 
antimicrobial agents for UTIs in dogs [47, 84].  Although >80% of UPEC in dogs still 
show susceptibility to enrofloxacin, there is evidence that fluoroquinolone resistance 
is emerging that will affect UTIs of both women and dogs [84-86].  Increased use of 
fluoroquinolones in human and veterinary medicine may lead to a continued rise in 
resistance but loss of PAIs and virulence factors within UPEC.  This is an area of 
research that will need to be followed closely in both fields of medicine. 
 
Comparison of Susceptibility within Shared E. coli Clones 
 This study corroborated others’ results that susceptibility patterns can vary 
widely within a single clone of E. coli [79, 84, 175].  In our study, isolates in 25% of 
shared E. coli clones had identical susceptibility patterns, while isolates in 75% of 
shared clones had different susceptibility patterns.  Similarly, the Freitag study found 
that antimicrobial isolates in 33.3% of shared E. coli clones had identical 
susceptibility patterns, while isolates in 66.7% of shared E. coli clones had different 
susceptibility patterns [175].  This finding suggests that horizontal gene transfer is 
occurring between E. coli strains spreading genes for antimicrobial resistance on 
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plasmids or integrons.  This knowledge may be useful to clinicians who treat 
recurring UTIs.  These data have shown that basing classification of relapse versus 
reinfection on antimicrobial susceptibility pattern is not accurate.  Although 
technically difficult and expensive, PFGE can accurately differentiate between 
relapse and reinfection and can be a beneficial tool for diagnosing clinical cases as 
well as continued research studies. 
 
Comparison of Virulence Factors within Shared E. coli Clones 
 In contrast to the variety of susceptibility patterns seen within a single clone, 
virulence factors were more consistent within a clone.  Isolates within 78% of shared 
clones had identical virulence factor patterns, while isolates within 22% of clones had 
different virulence factor patterns.  This was also seen in Drazenovich’s study, where 
PCR assays for urovirulence factors almost always found the same results each time 
the same PFGE clone was observed; the same virulence factors were found each time 
the same clone was found in the same dog, except for in two clones [79].  In contrast, 
in the Usein study, 14 human UPEC clones were identified and isolates within 9 
(64%) clones had different virulence profiles [166].  Different virulence factor 
patterns may occur within a single clone due to horizontal gene transfer of PAIs 
containing various virulence factors. 
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Comparing Susceptibility and Virulence Factors within Shared Clones 
 Only 6/36 shared clones had isolates with identical susceptibility patterns and 
identical virulence factors, but no clones carried both an antimicrobial resistant 
phenotype and genes for virulence factors.  In one clone with MDR E. coli, 
ciprofloxacin and nalidixic acid resistance may have contributed to decreased 
presence of virulence factors, as reported elsewhere [176, 177].  These results suggest 
genes for resistance and these 4 virulence factors may not be linked together on 
plasmids or integrons, but studies including antimicrobial genetic testing would be 
required to further investigate this issue.  None of these shared clones were shared 
within households; all were shared between various combinations of participants 
across-households, suggesting these E. coli strains may found in environmental 
reservoirs rather than being transmitted by direct contact between hosts.    
 
Limitations 
 A longitudinal study design may have increased the sensitivity for detecting 
within-household sharing over a cross-sectional design, since E. coli clones can be 
detected inconsistently in a particular individual [120].  Limitations of the study 
population were including only one dog and owner from each household rather than 
including all family members and pets, and including only adults rather than children 
who may have closer contact with pets and less stringent hygiene habits [100, 108].  
Another limitation was the possibility of Type II error in stating that dogs and owners 
did not have different susceptibility or virulence factor results; increasing the sample 
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size and number of isolates per participant would have increased the overall power of 
the study and may have allowed identification of differences if they existed.  It is also 
acknowledged that the population sampled in this study did not represent the general 
population because most human participants had occupational exposure to either 
human or veterinary hospitals. 
 The questionnaire was piloted prior to use, but in retrospect several questions 
needed more clarification and other questions could have been added.  As discussed 
in the Results section, under Relationship with Dog Results, the question regarding 
feeding of raw foods was too vague and should have specified raw meat vs. 
vegetables or fruits.  In light of linking cases of human Salmonella to handling dry 
dog food, the questionnaire should have asked about washing hands after feeding 
dogs as well as before feeding dogs [165].  Participants should have been asked if 
they routinely wash their hands after using the restroom.  Participants who work at 
veterinary clinics should have been asked if they routinely clean up feces of dogs 
other than their own. 
Disc diffusion susceptibility testing could have been complimented by 
molecular testing for presence of resistance genes.  In the Srinivasan study not all E. 
coli displaying phenotypic resistance to an antimicrobial carried a gene conferring 
resistance to that particular antimicrobial, and many susceptible strains did carry 
genes for resistance [179].  This suggests that mechanisms of resistance exist beyond 
recognized resistance genes, and that not all genes for resistance are expressed [179].  
In our study, knowing which isolates carried resistance genes would have allowed 
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further comparison between dog and owner isolates and provided more information 
regarding linkage of antimicrobial agents on mobile genetic elements. 
Antimicrobial susceptibility testing included those agents routinely monitored 
by the NARMS, but for veterinary application adding enrofloxacin would have 
provided useful information.  Specific benefits would have included knowing the 
level of enrofloxacin-resistant E. coli in the normal flora of dogs and their owners, 
knowing the association of resistance with historical use of enrofloxacin, and 
knowing the association of resistance with presence of urovirulence factors.  One 
limitation of the questionnaire was participant recall with history of antimicrobial 
therapy; participants reported 13 courses of therapy with unknown antimicrobial 
agents which they or their dogs had received, which may have altered statistical 
analyses.   
 A limitation of PFGE analysis was that it was only performed on 2 isolates per 
participant due to financial and time limitations.  Other researchers have increased the 
power of detecting within-household sharing by comparing up to 20 isolates from 
each household member [159].  While XbaI is a commonly used restriction enzyme 
for PFGE of E. coli, adding a second restriction enzyme such as BlnI may help 
improve discriminating ability between fingerprints from study participants.  Directly 
comparing each isolate between owners and controls and between dogs and controls 
using similarity matrices rather than analysis of dendrograms may have found 
additional across-household sharing clones. 
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 The 4 virulence factors tested were chosen because they have been identified  
previously from both human being and canine UPEC isolates; however testing for a 
larger panel of virulence factors would have provided additional useful information 
[57, 58, 66, 78, 120].  Direct testing for presence of PAIs using PCR would have 
supplemented the study as well [10].   Multiplex PCR is one way to test for multiple 
virulence factors, but microarray may be the best technology for this objective 
because it can test for significantly more virulence factors at one time [9].      
 
Conclusion 
There was a wide diversity of E. coli strains identified in fecal samples from 
both human beings and dogs.  Sharing of fecal E. coli between dog and owner pairs 
occurred within households with 9.8% prevalence, but no difference was found in 
susceptibility patterns or virulence factor prevalence between paired dogs and their 
owners.  No specific risk factors were identified that were associated with increased 
sharing of fecal E. coli clones between dogs and their owners.  Direct contact between 
dogs and owners may be responsible for sharing of bacteria and mobile genetic units 
within households, and good hygiene, including frequent hand-washing, is 
recommended.  Sharing of fecal E. coli also occurred across-households with 0.26% 
prevalence, suggesting environmental reservoirs of E. coli may exist to which 
participants may have common exposure.  Both direct contact and environmental 
reservoirs may be important routes allowing sharing of bacteria or horizontal transfer 
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of genes for antimicrobial resistance and virulence factors between species.  Public 
health concerns regarding cross-species sharing of E. coli are warranted, and efforts 
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Appendix A.  Questionnaire for study on E. coli organisms in dogs and their 
owners 
Dog Owner Participants 
Date____________ 
 
Dog Information: (this should only reflect the dog participating in the study) 
 
Dog’s Study ID# ___________    Breed ____________    Age ______ years 
 
Is your dog: Male Intact    Female Intact   
  Male Neutered   Female Spayed   
 
How old was your dog when you adopted him/her? 
  Puppy (<1 year old)  
  1-4 years old   
  4-7 years old   
  7-10 years old   
  >10 years old   
  unknown   
 
Dog’s Health 
Does your dog currently have loose stool or diarrhea?   Yes   No  
 
Has your dog ever been diagnosed with any of the following diseases? 
 Diabetes mellitus     Yes   No  
 Hyperadrenocorticism (Cushing’s Disease)  Yes   No  
 Cancer       Yes   No  
  If yes, what type (if known) _______________________________  
  If yes, when was the diagnosis made? ______________month/year 
Urinary Tract infection    Yes   No  
 If yes, on how many different occasions?     __________________ 
 When was the most recent urinary tract infection? ____month/year 
   
Which bacteria was it caused by:  Enterococcus    Streptococcus    
          E. coli          Other                
                  Proteus          Unknown         
          Staphylococcus      
From where did you get your dog? 
 Animal Shelter  
 Breeder   
 Pet Store   





Has your dog received antibiotics in the past month?  Yes  No  
If yes, reason for administration: 
  Dental disease     Skin/trauma/wound    
  Gastrointestinal infection   Urinary tract infection  
  Respiratory infection    Other/Unknown  
       
  If yes, type of antibiotic: 
   Amikacin     Doxycycline   
Amoxicillin    Enrofloxacin (Baytril®)  
   Azithromycin    Erythromycin   
Cefpodoxime (Simplicef®)   Gentamicin   
Cephalexin    Marbofloxacin  
Chloramphenicol    Metronidazole   
Clavamox®    Sulfa antibiotic  
Clindamycin    Other/unknown    
 
  How were these antibiotics administered? 
    Oral    Into eyes  
    Injectable   Onto skin   
    Into ears   Other    
 When was the last date of administration? _________mm/dd/2006 
 
To the best of your memory: please summarize your dog’s antibiotic history 
over the past year by providing the month/year, type of antibiotic, route of 
administration, number of days the antibiotic was given, and reason for antibiotic 
usage. 
Month/Year Type of Antibiotic Route  #Days  Reason 
Example:  Feb 2004 Clavamox Orally  14 days             abscess               
 
 
Has your dog received chemotherapy in the past month? Yes   No  
Has your dog received prednisone in the past month? Yes   No  
  If yes, please list reason if known___________________________ 
Has your dog received any other known immunosuppressive medication in the past 
month?       Yes   No  
  If yes, please list medications ______________________________ 




Study ID # ______________         Age _________years        Male   Female   
 
Faculty ______  Student_______ or Staff _______ 
Note: “staff” includes house officers, technicians and veterinary assistants. 
 
Has your role at the University of Tennessee Veterinary Teaching Hospital included 
routine handling of canine patients in the previous 7 days?    
        Yes   No  
 
If you are a veterinary student, in which year of study are you? 
 First   Second   Third   Fourth  
 
Do you work or volunteer at another veterinary clinic other than the University of 
Tennessee Veterinary Teaching Hospital?   Yes   No  
 
 If so, how many hours per week do you work at this other clinic? 
    0-10 hours  
    11-20 hours  
    21-30 hours  
    30+ hours  
 
Is there anyone in your household that works or volunteers regularly in a human 
hospital?       Yes   No  
 
Has any human from your household been hospitalized in the past month? 
        Yes   No  
 
Are there any children in your household?   Yes   No  
 
If so, please list their ages, if diarrhea is currently present, and any antibiotics 
they have received in the past 30 days, including the last date this medication 
was given. 
 
  Age__________Diarrhea?  Antibiotic Last Date Given 






Owner’s Medical History 
Have you been diagnosed with an immunosuppressive disease (such as HIV, diabetes 
mellitus, or cancer)?      Yes   No  
Are you currently taking any immunosuppressive therapy (such as prednisone or 
chemotherapy)?      Yes   No  
   
Have you ever been diagnosed with a urinary tract infection?Yes   No  
    If yes, on how many different occasions?     _____________________ 
                When was the most recent urinary tract infection?________month/year 
   
Do you currently have loose stool or diarrhea?    Yes   No  
 
Does any other human in your household have loose stool or diarrhea? 
        Yes   No  
Owner’s Medications: 
Have you received antibiotics in the past month?  Yes   No  
If yes, reason for administration: 
  Dental disease    Skin/trauma/wound        
  Gastrointestinal infection  Urinary tract infection       
  Respiratory infection   Other                     
        
 If yes, type of antibiotic: 
Amikacin    Doxycycline   
Amoxicillin   Erythromycin   
    Augmentin®             Gentamicin  
    Azithromycin   Metronidazole   
Cephalexin    Sulfa antibiotic  
Chloramphenicol   Other              
    Ciprofloxacin   Unknown   
  
How were these antibiotics administered? 
    Oral    Onto skin   
    Injectable   Into eyes   
    Into ears   Other    
 When was the last date of administration? _________mm/dd/2006 
 
To the best of your memory: please summarize your antibiotic history for the past 
year by providing the month/year, type of antibiotic, route of administration, number 
of days the antibiotic was given, and reason for antibiotic usage. 
 
Month/Year Type of Antibiotic Route  #Days Reason____ 
Example: Feb 2004 Augmentin  Orally  14 days     abscess_____ 
________________________________________________________________ 
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Relationship with Dog 
 
How much awake time per week do you spend with your dog?  
     0-10 hours   21-30 hours  
     11-20 hours   30+ hours  
 
Does your dog sleep in your bed at night?  Yes    No  
 
Does your dog lick/kiss you on the face?  Yes    No  
 
Do you wash your hands after petting your dog? Yes    No  
 
Are you the primary person who feeds your dog? Yes    No  
 
Does your dog eat table scraps?    Yes    No  
  If yes, please list:_______________________________________ 
 
Does your dog eat raw foods?   Yes    No  
  If yes, please list:_______________________________________ 
 
Do you wash your hands before feeding your dog? Yes    No  
 
Do you wash your hands before eating?  Yes    No   
       
How many times per week do you personally dispose of your dog’s feces? 
     Never    3-4 times  
     1-2 times   5+ times  
    
Do you wash your hands after disposing of your dog’s feces?  Yes  No  
 
Does your dog drink out of the toilet?        Yes  No  
 
How much time do you and your dog spend at dog parks per week? 
     0-2 hours   7-10 hours  
     3-6 hours   11+ hours  
            
Do you have other pets in the household?       Yes                     No  
If so, please list the species and age of these pets, if diarrhea is currently 
present, and any antibiotics they have received in the past 30 days, including 
the last date this medication was given.   
___________Species Age Diarrhea? Antibiotic_       Last Date Given__ 
Example cat  2 yrs___no  none   not applicable________ 
_____________________________________________________________________ 
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Study ID # ______________         Age _________years       Male    Female   
 
Do you work at a human hospital or medical office?  Yes   No  
If yes, do you have routine exposure to human fecal material at work? 
        Yes   No  
 If yes, do you have routine exposure to human urine samples at work? 
        Yes   No  
 
Do you work or volunteer at a veterinary clinic?   Yes   No   
Do you have regular contact (>1 hour/week) with any dogs?Yes   No  
 
Do any animals live in your household?   Yes   No  
If so, please list the species and age of these pets, if diarrhea is currently 
present, and any antibiotics they have received in the past 30 days, including 
the last date this medication was given. 
   
___________Species Age Diarrhea? Antibiotic_       Last Date Given__ 







         
Are there any children in your household?   Yes   No  
If so, please list their ages, if diarrhea is currently present, and any antibiotics 
they have received in the past 30 days, including the last date this medication 
was given. 
  Age__________Diarrhea?  Antibiotic Last Date Given 






Have you been diagnosed with an immunosuppressive disease (such as HIV, diabetes 
mellitus, or cancer)?      Yes   No  
 185
Are you currently taking any immunosuppressive therapy (such as prednisone or 
chemotherapy)?      Yes   No  
   
Have you ever been diagnosed with a urinary tract infection?Yes   No  
    If yes, on how many different occasions?     _____________________ 
                When was the most recent urinary tract infection?________month/year 
   
Do you currently have loose stool or diarrhea?    Yes   No  
 
Does any other person in your household have loose stool or diarrhea? 
        Yes   No  
 
Have you taken antibiotics in the past month?  Yes   No  
  
If yes, reason for administration: 
  Dental disease    Skin/trauma/wound       
  Gastrointestinal infection  Urinary tract infection      
  Respiratory infection   Other         
        
 If yes, type of antibiotic: 
Amikacin    Doxycycline   
Amoxicillin   Erythromycin   
    Augmentin®             Gentamicin  
    Azithromycin   Metronidazole   
Cephalexin    Sulfa antibiotic  
Chloramphenicol   Other              
    Ciprofloxacin   Unknown   
How were these antibiotics administered? 
    Oral    Onto skin   
    Injectable   Into eyes   
    Into ears   Other    
 When was the last date of administration? _________mm/dd/2006 
 
To the best of your memory: please summarize your antibiotic history during the past 
year by providing the month/year, type of antibiotic, route of administration, number 
of days the antibiotic was given, and reason for antibiotic usage. 
 
Month/Year Type of Antibiotic Route  #Days Reason_________ 





Appendix B.  Antimicrobial disc diffusion zone diameter interpretive standards 
[127, 128]. 






C Resistant Intermediate Susceptible
amikacin AN       <14mm 15-16 >17 
ampicillin AM       <13 14-16 >17 
amoxicillin-clavulanic acid AmC       <13 14-17 >18 
cefoxitin FOX       <14 15-17 >18 
ceftiofur XNL       <17 18-20 >21 
cefpodoxime CPD       <17 18-20 >21 
ceftriaxone CRO       <13 14-20 >21 
cephalothin CF       <14 15-17 >18 
chloramphenicol C       <12 13-17 >18 
ciprofloxacin CIP       <15 16-20 >21 
gentamicin GM       <12 13-15 dogs >16 dogs 
        <12 13-14 people >15 people
imipenem IPM       <13 14-15 >16 
kanamycin K       <13 14-17 >18 
nalidixic acid NA       <13 14-18 >19 
streptomycin S       <11 12-14 >15 
tetracycline Te       <14 15-18 >19 
trimethoprim-
sulfamethoxazole TMS       <10 11-15 >16 
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Appendix C.  Quality control testing results of antimicrobial susceptibility test 
discs using ATCC E. coli 25922 and S. aureus 25923, performed on 8/30/06 [127, 
128]. 
Antimicrobial 
Agent  E. coli 25922
Range for     
E. coli 25922 
S. aureus 
25923 
Range for     
S. aureus 
25923 
amikacin  AN 26mm 19-26 21 20-26 
ampicillin  AM 21 16-22 34 27-35 
amoxicillin-
clavulanic acid  AmC 23 18-24 29 28-36 
cefoxitin FOX 29 23-29 28 23-29 
ceftiofur NXL 30 26-31  30 27-31  
cefpodoxime CPD 28 23-28 24 19-25 
ceftriaxone CRO 35 29-35 27 22-28 
cephalothin CF 20 15-21 33 29-37 
chloramphenicol  C 27 21-27 26 19-26 
ciprofloxacin CIP 40 30-40 24 22-30 
gentamicin GM 26 19-26 22 19-27 
imipenem IPM 32 26-32 34  - 
kanamycin  K 25 17-25 24 19-26 
nalidixic acid  NA 28 22-28 10 -  
streptomycin  S 20 12-20 14 14-22 
tetracycline Te 25 18-25 30 24-30 
trimethoprim-








Factor Primer sequence (5'-3') Size of product (bp) 




factor F atcttatactggatgggatcatcttgg 974 
    R gcagaacgacgttcttcataagtatc   
        
hlyD hemolysin F ctccggtacgtgaaaaggac 904 
    R gccctgattactgaagcctg   
        
sfa 
S fimbriae 
adhesin F ctccggagaactgggtgcatcttac 410 
    R cggaggagtaattacaaacctggca   





GIII allele F ggcctgcaatggatttacctgg 258 

















































































































































Figure 3.  Prevalence of human and canine participants with history of urinary tract infections.  More women had a 
history of UTI than men (p<0.001).  There was no difference in number of female dogs vs. male dogs with a history 

























Figure 4.  Number of lifetime episodes of UTI in women with reported UTI history.  Seventy-five percent of women 






















Figure 5.  Number of lifetime episodes of UTI in dogs with reported UTI history.  Fifty percent of dogs with history 





















Figure 6.  Prevalence of dog-owner households owning other pets.  Eighty-two percent of households owned pets in 


















Figure 7.  Average awake-time owner spends with dog per week.  Fifty-four percent of owners spent 30 or more 
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Figure 10.  Times per week owner disposed of dog's feces.  Forty-seven percent of owners reported disposing of 
their dogs’ feces at least once during an average week. 
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Figure 11.  Original and website printout results of API-20E for an E. coli 
isolate.  (bioMerieux, Durham, NC). 
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Table 2.  Number (%) of biochemical reactions results found in                            
E. coli isolates. N=456. 
β-galactosidase 456 (100%)  
Arginine Dihydrolase 87 (19.1%)
Lysine Decarboxylase 434 (95.2%)
Ornithine Decarboxylase 355 (77.9%)
Citrate Utilization 0 (0%)
H2S Production 0 (0%)
Urease Production 3 (0.6%)
Tryptophane Deaminase 0 (0%)
Indole Production 455 (99.8%)
Acetoin Production 0 (0%)
Gelatinase 0 (0%)
Glucose Fermentation 456 (100%)
Mannitol Fermentation 456 (100%)
Inositol Fermentation 1 (0.2%)
Sorbitol Fermentation 453 (99.3%)
Rhamnose Fermentation 437 (95.8%)
Saccharose Fermentation 270 (59.2%)
Melibiose Fermentation 434 (95.2%)
Amygdalin Fermentation 8 (1.8%)
Arabinose Fermentation 456 (100%)
Cytochrome Oxidase 0 (0%)









Figure 12.  Predominant fecal coliform isolated from human participants.  E. coli was isolated from 96% of human 







Table 3.  Number (%) of participants with E. coli susceptible, intermediate, or resistant to each antimicrobial agent. 
  
Canine 
(N=61)    Owner (N=61)   
Control 
(N=30)  
 Susceptible Intermediate Resistant  Susceptible Intermediate Resistant  Susceptible Intermediate Resistant 
AN 61 (100%) 0 0  60 (98%) 0 1 (2%)  30 (100%) 0 0 
AM 41 (67%) 10 (16%) 10 (16%)  37 (61%) 9 (15%) 15 (25%)  15 (50%) 6 (20%) 9 (30%) 
AmC 49 (80%) 9 (15%) 3 (5%)  53 (87%) 6 (10%) 2 (3%)  24 (80%) 6 (20%) 0 
FOX 58 (95%) 0 3 (5%)  60 (98%) 0 1 (2%)  30 (100%) 0 0 
NXL 58 (95%) 0 3 (5%)  59 (97%) 0 2 (3%)  30 (100%) 0 0 
CPD 57 (93%) 0 4 (7%)  58 (95%) 0 3 (5%)  30 (100%) 0 0 
CRO 58 (95%) 1 (2%) 2 (3%)  59 (97%) 0 2 (3%)  30 (100%) 0 0 
CF 29 (48%) 25 (41%) 7 (11%)  36 (59%) 18 (30%) 7 (11%)  18 (60%) 11 (37%) 1 (3%) 
C 58 (95%) 0 3 (5%)  59 (97%) 1 (2%) 1 (2%)  28 (93%) 0 2 (7%) 
CIP 60 (98%) 0 1 (2%)  58 (95%) 0 3 (5%)  28 (93%) 0 2 (7%) 
GM 60 (98%) 0 1 (2%)  58 (95%) 1 (2%) 2 (3%)  30 (100%) 0 0 
IPM 61 (100%) 0 0  61 (100%) 0 0  30 (100%) 0 0 
K 56 (92%) 3 (5%) 2 (3%)  54 (89%) 4 (7%) 3 (5%)  28 (93%) 0 2 (7%) 
NA 58 (95%) 0 3 (5%)  55 (90%) 1 (2%) 5 (8%)  28 (93%) 0 2 (7%) 
S 34 (56%)  23 (38%) 4 (7%)  39 (64%) 15 (25%) 7 (11%)  18 (60%) 9 (30%) 3 (10%) 
Te 56 (92%) 1 (2%) 4 (7%)  54 (89%) 1 (2%) 6 (10%)  26 (87%) 1 (3%) 3 (10%) 











Table 4.  Number (%) of E. coli isolates susceptible, intermediate, or resistant to each antimicrobial agent. 
  
Canine 
(N=183)    Dog Owner (N=183)   
Control 
(N=90)  
 Susceptible Intermediate Resistant  Susceptible Intermediate Resistant  Susceptible Intermediate Resistant 
AN 183 (100%) 0 0   181 (98.9%) 0 2 (1.1%)   90 (100%) 0 0 
AM 136 (74.3%) 24 (13.1%) 
23 
(12.6%)   117 (63.9%) 23 (12.6%) 
43 
(23.5%)   49 (54.4%) 14 (15.6%) 27 (30%) 
AmC 159 (86.9%) 19 (10.4%) 5 (2.7%)   164 (89.6%) 15 (8.2%) 4 (2.2%)   76 (84.4%) 14 (15.6%) 0 
FOX 178 (97.3%) 0 5 (2.7%)   181 (98.9%) 0 2 (1.1%)   90 (100%) 0 0 
NXL 178 (97.3%) 0 5 (2.7%)   180 (98.4%) 0 3 (1.6%)   90 (100%) 0 0 
CPD 177 (96.7%) 0 6 (3.3%)   177 (96.7%) 0 6 (3.3%)   90 (100%) 0 0 
CRO 178 (97.3%) 1 (0.5%) 4 (2.2%)   180 (98.4%) 0 3 (1.6%)   90 (100%) 0 0 
CF 107 (58.5%) 63 (34.4%) 13 (7.1%)   120 (65.6%) 47 (25.7%) 16 (8.7%)   62 (68.9%) 25 (27.8%) 3 (3.3%) 
C 180 (98.4%) 0 3 (1.6%)   177 (96.7%) 3 (1.6%) 3 (1.6%)   84 (93.3%) 0 6 (6.7%) 
CIP 180 (98.4%) 0 3 (1.6%)   176 (96.2%) 0 7 (3.8%)   84 (93.3%) 0 6 (6.7%) 
GM 182 (99.5%) 0 1 (0.5%)   177 (96.7%) 2 (1.1%) 4 (2.2%)   90 (100%) 0 0 
IPM 183 (100%) 0 0   183 (100%) 0 0   90 (100%) 0 0 
K 177 (96.7%) 4 (2.2%) 2 (1.1%)   169 (92.3%) 8 (4.4%) 6 (3.3%)   84 (93.3%) 0 6 (6.7%) 
NA 178 (97.3%) 0 5 (2.7%)   170 (92.9%) 3 (1.6%) 10 (5.5%)   84 (93.3%) 0 6 (6.7%) 
S 123 (67.2%)  53 (29%) 7 (3.8%)   124 (67.8%) 40 (21.9%) 
19 
(10.4%)   58 (64.4%) 23 (25.6%) 9 (10%) 
Te 173 (94.5%) 3 (1.6%) 7 (3.8%)   163 (89.1%) 3 (1.6%) 17 (9.3%)   78 (86.7%) 3 (3.3%) 9 (10%) 
TMS 178 (97.3%) 0 5 (2.7%)   164 (89.6%) 0 
19 
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Table 5.  Wilcoxon signed ranks test results comparing antimicrobial susceptibility between dog-owner pairs.  
There were no differences in susceptibility results between dog owner pairs for any of the 17 antimicrobial agents. 
Antimicrobial Agent Z-score p value 
amikacin -1.000 0.317 
ampicillin -1.038 0.299 
ampicillin-clavulanic acid -1.031 0.302 
cefoxitin -1.000 0.317 
ceftiofur -0.577 0.564 
cefpodoxime -0.447 0.655 
ceftriaxone -0.272 0.785 
cephalothin -0.895 0.371 
chloramphenicol -0.849 0.396 
ciprofloxacin -1.000 0.317 
gentamicin -0.756 0.450 
imipenem 0.000 1.000 
kanamycin -0.548 0.584 
nalidixic acid -1.055 0.291 
streptomycin -0.253 0.800 
tetracycline -0.807 0.420 








Table 6.  Mann-Whitney test results comparing antimicrobial susceptibility between owners and controls.  There 
were no differences in susceptibility results between owners and controls for any of the 17 antimicrobial agents. 
 
% owners and 
controls  %  isolates from owners and controls 
Antimicrobial Agent Z-Score p value  Z-Score p value 
amikacin -0.701 0.483  -0.994 0.320 
ampicillin -0.883 0.377  -1.484 0.138 
amoxicillin-clavulanic acid -0.769 0.442  -1.148 0.251 
cefoxitin -0.701 0.483  -0.994 0.320 
ceftiofur -0.997 0.319  -1.219 0.223 
cefpodoxime -1.228 0.219  -1.734 0.083 
ceftriaxone -0.997 0.319  -1.219 0.223 
cephalothin -0.373 0.709  -0.793 0.428 
chloramphenicol -0.761 0.447  -1.322 0.186 
ciprofloxacin -0.342 0.732  -1.034 0.301 
gentamicin -1.228 0.219  -1.734 0.083 
imipenem 0.000 1.000  0.000 1.000 
kanamycin -0.652 0.514  -0.206 0.837 
nalidixic acid -0.482 0.630  -0.100 0.920 
streptomycin -0.266 0.790  -0.460 0.645 
tetracycline -0.231 0.817  -0.544 0.587 







Table 7.  Mann-Whitney test results comparing antimicrobial susceptibility between dogs and controls.  Control 
isolates were more resistant than canine isolates. 
 % dogs and controls % isolates from dogs and controls 
Antimicrobial agent Z-Score p value Z-Score P value 
amikacin 0 1.000 0 1.000 
ampicillin -1.679 0.093 -3.559 <0.001** 
amoxicillin-clavulanic acid -0.073 0.942 -0.451 0.652 
cefoxitin -1.228 0.219 -1.580 0.114 
ceftiofur -1.228 0.219 -1.580 0.114 
cefpodoxime -1.427 0.154 -1.734 0.083 
ceftriaxone -1.228 0.219 -1.580 0.114 
cephalothin -1.322 0.186 -1.768 0.077 
chloramphenicol -0.342 0.732 -2.183 0.029* 
ciprofloxacin -1.256 0.209 -2.183 0.029* 
gentamicin -0.701 0.483 -0.701 0.483 
imipenem 0.000 1.000 0.000 1.000 
kanamycin -0.201 0.841 -1.336 0.182 
nalidixic acid -0.342 0.732 -1.551 0.121 
streptomycin -0.217 0.829 -0.760 0.448 
tetracycline -0.758 0.448 -2.250 0.024* 
trimethoprim-sulfamethoxazole -1.850 0.064 -3.659 <0.001** 






Table 8.  Antibiogram patterns for E. coli isolates from dogs, owners, and controls. 
 Number of isolates resistant to antimicrobial agents (%) 







ampicillin and amoxicillin-clavulanic acid 9(2.0%) 5(2.7%) 4(2.2%) 0 
ampicillin and cephalothin 21(4.6%) 8(4.4%) 10(5.5%) 3(3.3%) 
ampicillin and chloramphenicol 8(1.8%) 2(1%) 0 6(6.7%) 
ampicillin and kanamycin 12(2.6%) 2(1%) 4(2.2%) 6(6.7%) 
ampicillin and streptomycin 27(5.9%) 7(3.8%) 11(6%) 9(10%) 
ampicillin and tetracycline 20(4.4%) 5(2.7%) 9(4.9%) 6(6.7%) 
ampicillin and trimethoprim-sulfamethoxazole 28(6.1%) 5(2.7%) 13(7.1%) 10(11.1%) 
cephalothin and streptomycin 12(2.6%) 4(2.2%) 5(2.7%) 3(3.3%) 
ciprofloxacin and nalidixic acid 16(3.5%) 3(1.6%) 7(3.8%) 6(6.7%) 
ampicillin, cephalothin, and streptomycin 10(2.2%) 4(2.2%) 3(1.6%) 3(3.3%) 
ampicillin, streptomycin, and trimethoprim-sulfamethoxazole 22(4.8%) 5(2.7%) 10(5.5%) 7(7.8%) 
ampicillin, tetracycline, and trimethoprim-sulfamethoxazole 14(3.1%) 2(1%) 9(4.9%) 3(3.3%) 
ciprofloxacin, nalidixic acid, and trimethoprim-
sulfamethoxazole 7(1.5%) 1(0.5%) 0 6(6.7%) 
ampicillin, streptomycin, tetracycline, and trimethoprim-





Table 9.  Susceptibility results of canine MDR fecal E. coli isolates.  
Antimicrobial 
Agent 
Dog   
#6B 









Dog   
#64A,B,C
amikacin S S S S S S 
ampicillin R R R R R R 
amoxicillin-
clavulanic acid R S R I S R 
cefoxitin R S R S S R 
ceftiofur R S R S S R 
cefpodoxime R S R S S R 
ceftriaxone R S I S S R 
cephalothin R I R I I R 
chloramphenicol S R R S S S 
ciprofloxacin S S R R R S 
gentamicin S S R S S S 
imipenem S S S S S S 
kanamycin S R R S S S 
nalidixic acid S R R R R S 
streptomycin I R R S S R 
tetracycline S R R S S S 
trimethoprim-
sulfamethoxazole S R R S S R 
Number Resistant 7 7 14 3 3 9 











Table 10.  Susceptibility results of owner MDR E. coli isolates. 
Antimicrobial 
Owner   
#66A/B 














amikacin S S R R S S 
 
S 




clavulanic acid S I S S S S 
 
R 
cefoxitin S S R R S S 
 
S 
ceftiofur S S R R S S 
 
S 
cefpodoxime S S R R S S 
 
R 
ceftriaxone S S R R S S 
 
S 
cephalothin I I R R I I 
 
R 
chloramphenicol S S S S S S 
 
S 
ciprofloxacin R R S S R R 
 
S 
gentamicin S S I I R R 
 
S 
imipenem S S S S S S 
 
S 
kanamycin S S R R I I 
 
S 
nalidixic acid R R R R R R 
 
S 
streptomycin S S R R S I 
 
S 




sulfamethoxazole S S S S S S 
 
S 
Number Resistant 3 3 9 9 4 4 
 
4 




















Owner  # 
123 A,B,C 
Owner   # 
124A 
amikacin S S S S S S 
ampicillin R R R R R R 
amoxicillin-
clavulanic acid I S I I S R 
cefoxitin S S S S S S 
ceftiofur S S S S S R 
cefpodoxime S S S S S R 
ceftriaxone S S S S S R 
cephalothin I S R S I R 
chloramphenicol S S S S S S 
ciprofloxacin S S S S S R 
gentamicin S S S S S R 
Imipenem S S S S S S 
kanamycin S S S S R R 
nalidixic Acid S S S S S R 
streptomycin R R R R I S 
tetracycline S S R R R S 
trimethoprim-
sulfamethoxazole R R R R R S 
Number Resistant 3 3 5 4 4 10 









Table 11.   Susceptibility results of control MDR E. coli isolates. 
Antimicrobial 
















amikacin S S S S S S 
 
S 




clavulanic acid S S S I I S 
 
S 
cefoxitin S S S S S S 
 
S 
ceftiofur S S S S S S 
 
S 
cefpodoxime S S S S S S 
 
S 
ceftriaxone S S S S S S 
 
S 
cephalothin S I I I R S 
 
S 
chloramphenicol S S S S R S 
 
S 
ciprofloxacin R R R S R S 
 
S 
gentamicin S S S S S S 
 
S 
imipenem S S S S S S 
 
S 
kanamycin S S S S R S 
 
R 
nalidixic acid R R R S R S 
 
S 
streptomycin S I S R R R 
 
I 




sulfamethoxazole R R R R R R 
 
R 
Number Resistant 3 3 3 3 9 3 
 
3 
























Percentage of Participants with MDR E. coli Percentage of Isolates having MDR E. coli
 
Figure 16.  Comparison of multiple drug resistant E. coli between groups.  There was no difference in number of 
MDR isolates between dogs and owners (p=0.109), but controls had more MDR E. coli isolates than dogs (p=0.003).  
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Figure 17.  Percent resistance among MDR E. coli isolates.  Canine MDR isolates were more resistant to beta-
lactam antimicrobial agents, especially cephalosporins than human MDR isolates.  Control MDR isolates were 




Table 12.  Mann-Whitney comparisons of antimicrobial susceptibility of multiple drug resistant E. coli isolates.  
Canine MDR isolates were more resistant than owner and control MDR isolates to cefoxitin, and more resistant 
than control isolates to ceftiofur, cefpodoxime, and ceftriaxone.  Control MDR isolates were more resistant than 
owner MDR isolates to trimethoprim-sulfamethoxazole. 
  Dogs and Owners Dogs and Controls Owners and Controls 
amikacin p=0.416 p=1.000 p=0.301 
ampicillin p=0.417 p=0.152 p=0.173 
amoxicillin-
clavulanic acid p=0.042 p=0.009 p=0.208 
cefoxitin *p=0.001 *p=0.001 p=0.301 
ceftiofur p=0.004 *p=0.001 p=0.199 
cefpodoxime p=0.048 *p=0.001 p=0.058 
ceftriaxone p=0.006 *p=0.002 p=0.199 
cephalothin p=0.107 p=0.017 p=0.125 
chloramphenicol p=0.011 p=0.922 p=0.014 
ciprofloxacin p=0.616 p=0.704 p=0.269 
gentamicin p=0.536 p=0.202 p=0.058 
imipenem p=1.000 p=1.000 p=1.000 
kanamycin p=0.686 p=0.344 p=0.364 
nalidixic acid p=0.487 p=0.867 p=0.549 
streptomycin p=0.534 p=0.903 p=0.492 
tetracycline p=0.572 p=0.503 p=0.915 
trimethoprim-




Table 13.  Susceptibility and virulence factor results of MDR E. coli isolates from 2 households. 










amikacin S S  S S 
ampicillin R R  R R 
amoxicillin-
clavulanic acid R I  R R 
cefoxitin R S  R S 
ceftiofur R S  R R 
cefpodoxime R S  R R 
ceftriaxone R S  R R 
cephalothin R I  R R 
chloramphenicol S S  S S 
ciprofloxacin S R  S R 
gentamicin S S  S R 
imipenem S S  S S 
kanamycin S S  S R 
nalidixic acid S R  S R 
streptomycin I S  R S 
tetracycline S S  S S 
trimethoprim-
sulfamethoxazole S S  R S 
      
cnf - -  - - 
hlyD - -  - - 
sfa + -  - - 





Figure 18. Representative agarose gel showing PFGE patterns of XbaI-digested genomic DNA from E. coli isolates 
from dog-owner pairs in 3 households.  Lanes 1, 8, and 15 contain Low Range PFG markers.   Household #35 had 
dog and owner isolates with 100% PFGE similarity. 
          Household #33        Household #34         Household #35         
            Dog   Owner       Dog            Owner     Dog     Owner 





























Figure 19. Distribution of across-household sharing of E. coli clones.  Cross-species sharing of E. coli clones between 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 14.  Percent PFGE profile similarity between dog and owner fecal E. coli. 
Household # Dog ID# Owner ID# 
Dog-owner        
% PFGE 
similarity 
1 5 65 74 
2 6 66 77 
3 7 67 78 
4 8 68 77 
5 9 69 71 
6 10 70 92 
7 11 71 92 
8 12 72 84 
9 13 73 88 
10 14 74 82 
11 15 75 74 
12 16 76 78 
13 17 77 92 
14 18 78 84 
15 19 79 97 
16 20 80 87 
17 21 81 95 
18 22 82 94 
19 23 83 94 
20 24 84 82 
21 25 85 78 
22 26 86 79 
23 27 87 74 
24 28 88 78 
25 29 89 84 
26 30 90 84 
27 31 91 88 
28 32 92 80 
29 33 93 89 
30 34 94 78 
31 35 95 78 
32 36 96 83 
 
 232
Table 14, continued. 
Household # Dog ID# Owner ID# 
Dog-owner        
% PFGE 
similarity 
33 37 97 85 
34 38 98 88 
35 39 99 100 
36 40 100 83 
37 41 101 78 
38 42 102 92 
39 43 103 80 
40 44 104 84 
41 45 105 85 
42 46 106 85 
43 47 107 83 
44 49 109 77 
45 51 111 79 
46 52 112 85 
47 53 113 70 
48 54 114 84 
49 55 115 88 
50 56 116 91 
51 57 117 75 
52 58 118 94 
53 59 119 91 
54 60 120 75 
55 61 121 88 
56 62 122 84 
57 63 123 91 
58 64 124 80 
59 175 125 88 
60 177 127 73 
















































































































Appendix D.  Spectrophotometry results for nucleic acid 





Ratio of Sample 
Absorbance (260/280) 
5A 684 1.90 
5B 651 1.83 
5C 1150 1.81 
6A 635 1.94 
6B 940 1.68 
6C 1521 1.82 
7A 870 1.90 
7B 669 1.86 
7C 939 1.68 
8A 592 1.74 
8B 734 1.69 
8C 1108 1.81 
9A 544 1.87 
9B 848 1.81 
9C 1076 1.87 
10A 1131 1.95 
10B 1089 1.67 
10C 1803 1.82 
11A 1972 1.96 
11B 1053 1.73 
11C 671 1.84 
12A 852 1.95 
12B 1417 1.74 
12C 584 1.78 
13A 995 1.79 
13B 1039 1.75 
13C 2003 1.83 





Ratio of Sample 
Absorbance (260/280) 
14B 830 1.76 
14C 2158 1.73 
15A 1158 1.84 
15B 1468 1.81 
15C 2863 1.82 
16A  805 1.82 
16B 986 1.81 
16C 1010 1.85 
17A 1109 1.88 
17B 1053 1.77 
17C 1500 1.74 
18A 1011 1.87 
18B 732 1.75 
18C 1880 1.81 
19A 760 1.82 
19B 738 1.80 
19C 1245 1.82 
20A 1543 1.98 
20B 1044 1.89 
20C 970 1.77 
21A 1176 1.90 
21B 938 1.85 
21C 624 1.82 
22A 1046 1.95 
22B 724 1.90 
22C 1297 1.81 
23A 1075 1.87 
23B 647 1.87 
23C 1156 1.78 
24A 1352 1.88 
24B 714 1.92 
24C 830 1.80 
25A 1461 1.90 





Ratio of Sample 
Absorbance (260/280) 
25C 732 1.78 
26A 867 1.78 
26B 565 1.77 
26C 767 1.95 
27A 1008 1.82 
27B 1115 1.79 
27C 805 1.84 
28A 1202 1.84 
28B 889 1.89 
28C 678 1.77 
29A 1037 1.83 
29B 735 1.81 
29C 686 1.72 
30A 1368 1.88 
30B 946 1.78 
30C 638 1.79 
31A 1151 1.82 
31B 919 1.77 
31C 558 1.71 
32A 857 1.82 
32B 1030 1.77 
32C 746 1.74 
33A 1338 1.77 
33B 528 1.78 
33C 790 1.85 
34A 974 1.85 
34B 797 1.96 
34C 788 1.78 
35A 1329 1.88 
35B 938 1.81 
35C 765 1.79 
36A 1552 1.82 
36B 659 1.86 





Ratio of Sample 
Absorbance (260/280) 
37A 929 1.81 
37B 1112 1.77 
37C 870 1.86 
38A 872 1.84 
38B 956 1.70 
38C 769 1.81 
39A 826 1.87 
39B 790 1.84 
39C 669 1.86 
40A 988 1.82 
40B 1050 1.77 
40C 809 1.86 
41A 811 1.80 
41B 900 1.84 
41C 884 1.82 
42A 983 1.83 
42B 1138 1.77 
42C 743 1.77 
43A 929 1.88 
43B 1182 1.78 
43C 820 1.81 
44A 1031 1.87 
44B 1055 1.76 
44C 962 1.92 
45A 1093 1.87 
45B 1224 1.73 
45C 721 1.91 
46A 954 1.78 
46B 840 1.86 
46C 750 1.88 
47A 1311 1.93 
47B 1569 1.74 
47C 657 1.82 





Ratio of Sample 
Absorbance (260/280) 
49B 513 1.72 
49C 1053 1.72 
51A 1114 1.79 
51B 1323 1.72 
51C 645 1.81 
52A 1514 1.79 
52B 1188 1.69 
52C 744 1.85 
53A 1404 1.75 
53B 1095 1.84 
53C 874 1.80 
54A 2063 1.92 
54B 749 1.90 
54C 865 1.81 
55A 926 1.88 
55B 984 1.68 
55C 592 1.67 
56A 1331 1.86 
56B 1129 1.75 
56C 888 1.82 
57A 1046 1.82 
57B 1162 1.76 
57C 861 1.88 
58A 1346 1.83 
58B 981 1.85 
58C 742 1.77 
59A 1017 1.82 
59B 1271 1.75 
59C 776 1.80 
60A 1304 1.92 
60B 1041 1.75 
60C 933 1.89 
61A 1183 1.83 





Ratio of Sample 
Absorbance (260/280) 
61C 942 1.87 
62A 1208 1.90 
62B 1004 1.74 
62C 792 1.80 
63A 1433 1.77 
63B 997 1.68 
63C 698 1.75 
64A 1246 1.84 
64B 837 1.85 
64C 651 1.75 
175A 884 1.86 
175B 960 1.88 
175C 748 1.78 
177A 901 1.83 
177B 848 1.89 
177C 736 1.78 
178A 925 1.82 
178B 1072 1.90 
178C 568 1.79 
65A 937 1.80 
65B 929 1.70 
65C 660 1.82 
66A 645 1.73 
66B 557 1.68 
66C 509 1.56 
67A 898 1.75 
67B 513 1.69 
67C 1041 1.68 
68A 1027 1.81 
68B 1087 1.72 
68C 651 1.69 
69A 926 1.88 
69B 1001 1.91 





Ratio of Sample 
Absorbance (260/280) 
70A 799 1.89 
70B 805 1.86 
70C 632 1.80 
71A 792 1.88 
71B 496 1.78 
71C 584 1.83 
72A 1095 1.86 
72B 554 1.80 
72C 686 1.85 
73A 900 1.88 
73B 865 1.82 
73C 872 1.89 
74A 796 1.82 
74B 642 1.80 
74C 786 1.69 
75A 742 1.77 
75B 465 1.71 
75C 733 1.77 
76A 571 1.69 
76B 676 1.82 
76C 630 1.72 
77A 1092 1.85 
77B 1034 1.71 
77C 648 1.74 
78A 979 1.88 
78B 552 1.74 
78C 751 1.81 
79A 920 1.83 
79B 700 1.78 
79C 783 1.79 
80A 1156 1.80 
80B 539 1.77 
80C 1055 1.80 





Ratio of Sample 
Absorbance (260/280) 
81B 869 1.88 
81C 703 1.77 
82A 1031 1.97 
82B 912 1.84 
82C 894 1.81 
83A 1140 1.83 
83B 1142 1.72 
83C 928 1.87 
84A 1060 1.89 
84B 1468 1.68 
84C 836 1.84 
85A 1156 1.90 
85B 1047 1.80 
85C 734 1.79 
86A 1064 1.91 
86B 1237 1.90 
86C 753 1.81 
87A 1193 1.91 
87B 1194 1.86 
87C 877 1.76 
88A 699 1.92 
88B 903 1.90 
88C 722 1.80 
89A 925 1.88 
89B 1000 1.78 
89C 635 1.84 
90A 891 1.91 
90B 974 1.90 
90C 724 1.83 
91A 805 1.82 
91B 1383 1.80 
91C 684 1.89 
92A 1053 1.88 





Ratio of Sample 
Absorbance (260/280) 
92C 917 1.85 
93A 960 1.86 
93B 1221 1.80 
93C 760 1.85 
94A 465 1.81 
94B 733 1.81 
94C 690 1.77 
95A 796 1.79 
95B 740 1.71 
95C 590 1.72 
96A 936 1.91 
96B 1154 1.69 
96C 695 1.85 
97A 849 1.89 
97B 1492 1.65 
97C 690 1.74 
98A 837 1.85 
98B 1140 1.72 
98C 674 1.78 
99A 929 1.80 
99B 902 1.76 
99C 682 1.80 
100A 947 1.91 
100B 1295 1.82 
100C 710 1.83 
101A 745 1.94 
101B 938 1.84 
101C 765 1.80 
102A 1036 1.94 
102B 1507 1.69 
102C 808 1.94 
103A 993 1.86 
103B 1551 1.72 





Ratio of Sample 
Absorbance (260/280) 
104A 920 1.82 
104B 1376 1.77 
104C 913 1.75 
105A 788 1.86 
105B 1129 1.64 
105C 714 1.79 
106A 738 1.82 
106B 852 1.71 
106C 495 1.75 
107A 787 1.80 
107B 995 1.69 
107C 565 1.72 
109A 1111 1.88 
109B 1532 1.73 
109C 806 1.85 
111A 758 1.74 
111B 789 1.70 
111C 663 1.75 
112A 842 1.89 
112B 1707 1.73 
112C 843 1.80 
113A 825 1.92 
113B 1577 1.71 
113C 515 1.77 
114A 948 1.81 
114B 1174 1.75 
114C 815 1.83 
115A 800 1.88 
115B 712 1.85 
115C 578 1.68 
116A 1176 1.90 
116B 1090 1.90 
116C 703 1.78 





Ratio of Sample 
Absorbance (260/280) 
117B 786 1.89 
117C 546 1.72 
118A 1261 1.92 
118B 651 1.83 
118C 649 1.66 
119A 902 1.81 
119B 1027 1.93 
119C 714 1.80 
120A 996 1.89 
120B 887 1.94 
120C 700 1.78 
121A 1251 1.98 
121B 1055 1.97 
121C 572 1.75 
122A 675 1.79 
122B 1185 1.75 
122C 663 1.85 
123A 930 1.76 
123B 1230 1.72 
123C 749 1.86 
124A 784 1.86 
124B 578 1.80 
124C 717 1.79 
125A 958 1.86 
125B 1145 1.87 
125C 740 1.84 
127A 928 1.78 
127B 518 1.73 
127C 992 1.80 
128A 1130 1.86 
128B 1128 1.88 
128C 583 1.78 
140A 780 1.83 





Ratio of Sample 
Absorbance (260/280) 
140C 1067 1.87 
141A 937 1.86 
141B 834 1.89 
141C 951 1.81 
142A 765 1.84 
142B 1146 1.95 
142C 769 1.80 
144A 884 1.75 
144B 940 1.87 
144C 574 1.70 
145A 614 1.80 
145B 1598 1.87 
145C 693 1.80 
146A 758 1.85 
146B 454 1.66 
146C 1430 1.74 
147A 943 1.88 
147B 1076 1.89 
147C 505 1.74 
148A 662 1.74 
148B 740 1.64 
148C 676 1.77 
149A 759 1.87 
149B 1348 1.90 
149C 680 1.88 
150A 711 1.83 
150B 523 1.80 
150C 505 1.77 
151A 894 1.78 
151B 538 1.75 
151C 735 1.75 
152A 776 1.84 
152B 575 1.68 





Ratio of Sample 
Absorbance (260/280) 
155A 845 1.81 
155B 941 1.81 
155C 715 1.74 
156A 787 1.80 
156B 1091 1.75 
156C 778 1.79 
157A 1008 1.80 
157B 824 1.63 
157C 801 1.77 
158A 710 1.83 
158B 1466 1.71 
158C 568 1.69 
159A 919 1.83 
159B 1110 1.84 
159C 775 1.75 
160A 1016 1.86 
160B 1144 1.85 
160C 706 1.76 
161A 780 1.79 
161B 736 1.80 
161C 793 1.84 
162A 897 1.84 
162B 717 1.82 
162C 640 1.83 
163A 560 1.73 
163B 770 1.72 
163C 541 1.69 
164A 848 1.91 
164B 1198 1.79 
164C 670 1.79 
165A 988 1.81 
165B 713 1.80 
165C 948 1.73 





Ratio of Sample 
Absorbance (260/280) 
166B 787 1.67 
166C 510 1.72 
167A 887 1.84 
167B 1178 1.75 
167C 894 1.85 
168A 874 1.85 
168B 588 1.75 
168C 558 1.72 
169A 972 1.86 
169B 976 1.68 
169C 818 1.79 
170A 1472 1.82 
170B 706 1.71 
170C 578 1.74 
172A 698 1.89 
172B 671 1.81 
172C 1046 1.85 
173A 734 1.80 
173B 803 1.86 
173C 591 1.69 
J96 940 1.87 






Figure 30.  Example of a gel electrophoresis image from multiplex PCR.  Lanes 
1, 20, 21, and 40 contain 100bp DNA ladder.  Lanes 2, 19, 22, and 39 contain a 
positive control for all 4 virulence factors.  Lanes 31 and 32 contain negative 
controls.  The remaining lanes contain participant samples.  Band sizes for each 
virulence factor are: cnf 974bp, hlyD 904bp, sfa 410bp, and papGIII 258bp. 
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Table 15.  PCR results for presence or absence of virulence factors in E. coli 
isolates, with dog-owner pairs in the same rows. 
Dog 
ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII
5A neg neg neg neg  65A pos pos pos neg 
5B neg neg neg neg  65B pos pos pos neg 
5C neg neg neg neg  65C pos pos pos neg 
                     
6A neg neg neg neg  66A neg neg neg neg 
6B neg neg pos neg  66B neg neg neg neg 
6C neg neg neg neg  66C neg neg neg neg 
                
7A neg neg neg neg  67A neg neg neg neg 
7B neg neg neg neg  67B neg neg neg neg 
7C neg neg neg neg  67C neg neg neg neg 
                     
8A neg neg neg neg  68A neg neg neg neg 
8B neg neg neg neg  68B neg neg neg neg 
8C neg neg neg neg  68C neg neg neg neg 
                     
9A neg neg neg neg  69A neg neg neg neg 
9B neg neg neg neg  69B neg neg neg neg 
9C neg neg neg neg  69C neg neg neg neg 
                     
10A pos pos pos pos  70A neg neg neg neg 
10B pos pos pos pos  70B neg neg neg neg 
10C pos pos pos pos  70C neg neg neg neg 
                     
11A neg neg neg neg  71A neg neg neg neg 
11B neg neg neg neg  71B neg neg neg neg 
11C neg neg neg neg  71C neg neg neg neg 
                     
12A neg neg neg neg  72A neg neg neg neg 
12B neg neg neg neg  72B neg neg neg neg 
12C neg neg neg neg  72C neg neg neg neg 
                     
13A neg neg pos neg  73A neg neg neg neg 
 
 256
Table 15, continued. 
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
13B neg neg neg neg  73B neg neg neg neg 
13C neg neg neg neg  73C neg neg neg neg 
                
14A neg neg neg neg  74A neg neg neg neg 
14B neg neg neg neg  74B neg neg neg neg 
14C neg neg neg neg  74C neg neg neg neg 
                     
15A pos pos pos neg  75A neg neg neg neg 
15B pos pos pos neg  75B neg neg neg neg 
15C neg neg pos neg  75C neg neg neg neg 
                     
16A  neg neg neg neg  76A neg neg neg neg 
16B neg neg neg neg  76B neg neg neg neg 
16C neg neg neg neg  76C neg neg neg neg 
                     
17A neg neg neg neg  77A neg neg neg neg 
17B neg neg neg neg  77B neg neg neg neg 
17C neg neg neg neg  77C neg neg neg neg 
                     
18A neg neg neg neg  78A neg neg neg neg 
18B neg neg neg neg  78B neg neg neg neg 
18C neg neg neg neg  78C neg neg neg neg 
                     
19A neg neg neg neg  79A neg neg neg neg 
19B neg neg neg neg  79B neg neg neg neg 
19C neg neg neg neg  79C neg neg neg neg 
                     
20A pos pos pos pos  80A neg neg neg neg 
20B pos pos pos pos  80B neg neg neg neg 
20C pos pos pos pos  80C neg neg neg neg 
                     
21A neg neg neg neg  81A neg neg neg neg 
21B neg neg neg neg  81B neg neg neg neg 
21C neg neg neg neg  81C neg neg neg neg 
 
 257
Table 15, continued. 
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
22A pos pos pos pos  82A neg neg neg neg 
22B pos pos pos pos  82B neg neg neg neg 
22C pos pos pos pos  82C neg neg neg neg 
                     
23A pos pos neg pos  83A neg neg neg neg 
23B pos pos neg pos  83B neg neg neg neg 
23C pos pos neg pos  83C neg neg neg neg 
                     
24A neg neg neg neg  84A neg neg neg neg 
24B neg neg neg neg  84B neg neg neg neg 
24C neg neg neg neg  84C neg neg neg neg 
                     
25A neg neg neg neg  85A neg neg neg neg 
25B neg neg neg neg  85B neg neg neg neg 
25C neg neg neg neg  85C neg neg neg neg 
                     
26A neg neg neg neg  86A pos pos pos pos 
26B neg neg neg neg  86B pos pos pos pos 
26C neg neg neg neg  86C pos pos pos pos 
                     
27A neg neg neg neg  87A neg neg neg neg 
27B neg neg neg neg  87B neg neg neg neg 
27C neg neg neg neg  87C neg neg neg neg 
                     
28A neg neg neg neg  88A neg neg neg neg 
28B neg neg neg neg  88B neg neg neg neg 
28C neg neg neg neg  88C neg neg neg neg 
                     
29A neg neg neg neg  89A pos pos pos pos 
29B neg neg neg neg  89B pos pos pos pos 
29C neg neg neg neg  89C pos pos pos pos 
                     
30A neg neg neg neg  90A neg neg neg neg 





Table 15, continued. 
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
30C neg neg neg neg  90C neg neg neg neg 
           
31A neg neg pos neg  91A neg neg neg neg 
31B neg neg pos neg  91B neg neg neg neg 
31C neg neg pos neg  91C neg neg neg neg 
                     
32A neg neg neg neg  92A neg neg neg neg 
32B neg neg neg neg  92B neg neg neg neg 
32C neg neg neg neg  92C neg neg neg neg 
                     
33A neg neg neg neg  93A neg neg neg neg 
33B neg neg neg neg  93B neg neg neg neg 
33C neg neg neg neg  93C neg neg neg neg 
                     
34A neg neg neg neg  94A neg neg neg neg 
34B neg neg neg neg  94B neg neg neg neg 
34C neg neg neg neg  94C neg neg neg neg 
                     
35A neg neg neg neg  95A neg neg neg neg 
35B neg neg neg neg  95B neg neg neg neg 
35C neg neg neg neg  95C neg neg neg neg 
                     
36A neg neg neg neg  96A neg neg neg neg 
36B neg neg neg neg  96B neg neg neg neg 
36C neg neg neg neg  96C neg neg neg neg 
                     
37A neg neg neg neg  97A pos pos pos pos 
37B neg neg neg neg  97B pos pos pos pos 
37C neg neg neg neg  97C pos pos pos pos 
                     
38A pos pos pos pos  98A neg neg neg neg 
38B pos pos pos pos  98B neg neg neg neg 
38C pos pos pos pos  98C neg neg neg neg 




Table 15, continued.  
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
39A neg neg neg neg  99A pos pos pos neg 
39B neg neg neg neg  99B neg neg neg neg 
39C neg neg neg neg  99C neg neg neg neg 
           
40A neg neg neg neg  100A pos pos pos neg 
40B neg neg neg neg  100B pos pos pos neg 
40C neg neg neg neg  100C pos pos pos neg 
                     
41A neg neg neg neg  101A neg neg neg neg 
41B neg neg neg neg  101B neg neg neg neg 
41C neg neg neg neg  101C neg neg neg neg 
                     
42A neg neg neg neg  102A pos pos pos neg 
42B neg neg neg neg  102B neg neg neg neg 
42C neg neg neg neg  102C neg neg neg neg 
                     
43A neg neg neg neg  103A neg neg neg neg 
43B neg neg neg neg  103B neg neg neg neg 
43C neg neg neg neg  103C neg neg neg neg 
                     
44A neg neg neg neg  104A neg neg neg neg 
44B neg neg neg neg  104B neg neg neg neg 
44C neg neg neg neg  104C neg neg neg neg 
                     
45A neg neg neg neg  105A neg neg neg neg 
45B neg neg neg neg  105B neg neg neg neg 
45C neg neg neg neg  105C neg neg neg neg 
                     
46A neg neg neg neg  106A neg neg neg neg 
46B neg neg neg neg  106B neg neg neg neg 
46C neg neg neg neg  106C neg neg neg neg 
                     
47A pos pos pos pos  107A neg neg neg neg 





Table 15, continued. 
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
47C pos pos pos pos  107C neg neg neg neg 
           
49A neg neg neg neg  109A neg neg neg neg 
49B neg neg pos neg  109B neg neg neg neg 
49C neg neg pos neg  109C neg neg neg neg 
           
51A neg neg neg neg  111A neg neg neg neg 
51B neg neg neg neg  111B neg neg neg neg 
51C neg neg neg neg  111C neg neg neg neg 
                     
52A neg neg pos neg  112A neg neg neg neg 
52B neg neg pos neg  112B neg neg neg neg 
52C neg neg pos neg  112C neg neg neg neg 
                     
53A neg neg neg neg  113A neg neg neg neg 
53B neg neg neg neg  113B neg neg neg neg 
53C neg neg neg neg  113C neg neg neg neg 
                     
54A pos pos pos neg  114A pos pos pos neg 
54B pos pos pos neg  114B pos pos pos neg 
54C pos pos pos neg  114C pos pos pos neg 
                     
55A pos pos pos pos  115A neg neg neg neg 
55B pos pos pos pos  115B neg neg neg neg 
55C neg neg pos neg  115C neg neg neg neg 
                     
56A neg neg neg neg  116A neg neg neg neg 
56B neg neg neg neg  116B neg neg neg neg 
56C neg neg neg neg  116C neg neg neg neg 
                     
57A neg neg neg neg  117A pos pos pos pos 
57B neg neg neg neg  117B pos pos pos pos 
57C neg neg neg neg  117C pos pos pos neg 





Table 15, continued. 
Dog ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
58A neg neg pos neg  118A neg neg neg neg 
58B neg neg pos neg  118B neg neg neg neg 
58C neg neg pos neg  118C neg neg neg neg 
                     
59A neg neg neg neg  119A neg neg neg neg 
59B neg neg neg neg  119B neg neg neg neg 
59C neg neg neg neg  119C neg neg neg neg 
                     
60A neg neg neg neg  120A neg pos neg neg 
60B neg neg neg neg  120B neg pos neg neg 
60C neg neg neg neg  120C neg pos neg neg 
                     
61A neg neg neg neg  121A neg neg neg neg 
61B neg neg neg neg  121B neg neg neg neg 
61C neg neg neg neg  121C neg neg neg neg 
                     
62A neg neg neg neg  122A pos pos pos pos 
62B neg neg neg neg  122B pos pos pos pos 
62C neg neg neg neg  122C pos pos pos pos 
                     
63A pos pos pos pos  123A neg neg neg neg 
63B pos pos pos pos  123B neg neg neg neg 
63C pos pos pos pos  123C neg neg neg neg 
                     
64A neg neg neg neg  124A neg neg neg neg 
64B neg neg neg neg  124B neg neg neg neg 
64C neg neg neg neg  124C neg neg neg neg 
                     
175A neg neg neg neg  125A neg neg neg neg 
175B neg neg neg neg  125B neg neg neg neg 
175C neg neg neg neg  125C neg neg neg neg 
                     
177A neg neg neg neg  127A neg neg neg neg 






Table 15, continued. 
Dog 
ID# cnf hlyD sfa papGIII  Owner ID# cnf hlyD sfa papGIII 
177C neg neg neg neg  127C neg neg neg neg 
           
178A neg neg neg neg  128A neg neg neg Neg 
178B neg neg neg neg  128B neg neg neg Neg 










Table 16.  PCR results for presence or absence of virulence factors in E. coli 
isolates from controls 
Control ID# cnf hlyD sfa papGIII 
140A neg neg neg neg 
140B neg neg neg neg 
140C neg neg neg neg 
          
141A neg neg neg neg 
141B neg neg neg neg 
141C neg neg neg neg 
          
142A pos pos pos neg 
142B pos pos pos neg 
142C pos pos pos neg 
          
144A neg neg neg neg 
144B neg neg neg neg 
144C neg neg neg neg 
          
145A neg neg neg neg 
145B neg neg neg neg 
145C neg neg neg neg 
          
146A pos pos pos neg 
146B pos pos pos neg 
146C neg neg neg neg 
     
147A neg neg neg neg 
147B neg neg neg neg 
147C neg neg neg neg 
          
148A pos pos neg pos 
148B pos pos neg pos 
148C pos pos neg pos 
          
149A neg neg neg neg 
149B neg neg neg neg 
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Table 16, continued. 
Control ID# cnf hlyD sfa papGIII 
149C neg neg neg neg 
          
150A neg neg neg neg 
150B neg neg neg neg 
150C neg neg neg neg 
          
151A neg neg neg neg 
151B neg neg neg neg 
151C neg neg neg neg 
          
152A neg neg neg neg 
152B neg neg neg neg 
152C neg neg neg neg 
          
155A neg neg neg neg 
155B neg neg neg neg 
155C neg neg neg neg 
          
156A neg neg neg neg 
156B neg neg neg neg 
156C neg neg neg neg 
          
157A neg neg neg neg 
157B neg neg neg neg 
157C neg neg neg neg 
          
158A neg pos neg neg 
158B neg pos neg neg 
158C neg pos neg neg 
          
159A neg neg neg neg 
159B neg neg neg neg 
159C neg neg neg neg 
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Table 16, continued. 
Control ID# cnf hlyD sfa papGIII 
160A neg neg neg neg 
160B neg neg neg neg 
160C neg neg neg neg 
          
161A neg neg neg neg 
161B neg neg neg neg 
161C neg neg neg neg 
          
162A neg neg neg neg 
162B neg neg neg neg 
162C neg neg neg neg 
          
163A neg neg neg neg 
163B neg neg neg neg 
163C neg neg neg neg 
          
164A neg neg neg neg 
164B neg neg neg neg 
164C neg neg neg neg 
          
165A neg neg neg neg 
165B pos pos pos pos 
165C neg neg neg neg 
          
166A neg neg neg neg 
166B neg neg neg neg 
166C neg neg neg neg 
          
167A neg neg neg neg 
167B neg neg neg neg 
167C neg neg neg neg 
          
168A neg neg neg neg 
168B neg neg neg neg 
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Table 16, continued. 
Control ID# cnf hlyD sfa papGIII 
168C neg neg neg neg 
          
169A neg neg neg neg 
169B neg neg neg neg 
169C neg neg neg neg 
          
170A pos pos neg pos 
170B pos pos neg pos 
170C pos pos neg pos 
          
172A neg neg neg neg 
172B neg neg neg neg 
172C neg neg neg neg 
          
173A neg neg neg neg 
173B neg neg neg neg 
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Table 17.  Number (%) dogs, owners, and controls with E. coli displaying each virulence factor pattern. 
 Virulence Factor Pattern dogs owners controls 
 N=61 N=61 N=30 
hlyD 0 1(1.6%) 0 
sfa 6(9.8%) 0 1(3.3%) 
cnf+hlyD+sfa 2(3.3%) 5(8.2%) 2(6.7%) 
cnf+hlyD+papGIII 1(1.6%) 0 2(6.7%) 






   
Table 18.  McNemar Chi-Square results comparing virulence factor prevalence within dog-owner pairs.  There was 
no difference in presence or absence of any of the 4 virulence factors in dogs and owners in the same households. 














Table 19.  Chi-Square results comparing virulence factor prevalence between owners and controls.  There was no 
difference in presence or absence of virulence factors between owners and controls. 
 Prevalence in owners vs. 
controls 
Prevalence in owner isolates 
vs. control isolates 
Virulence Factor Chi-Square p-value  Chi-Square p-value 
cnf 0.001 0.974  0.038 0.844
hlyD 0.026 0.872  0.030 0.863
sfa 0.671 0.413  3.315 0.069




Table 20.  Chi-Square results comparing virulence factor prevalence between dogs and controls.  Canine isolates 
were sfa positive more often than control isolates. 
 Prevalence in dogs vs. 
controls 
Prevalence in canine isolates 
vs. control isolates 
Virulence Factor Chi-Square p-value  Chi-Square p-value 
cnf 0.001 0.974  0.187 0.666
hlyD 0.001 0.974  0.085 0.771
sfa 2.698 0.100  9.937 *0.002
papGIII 0.184 0.668  1.415 0.234







Table 21.  Comparisons of virulence factors within groups using the Kappa measure of agreement.  There was 
perfect agreement between cnf-hlyD in canine isolates, and between cnf-sfa in owner isolates. 
  Dogs Owners Controls All Participants 
cnf-hlyD K=1.000, p<0.001 K=0.936, p<0.001 K=0.870, p<0.001 K=0.949, p<0.001 
cnf-sfa K=0.667, p<0.001 K=1.000, p<0.001 K=0.634, p<0.001 K=0.795, p<0.001 
cnf-papGIII K=0.886, p<0.001 K=0.667, p<0.001 K=0.708, p<0.001 K=0.774, p<0.001 
hlyD-sfa K=0.667, p<0.001 K=0.936, p<0.001 K=0.526, p<0.001 K=0.753, p<0.001 
hlyD-papGIII K=0.886, p<0.001 K=0.611, p<0.001 K=0.593, p<0.001 K=0.726, p<0.001 
sfa-papGIII K=0.566, p<0.001 K=0.667, p<0.001 K=0.088, p=0.400 K=0.549, p<0.001 
K=Kappa; Poor agreement: K<0.2;  Fair agreement: K=0.2-0.4;  Moderate agreement: K=0.4-0.6; 
Good agreement: K=0.6-0.8; Very good agreement: K=0.8-1.0;  Perfect agreement: K=1.0  [131] 
 
 









































Table 22.  Mann-Whitney comparison (p-values given) between virulence factors and antimicrobial susceptibility of 
456 E. coli isolates.  Associations were found between antimicrobial resistance and decreased virulence. 
  Virulence Factors  
Antimicrobial 
agents cnf hlyD sfa papGIII 
AN 0.560 0.540 0.540 0.644 
AM 0.765 0.939 0.314 0.205 
AmC 0.684 0.495 0.799 0.565 
FOX 0.273 0.249 0.913 0.384 
NXL 0.241 0.217 0.797 0.352 
CPD 0.294 0.376 0.092 0.068 
CRO 0.241 0.217 0.799 0.352 
CF 0.224 0.080 0.058 *0.006 
C 0.527 0.639 0.089 0.163 
CIP 0.094 0.078 0.078 0.184 
GM 0.273 0.249 0.249 0.384 
IPM 1.000 1.000 1.000 1.000 
K *0.031 *0.023 *0.023 0.087 
NA *0.039 *0.030 *0.030 0.100 
S *0.001 *0.008 **<0.001 *0.003 
Te 0.358 0.919 0.258 *0.027 






Table 23.  Susceptibility patterns of an E. coli clone containing susceptible isolates and MDR isolates. 
 ID#28A ID#28B ID#112A ID#112B ID#123B 
amikacin (AN) S S S S S 
ampicillin (AM) S S R R R 
amoxicillin-clavulanic 
acid (AmC) S S I I S 
cefoxitin (FOX) S S S S S 
ceftiofur (NXL) S S S S S 
cefpodoxime (CPD) S S S S S 
ceftriaxone (CRO) S S S S S 
cephalothin (CF) S S S S I 
chloramphenicol (C) S S S S S 
ciprofloxacin (CIP) S S S S S 
gentamicin (GM) S S S S S 
imipenem (IPM) S S S S S 
kanamycin (K) S S S S R 
nalidixic acid (NA) S S S S S 
streptomycin (S) S S R R I 
tetracycline (Te) S S R R R 
trimethoprim-




















10B, 47A, 47B Dog-Dog Across 94.6% 
cnf, hlyD, sfa, 
papGIII Susc. to all agents 
20B, 117A, 117B Dog-Owner Across 94.6% 
cnf, hlyD, sfa, 
papGIII Susc. to all agents 
26A, 29B Dog-Dog Across 94.7% none 
Int. to CF;  
Susc. to remaining agents
34B, 66C Dog-Owner Across 94.7% none 
Res. to AM, CIP, NA;  
Int. to AmC, CF;  
Susc. to remaining agents
75B, 82B Owner, Owner Across 94.1% none Susc. to all agents 
90A, 172C Owner, Control Across 94.4% none Susc. to all agents 
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